Wayne State University
Wayne State University Dissertations

1-1-2014

Evaluation Of Presynaptic Dopamine Dynamics
After: Toluene Inhalation Or Trkb Receptor
Activation
Aaron Kwaku Apawu
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Chemistry Commons, and the Neurosciences Commons
Recommended Citation
Apawu, Aaron Kwaku, "Evaluation Of Presynaptic Dopamine Dynamics After: Toluene Inhalation Or Trkb Receptor Activation"
(2014). Wayne State University Dissertations. Paper 960.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

EVALUATION OF PRESYNAPTIC DOPAMINE DYNAMICS AFTER:
TOLUENE INHALATION OR TRKB RECEPTOR ACTIVATION
by
AARON KWAKU APAWU
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2014
MAJOR: CHEMISTRY (Analytical)
Approved by:

Advisor

Date

© COPYRIGHT BY
Aaron Kwaku Apawu
2014
All Rights Reserved

DEDICATION
I dedicate this work to my late father James A. Apawu, my mum Gladys O.
Apawu, my siblings David, Joel, and Emmanuel, my lovely wife Alvis and our two
precious daughters Gladys and Danielle Apawu, my teachers and all whose love and
guidance have enabled me to attain my present height in education.

ii

ACKNOWLEDGMENTS
I would like to thank my advisor Dr. Tiffany Mathews for mentoring me during my
graduate education at Wayne State University. Her advice, encouragement, and
support together with the friendly atmosphere she created in her laboratory have
contributed immensely to my graduate development. I would like to express my
gratitude to her for believing in me. I would also like to express my appreciation to my
collaborator and a member of my dissertation committee, Dr. Scott Bowen for allowing
me to work in his laboratory and also for being available when I needed his help. Next, I
express my gratitude to the rest of my dissertation committee, Dr. Tamara Hendrickson
and Dr. Colin Poole for their counsel, comments, and insightful suggestions regarding
my research. Your contributions have been very helpful in shaping my research.
I thank Dr. Parastoo Hashemi, and Dr. Francis Maina for their comments, advice,
and help, the past members of the Mathew’s laboratory, Dr. Kelly Bosse, Dr. Madiha
Khalid, Dr. Johnna Birbeck, Stella, Christopher, Katie, Megan, Douglas, Michelle, and
James for the help they provided me in diverse ways to enable me to come this far. My
sincere thanks to my lab mate Brooke Newman for her assistance in my microdialysis
and tissue content work. I’m also grateful to Sean Callan from Dr. Bowen’s lab for
helping me with my toluene project. To all my friends I say thank you for your friendship.
Last but not the least, I thank my parents for investing in my education, my
brother David, my wife Alvis and our two daughters for all their sacrifices towards my
graduate studies.
Above all, I express my heartfelt gratitude to God for the gift of life and for all the
strides I have made in life.

iii

CONTRIBUTIONS
Chapter 2: Materials and Methods
The toluene project was collaborative with Dr. Scott Bowen from the Department
of Psychology at Wayne State University. This project spans chapters 3 through 5. All
experiments in the toluene project were performed with outbred male Swiss-Webster
mice, which required no in-house breeding, weaning, or genotyping.
The BDNF project described in chapter 6 involved genetically modified C57BL/6
mice; brain-derived neurotrophic factor (BDNF) heterozygote mice and their wildtype
littermates. These mice required in-house breeding. Weaning and genotyping of mice
was performed by Dr. Kelly Bosse and Brooke Newman with help from Dr. Johnna
Birbeck, Christopher Rogalla, Michelle Colombo, and Stephanie Godden.
Chapter 3: Striatal Dopamine Dynamics in Mice Following Acute and Repeated
Toluene Exposure
I performed all experiments in this chapter, which involved acute and 7 day
repeated exposures of mice to toluene, locomotor activity measurements during toluene
exposures, and slice fast scan cyclic voltammetry (FSCV). All behavior data analysis
and graphing were done by Dr. Scott Bowen. I performed all FSCV data analysis and
graphing. The results obtained from this work are in revision for publication in
Psychopharmacology. I performed literature searches, writing of the manuscript, and
corrections together with Dr. Scott Bowen and Dr. Tiffany Mathews.
Chapter 4: An In-depth Examination of Acute Toluene Exposure on the Striatal
Dopamine System
The work in this chapter includes toluene exposure, slice FSCV, tissue content

iv

analysis and in vivo microdialysis. I performed the acute exposure of mice to toluene
and the locomotor activity measurements with assistance from Sean Callan from Dr.
Bowen’s laboratory in the Department of Psychology. I performed all tissue content
analysis which involved taking mouse brain tissue, homogenizing tissue samples,
analysis by high performance liquid chromatography (HPLC), and running of protein
assays to normalize tissue content DA and its metabolites to tissue protein. I also
performed all slice FSCV measurements.
In vivo microdialysis experiments involved construction of a toluene exposure
chamber that allows toluene exposure, microdialysis sampling and locomotor activity
measurements simultaneously. This chamber was built through a collaborative effort
between Sean Callan and myself. I also performed microdialysis experiments with
assistance from Sean Callan. The microdialysis experiment involved stereotaxic
surgery, probe placement, microdialysis sample collection, and toluene exposure. I
performed all microdialysis sample analysis by HPLC. All behavior data analysis was
performed by Sean. I performed all neurochemical data analysis, graphing, literature
searches, and wrote this chapter.
Chapter 5: An In-depth Examination of the Effect of Repeated Toluene Exposure
on Striatal Dopamine System
I performed 7 day repeated exposures of mice to toluene with assistance from
Sean Callan. Additionally, l performed all FSCV experiments and all tissue content
analysis including protein assays. I performed microdialysis experiments with
assistance from Sean Callan. I performed all HPLC analysis of microdialysis samples.

v

All behavior data analysis was performed by Sean. I performed all neurochemical data
analysis, graphing, literature searches, and wrote this chapter.
Chapter 6: Probing the Ability of Presynaptic Tyrosine Kinase Receptors to
Regulate Striatal Dopamine Dynamics
I performed FSCV experiments involving genistein, tyrphostin 23, 7,8-dihydroxy
flavone (7,8-DHF) and the 7,8-DHF/K252a cocktail and analyzed and graphed the data.
Dr. Francis Maina performed FSCV with BDNF, K252a, and the BDNF/K252a cocktail
and analyzed and graphed the data. All electrochemical characterization of
pharmacological agents was done by James Taylor with my assistance and supervision.
The results obtained from this work were published in ACS Chemical Neuroscience
(Apawu et al., 2013). I performed literature searches and wrote the manuscript and
corrections together with Dr. Francis Maina and Dr. Tiffany Mathews.

vi

TABLE OF CONTENTS
Dedication.……………………………………………………………………………………….ii
Acknowledgments……………….……………………………………………………………...iii
Contributions………………………………………………………………………………….…iv
List of Tables.…………………………………………………………………………………..xiii
List of Figures……………….………………...…………………………………………….....xiv
Abbreviations ……………………………………………………….…………..…….……....xvii
CHAPTER 1: Introduction and Overview……………………………………………………..1
1.1 Fundamentals of neurochemistry………………………………………………...1
1.1.1 Biochemistry of the dopamine neurotransmitter………………………2
1.1.2 Brain derived neurotrophic factor (BDNF)……………………………..8
1.2 Addictive drugs and the dopamine system...……………………………….… 10
1.3 Toluene abuse…...……………………………………………………………..…11
1.3.1 Toluene as an inhalant…………………………......…………………..11
1.3.2 Behavioral and pharmacological effects of toluene....…..………..…12
1.3.3 Neurochemical evidence of toluene’s neural action…......……….…13
1.4 Tools to evaluate neurochemical function..……………………………….……14
1.4.1 In vivo microdialysis……………...……………………………….…….14
1.4.1.1 Separation and detection of dialysate samples……………17
1.4.1.2 Advantages and disadvantages of in vivo
microdialysis......………….…………………………………...18
1.4.2 Fast scan cyclic voltammetry (FSCV)................……………………..19
1.4.2.1 Slice fast scan cyclic voltammetry......................................21
1.4.2.2 Advances in fast scan cyclic voltammetry………………….25
vii

1.4.3 Brain tissue content analysis of neurotransmitters…….………….…26
1.4.4 Behavioral testing in animal models…………….…………………….28
1.5 Research objectives………………………………………………………………29
1.5.1 Research objective 1..…….….………………………………………....29
1.5.2 Research objective 2…...……………………………………………….30
CHAPTER 2: Materials and Methods…...………………………..………………….……...32
2.1 Chemicals.......…………………………………………………………………….32
2.2 Animal subjects..............................................................................................32
2.3 Toluene exposure procedure.......……………………………………………….33
2.4 Locomotor activity measurement......………………..……….…………………37
2.5 Slice fast scan cyclic voltammetry (FSCV)....……...……….………………….37
2.5.1 Brain slice preparation …….……………………………………………37
2.5.2 Electrode fabrication …….………...………...………………………….38
2.5.3 Microelectrode calibration………………………...……….……………40
2.5.4 FSCV data collection……………………………………………………42
2.5.5 FSCV data analysis……………………………………………………..43
2.6 In vivo microdialysis……...……………………………………………………….43
2.6.1 Stereotaxic surgery……...………………………………………………43
2.6.2 Simultaneous collection of microdialysis samples and behavioral
testing during toluene treatment..….…………………………………..45
2.6.3 Sample analysis using high performance liquid
chromatography (HPLC).........…………………….…………………...48
2.7 Histological verification of microdialysis probe placement….....…..………....48
2.8 Brain tissue content analysis of dopamine and its metabolites
following toluene exposure…..............………………………..…..…………....49
viii

2.9 Statistical data analysis…...……………………………………………………..51
CHAPTER 3: Striatal Dopamine Dynamics in Mice Following Acute and Repeated
Toluene Exposure….……………………………………………………….…52
3.1 Introduction…..........……………………………………………………………....52
3.2 Hypothesis….……...…...………………………………………………………....53
3.3 Materials and Methods………..…………………….…………………………....53
3.3.1 Data Analysis.…….…..………………………………………………....54
3.4 Results…..………...…….…………………………………………………….…...55
3.4.1 Distance traveled during and following acute toluene
exposure.....……..…………………………………………………….…55
3.4.2 Striatal dopamine release and uptake following acute toluene
exposure…..……………………….………………………………….....57
3.4.3 Distance traveled during and following repeated toluene
exposure………....……………………...………………………….……62
3.4.4 Striatal dopamine dynamics after repeated toluene exposure.….....64
3.5 Discussion....…......………….…………………………………………………....66
3.6 Conclusions........….……………………………………………………………....72
CHAPTER 4: An In-depth Examination of Acute Toluene Exposure on the Striatal
Dopamine System…………..………………………………………………....73
4.1 Introduction….…...…………..…………………………………………………....73
4.2 Materials and Methods...……………………...….……………………………....76
4.2.1 Toluene exposure and locomotor activity measurement…..............76
4.2.2 Slice fast scan cyclic voltammetry.............…….……………………..76
4.2.3 Brain tissue content analysis of dopamine and its metabolite..........77
4.2.4 Simultaneous in vivo microdialysis and locomotor activity
measurement…...……………………………………………………....77

ix

4.2.5 Data analysis....………………………………………………………....79
4.3 Results……………………………………………………………………………...79
4.3.1 Distance traveled during acute toluene exposure…........…..……....79
4.3.2 Dopamine release and uptake following acute toluene exposure...81
4.3.3 Effect of acute toluene exposure on presynaptic D3
autoreceptors…......…….……...……………………………………….84
4.3.4 Monitoring the effect of acute toluene exposure on locomotor
behavior and extracellular dopamine levels in the CPu ….....……...86
4.3.5 Effect of acute toluene exposure on extracellular dopamine
and catabolism............………………………………………………….90
4.4 Discussion...........................…………………………………..…………………..94
4.5 Conclusions…..........………...…..………………………….……………..……....98
CHAPTER 5: An In-depth Examination of the Effect of Repeated Toluene
exposure on Striatal Dopamine (DA) System.....……....………….……..100
5.1 Introduction……………………………………………………………………….101
5.2 Materials and Methods.………………………………………………………….102
5.2.1 Toluene exposure and locomotor activity measurements….…..….102
5.2.2 Slice fast scan cyclic voltammetry following repeated toluene
exposure………………………………………………………………..102
5.2.3 Brain tissue content analysis of DA and its metabolites. ………….102
5.2.4 In vivo microdialysis and locomotor activity measurement…… ….103
5.2.5 Data analysis. ………………………………………………………….104
5.3 Results... ………………………………………………………………………….104
5.3.1 Distance traveled during and following repeated toluene
exposure…….……....………………………………………………….104
5.3.2 DA release and uptake following repeated toluene exposure... ….107

x

5.3.3 Effect of repeated toluene exposure on presynaptic DA
autoreceptors…....…….……………………………………………….110
5.3.4 Simultaneous monitoring of the effect of repeated toluene
exposure on locomotor behavior and extracellular DA level..….....112
5.3.5 Effect of repeated toluene exposure on DA tissue content and
its catabolism………….………...………...…………………….……..118
5.4 Discussion….…..………………………………………………………………...120
5.5 Conclusions….. ………………………………………………………………….124
CHAPTER 6: Probing the Ability of Presynaptic Tyrosine Kinase Receptors to
Regulate Striatal Dopamine (DA) Dynamics….…………………………..125
6.1 Introduction…… ………………………………………………………………….125
6.2 Hypothesis……. ………………………………………………………………….127
6.3 Materials and Methods ………………………………………………………….127
6.3.1 Animals……... ………………………………………………………….127
6.3.2 Chemicals….. ………………………………………………………….128
6.3.3 Slice FSCV…. ………………………………………………………….130
6.3.4 Data Analysis. ………………………………………………………….131
6.4 Results and Discussion..........……………………………………………….….131
6.4.1 Characterization of the electrochemical properties of
7,8-dihydroxyflavone, K252a, gensitein, and tyrphostin 23….…....131
6.4.2 Effect of exogenous BDNF on electrically evoked DA release
in BDNF+/- mice….……………………………………………………..136
6.4.3 Effect of genistein and tyrphostin 23 (AG 18) on presynaptic DA
dynamics….…………………………………………………………….138
6.4.4 Effect of K252a on presynaptic DA dynamics in wildtype mice.…..142
6.4.5 K252a inhibits BDNF’s ability to acutely modulate striatal DA
release in BDNF+/- mice…….…………………………………………145

xi

6.4.6 Exogenous BDNF application has no effect on DA dynamics in
wildtype mice............…………………………………......…………...146
6.4.7 K252a does not modulate striatal DA transporter kinetics in
BDNF+/- mice........……………………………………………………...146
6.4.8 K252a modulates striatal DA transporter kinetics in the
presence or absence of exogenous BDNF in wildtype mice.….....147
6.4.9 TrkB agonist, 7,8-DHF potentiates electrically evoked DA release
in the CPu of only wildtype mice....................................................150
6.4.10 TrkB agonist, 7,8-DHF has no effect on DA transporter kinetics
in the CPu across the genotypes…..…………….…………….…..151
6.4.11 K252a blocks the ability of 7,8-DHF to increases DA release
in wildtype mice………………………………………………………153
6.4.12 K252a and 7,8-DHF have no effect on DA transporter kinetics
in wildtype mice………………………………………………………154
6.5 Conclusions.…..............………………………………………………………….157
CHAPTER 7: Summary and Conclusions……... ………………………………………….159
7.1 Understanding how toluene modulates the DA system…..............………….159
7.1.1 Overall conclusions and future directions…..........………………….164
7.2 Probing the ability of presynaptic tyrosine kinase receptors to regulate
striatal DA dynamics.....………………………………………………………….166
7.2.1 Overall conclusions and future directions….…….............………….167
References…………...……………………………………………………………………….169
Abstract……. ………………………………………………………………………………….209
Autobiographical Statement………….……………………………………….……………..211

xii

LIST OF TABLES
Table 6.1: The effect of TrkB agonist on dopamine uptake rate…… ………………….156

xiii

LIST OF FIGURES
Figure 1.1 The main projections of dopamine (DA) cell bodies as shown in sagittal
mouse brain slice.………………..………………………………………………...3
Figure 1.2 Biosynthesis of DA.................……………………………………………………..5
Figure 1.3 Pathway showing DA catabolism………..…………………………………….….6
Figure 1.4 Schematic illustration of synaptic DA transmission..........………….....……….7
Figure 1.5 Schematic illustration of the action of brain derived neurotrophic
factor (BDNF) through TrkB receptors.…………………………………………..9
Figure 1.6 Microdialysis sampling through a semi-permeable membrane.….……...…..16
Figure 1.7 Slice fast scan cyclic voltammetric (FSCV) measurement of
DA dynamics……………………………………………………………….……...23
Figure 1.8 Representative FSCV data .………………………….………………………….24
Figure 2.1 Schematic diagram of toluene exposure chamber………………………...…..35
Figure 2.2 Representative infrared spectrograph of toluene vapor in toluene
exposure chamber……………………………….………………………………..36
Figure 2.3 Stepwise illustration of carbon fiber microelectrode fabrication………….......39
Figure 2.4 Flow injection analysis (FIA) set-up showing calibration of a
microelectrode...….…..……………………………………………………………41
Figure 2.5 Dynamic toluene exposure set-up for simultaneous monitoring of
locomotor activity and dialysate samples collections…….....…………………47
Figure 3.1 Locomotor activity during and after acute toluene exposure…………….…...56
Figure 3.2 Acute toluene exposure increases electrically stimulated DA release
with no effect on DA uptake……………………………………………………...58
Figure 3.3 Right shift in toluene dose response curve after previous exposure to
toluene………………….……………………………………………………….….60
Figure 3.4 DA uptake during perfusion of cumulative concentrations of toluene
over the CPu….……...….…………………………………………………………61
.
Figure 3.5 Locomotor activity during and after repeated toluene exposure…….……….63
xiv

Figure 3.6 Repeated exposure to toluene attenuates electrically stimulated
DA release but not uptake in the nucleus accumbens (NAc)…………….….65
Figure 4.1 Graphical representation of the time-line for behavior and microdialysis
data collection….………....………………………………………………………78
Figure 4.2 Effect of acute toluene exposure on locomotor activity of mice.. .…..……....80
Figure 4.3 Effect of acute toluene exposure on DA release and uptake….. ….….....….83
Figure 4.4 Effect of D3 agonist, 7-OH-DPAT on presynaptic DA release and uptake
in the CPu of toluene exposed and air-control mice.…..………..…………....85
Figure 4.5 Effect of acute toluene exposure on locomotor behavior during
dialysate sample collection….………………………………………………......87
Figure 4.6 Effect of acute toluene exposure on extracellular DA levels…………….......89
Figure 4.7 Representative chromatograms for neurotransmitters and metabolites …...92
Figure 4.8 Effect of acute toluene exposure on tissue content DA and its
metabolites....................................................................................................93
Figure 5.1 Timeline for repeated toluene/air exposure and microdialysis
measurement…….…..………………………………………………………….103
Figure 5.2 Locomotor activity during and after repeated toluene (0, 2000 or
4000 ppm) exposure…………………………………………………………...106
Figure 5.3 Effect of repeated toluene exposure on DA release and uptake............….109
Figure 5.4 Effect of 7-OH-DPAT on presynaptic DA release and uptake in the
NAc core of toluene exposed and air-control mice….………………………111
.
Figure 5.5 Effect of repeated toluene exposure on locomotor activity of mice…… ….114
Figure 5.6 Effect of repeated toluene exposure on locomotor behavior during
dialysate sample collection….…………………………………………………115
Figure 5.7 Effect of repeated toluene exposure on extracellular DA levels ………….117
Figure 5.8 No difference in intracellular DA levels and its metabolites after
repeated toluene exposure.……………………………………………………119

xv

Figure 6.1 Chemical structures of TrkB receptor agonist and antagonists... ………….129
Figure 6.2 Background subtracted cyclic voltammograms and redox reactions
showing electrochemical properties of DA, 7,8-dihydroxyflavone and
K252a….……………………………………………………….………….……..134
Figure 6.3 Background subtracted cyclic voltammograms showing electrochemical
properties of genistein and tyrphostin 23.................…………………………135
Figure 6.4 Infusion of BDNF dose dependently increases electrically stimulated
DA release in the caudate-putamen of BDNF+/- mice…...……….………….137
Figure 6.5 Effect of genistein on electrically evoked DA release and uptake in the
CPu of wildtype (WT) and BDNF+/- mice….………..…………………………140
Figure 6.6 Effect of tyrphostin 23 on evoked DA release and uptake in the CPu of
wildtype (WT) and BDNF+/- mice…….....…..................……………………...141
Figure 6.7 Effect of TrkB inhibitor, K252a on stimulated DA release and uptake
in the CPu of WT mice...............……….....................……………………….144
Figure 6.8 Effect of exogenous application of BDNF (100 ng/mL) on DA release
and uptake rates in the CPu of WT and BDNF+/- mice….............................149
Figure 6.9 Effect of cumulative dose of TrkB agonist, 7,8-DHF on electrically
evoked DA release in the CPu of WT and BDNF+/- mice......……........……152
Figure 6.10 K252a blocks the effect of 7,8-DHF in the CPu of WT mice......................155
Figure 7.1 Schematic diagram summarizing the effects of acute toluene exposure
on striatal DA system…......................…...…………………………………….165
Figure 7.2 Schematic diagram showing a summary of the present work and
recommended studies to understand how TrkB modulates DA dynamics..168

xvi

ABBREVIATIONS
3-MT

3-methoxytyramine

7,8-DHF

7,8-dihydroxyflavone

5-HIAA

5-hydroxyindoleacetic acid

7-OH-DPAT

(±)-7-hydroxy-2-dipropylaminotetralin hydrobromide

AADC

L-aromatic

AC

adenylyl cyclase

aCSF

artificial cerebrospinal fluid

ADHD

attention deficit hyperactivity disorder

AMPA

alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid

BCA

bicinchoninic acid

BDNF

brain-derived neurotrophic factor

cAMP

cyclic adenosine monophosphate

CNS

central nervous system

COMT

catechol-O-methyltransferase

CPu

caudate putamen

CREB

cAMP response element binding protein

CV

cyclic voltammogram

DA

dopamine

DAT

dopamine transporter

DNA

2'-deoxyribonucleic acid

DOPAC

3,4-dihydroxyphenylacetic acid

amino acid decarboxylase

xvii

EDTA

ethylenediaminetetraacetic acid

ERK

extracellular signal-regulated kinase

FSCV

fast scan cyclic voltammetry

GABA

gamma-aminobutyric acid

HPLC

high-performance liquid chromatography

HVA

homovanillic acid

IC50

half maximal inhibitory concentration

IR

infrared

L-DOPA

L-3,4-dihydroxyphenylalanine

MAO

monoamine oxidase

MAPK

mitogen-activated protein kinase

nAChRs

nicotinic acetylcholine receptors

NAc

nucleus accumbens

NGF

nerve growth factor

NT

neurotrophin

NMDA

N-methyl-D-aspartate

p

pulse

p75

low-affinity nerve growth factor receptor

PCR

polymerase chain reaction

PI3K

phosphatidylinositol-3 kinase

PKC

protein kinase C

PLCγ

phospholipase C, γ

xviii

Ras

GTP binding protein

ROS

reactive oxygen

SEM

standard error of the mean

SHC

adaptor protein containing SH2 domain

SNc

substantia nigra pars compacta

TH

tyrosine hydroxylase

TrkA

tyrosine kinase receptor A

TrkB

tyrosine kinase receptor B

TrkC

tyrosine kinase receptor C

VMAT

vesicular monoamine transporter

Vmax

maximum velocity

VTA

ventral tegmental area

WINCS

wireless instantaneous neurotransmitter concentration sensing

WT

wildtype

xix

1

CHAPTER 1
Introduction and Overview
1.1 Fundamentals of neurochemistry
The brain communicates through specialized cells to execute a variety of
functions. These specialized cells, called neurons, are estimated to number in the
hundreds of billions in the brain.2 Neurons differ in their structure, chemistry, location
and connections depending on the specific task they perform in the central nervous
system (CNS).2 In general, a neuron consists of a cell body (also called a soma), which
houses the nucleus as well as cytoplasmic organelles and is the site for most cellular
processes including protein synthesis.2, 3 Extending from the cell body is a single long
structure called an axon, which terminates in multiple structures known as dendrites.
The axon is responsible for conducting outgoing neuronal information in the form of an
electrochemical signal to the nerve terminal to be propagated to another neuron.
Dendrites receive incoming neuronal information during synaptic communication and
transmit it to the cell body.
Neuronal communication involves both electrical and chemical processes. When
a neuron is at rest, the inside of the cell is more negative than its surrounding. In this
state, the neuron is described as being polarized, having a resting potential of -70 mV.2
During neurotransmission, sodium (Na+) channels located in the membrane open,
allowing an influx of Na+ ions into the cell causing the inside of the cell to become
depolarized. During depolarization, an action potential is produced and propagated
along the length of the axon. This process is described as neuronal firing. In response
to depolarization, there is a spontaneous and transient opening of the potassium (K +)
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channels causing K+ efflux to re-polarize the neuron. During the process of
repolarization, the cell rebalances it’s Na+ and K+ ions, here the cell is said to be in a
refractory period where it cannot fire until it is back to its polarized state.4 When the
action potential reaches the axon terminal, it triggers neurotransmitter release into the
synaptic space (a small gap 10-100 nm between two communicating neurons) in a
process called exocytosis5. In the synaptic space, neurotransmitters act on specific
receptors located on the post-synaptic terminal (dendrites) of the receiving neuron to
propagate neuronal information. The neurotransmitters that remain in the synaptic
space are metabolized or taken back to the presynaptic terminal to be re-packaged into
vesicles. Examples of neurotransmitters include monoamines such as dopamine (DA),
serotonin, norepinephrine, and histamine, or amino acids such as glutamate, gammaaminobutyric acid (GABA), and glycine.
1.1.1 Biochemistry of the dopamine neurotransmitter
DA plays a crucial role in brain function. As a chemical messenger, DA is
implicated in movement, learning, memory, cognition, and reward seeking behaviors.2
Alterations or dysfunctions of the DA system have been linked to neurological diseases
including attention deficit hyperactivity disorder (ADHD), Schizophrenia, Alzheimer’s
and Parkinson’s diseases, and addiction.2, 6
Most DA neurons are localized in the midbrain. From here their fibers project into
the forebrain and the striatum (Figure 1.1).2, 7 The DA neurons located in the substantia
nigra pars compacta (SNc) in the midbrain innervate the dorsal striatum (Caudate
putamen; CPu) via the nigrostriatal pathway that is involved in learning and voluntary
motor activity.2,

8, 9

This pathway is known to be susceptible to neuronal death or
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significant DA impairments during neurodegenerative disease like Parkinson’s.2, 10 The
mesolimbic dopaminergic pathway involves projections of DA fibers from the ventral
tegmental area (VTA) in the midbrain into the ventral striatum (nucleus accumbens;
NAc) and the fibers from the olfactory tubercle into the amygdala, septum, and
hippocampus.2,

7

The mesolimbic pathway has been implicated in memory, addiction,

and reward related behaviors.2,

7, 11

The DA neurons in the VTA also innervate the

cortex forming the mesocortical dopaminergic pathway which is involved in emotion,
motivation, and cognition.2 These VTA dopaminergic projections are together called the
mesocorticolimbic system.12, 13

Figure 1.1: The main projections of dopamine (DA) cell bodies as shown
in sagittal mouse brain slice. Projections have been color coded to
distinguish the three main pathways. Red shows DA cell body projecting from
the SNc to the CPu forming the nigrostriatal pathway. Black represents the
projection from the VTA to the cortex in the mesocortical pathway. Green
shows the mesolimbic pathway, which involves DA projections from the VTA
into the NAc. This saggital mouse brain was adapted from Mouse Brain Atlas
with permission from Elsevier.1, 2
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DA is synthesized from L-tyrosine. During synthesis, which occurs in two main
steps, L-tyrosine undergoes hydroxylation at its C3 carbon to produce L-3,4dihydroxyphenylalanine (L-DOPA). This reaction is rate limiting and is catalyzed by
tyrosine hydroxylase (TH) enzyme in the presence of Fe2+, O2, and tetrahydrobiopterin
as cofactors. L-DOPA subsequently undergoes decarboxylation in the presence of Laromatic amino acid decarboxylase (AADC) enzyme and pyridoxal phosphate cofactor
to form DA (Figure 1.2). Following synthesis, DA is packaged into vesicles by vesicular
monoamine transporter 2 (VMAT2), which protects vesicular DA from being metabolized
by monoamine oxidase (MAO) until it is transported across the presynaptic terminal
upon electrical stimuli. An action potential arriving at the axon terminal causes the
vesicles to move to the nerve terminal to fuse with the cell membrane, releasing DA into
the synaptic space. In the synaptic space, the primary role of DA is to activate specific
DA post-synaptic receptors (located on the receiving neuron) to propagate the neuronal
signal. There are two types of DA receptors: the DA D1-like receptors (sub-divided into
the D1 and D5 receptors) and the DA D2-like receptors (sub-divided into the D2, D3,
and D4 receptors). When DA D1-like receptors are activated, they increase cyclic
adenosine monophosphate (cAMP) and neuronal activity through stimulation of adenylyl
cyclase (AC). However, activation of DA D2-like receptors reduces cAMP levels and
neuronal activity by inhibition of AC. Termination of the synaptic DA signal is achieved
by: 1) the DA transporter (DAT) which takes DA back into the presynaptic terminal or, 2)
DA is enzymatically degraded by MAO and catechol-O-methyl transferase (COMT) into
its metabolites such as 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytryptamine
(3-MT), and homovanillic acid (HVA) (Figures 1.3 and 1.4).2, 3, 14

5

Figure 1.2: Biosynthesis of DA. TH catalyzes the conversion of L-Tyrosine to LDOPA. The conversion of L-DOPA to DA is catalyzed by AADC.

6

Figure 1.3: Pathway showing DA catabolism. This pathway involves conversion
of DA by MAO to DOPAC which is subsequently converted to HVA by COMT. DA
can also be converted into 3-MT in a reaction catalyzed by COMT and further
broken down to HVA.
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Figure 1.4: Schematic illustration of synaptic DA transmission. At the
presynaptic terminal, synthesized DA is housed in vesicles. During
neurotransmission, the arrival of an action potential at the presynaptic terminal
triggers exocytotic release of DA into the synaptic cleft where it binds to DA
receptors at the post-synaptic terminal of the receiving neuron to propagate
neural information via secondary messengers. Definitions; Gi and Gs: inhibitory
and stimulatory guanine nucleotide-binding proteins.
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1.1.2 Brain derived neurotrophic factor (BDNF)
The DA system works in conjunction with many other neurotransmitters,
neuromodulators and proteins within the brain. One key player in neuronal functions is a
27 kDa homodimeric protein, BDNF. BDNF belongs to a class of neurotrophins that
include nerve growth factor (NGF), neurotrophin-3, (NT-3), and neurotrophin – 4/5 (NT4/5).15 BDNF exerts its effect through activation of high affinity tyrosine kinase receptor,
TrkB (Figure 1.5). In addition, it binds to low affinity p75 receptors to form a complex
that regulate Trk mediated signaling by influencing the TrK receptor conformation.16-18
BDNF is synthesized in the cell body of neurons, packaged into vesicles and then
transported to the nerve terminal for local secretion.16 Following exocytotic release from
the nerve terminal, BDNF in the extracellular milieu binds to the TrkB receptor causing
receptor dimerization. This dimerization induces activation of kinases, which catalyze
phosphorylation of the tyrosine residue of the receptor to provide binding sites for
signaling proteins such as growth factor receptor-bound protein 2 (GBR2), adaptor
protein containing SH2 domain (SHC), and son of sevenless (SOS).15,

16

Subsequent

activation of these signaling proteins via phosphorylation triggers numerous signaling
cascades identified in three main pathways namely the phosphatidylinositol-3-kinase
(PI3K), the Ras/mitogen activated protein kinase (MAPK), and phospholipase C, γ
(PLCγ) pathways.15, 16, 18 Activation of these pathways leads to various cellular events
that modulate different neuronal functions including cell survival, neurogenesis, synaptic
plasticity, synaptic transmission, and neurotransmitter release.2,

19-21

Alteration in the

level and function of BDNF has been implicated in neurological diseases including
Parkinson’s disease and drug addiction.22-27
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Figure 1.5: Schematic illustration of the action of brain derived neurotrophic
factor (BDNF) through TrkB receptors. Activation of TrkB by BDNF triggers
neuronal cascades that activate cAMP response element binding protein (CREB).
The neuronal cascades involve phospholipase Cγ (PLCγ), the Ras/mitogen
activated protein kinase (MAPK), and phosphatidylinositol-3-kinase (PI3K)
pathways that leads to several functions including neuronal growth, differentiation,
and synaptic plasticity.
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1.2 Addictive drugs and the dopamine system
Drugs of abuse interfere with normal brain function causing neuroadaptations
that can lead to drug addiction.28 Drug addiction is a complex brain disorder that
involves persistent and compulsive intake of drugs regardless of their destructive
consequences.29,

30

Examples of addictive drugs include amphetamine, nicotine,

ethanol, cocaine, marijuana, opioids, and solvent inhalants.31, 32 Each of these drugs is
unique and may exert its effect through different neuronal substrates.29, 33 However, one
common property of addictive drugs is their action on the mesolimbic DA system, which
is integral to the brain reward mechanism.29 Addictive drugs activate the mesolimbic DA
circuitry, which subsequently leads to elevation of extracellular DA levels in the terminal
region, NAc.11,

29, 34

These drug induced alterations in extracellular DA levels may be

achieved through diverse mechanisms. For instance, ethanol increases DA neuron
firing in the VTA through inhibition of N-methyl-D-aspartate (NMDA) receptors or
activation of GABAA receptors.31,

35

Nicotine, which mediates its actions through

acetylcholine receptors, and opiates which act through opioid receptors, also indirectly
increase DA neuron firing in the VTA.31,

35

On the other hand, cocaine increases

extracellular DA levels by directly acting on the DA transporter (DAT) to inhibit DA reuptake, while amphetamine reverses the function of DAT to release DA from the
terminal region of DA neurons.11, 31 This common induced elevation in extracellular DA
levels has been linked to the reinforcement effect of most drugs of abuse.11 Meanwhile,
solvent inhalants including volatile organic solvents like toluene have also been reported
to influence the mesolimbic DA system; nonetheless, their mode of action is not well
understood.36-38 Taken together, although drugs of addiction involves several

11

neurotransmitters and affects multiple brain regions, the mesolimbic DA circuitry
appears to be a common pathway where the actions of drugs of abuse converge.29, 39
1.3 Toluene abuse
1.3.1 Toluene as an inhalant
Toluene is a widely used industrial solvent produced mainly from petroleum and
as a byproduct of the coke oven industry.40 It is found in several consumable products
such as paint, paint thinners, glue, degreasers, and adhesives.41,

42

Aside from its

conventional uses in these products, toluene is also abused as an inhalant for its
euphoric effect. This form of drug abuse is administered by directly inhaling vapors from
the products, inhaling concentrated vapor trapped in a bag or breathing from rags
soaked in toluene containing products.43,

44

Because solvents like toluene are legal,

easily accessible, and inexpensive, younger populations are at increased risk for its use
and abuse as inhalants.41, 45 In the United States, a recent epidemiology report showed
that, from 2002 to 2011, the number of first time inhalant users ranged between 719,000
to 877,000; while in 2012, a total of 584,000 people age 12 or older used inhalants for
the first time, of which 62.5% were under the age of 18.46
Solvents like toluene are known to cause diminished mental and physical
capabilities such as ataxia, dis-inhibition, dizziness, incoordination, lethargy, slowed
reflexes, slowed thinking and movement, slurred speech, and memory loss.47-51 There
are also substantial reports that have shown that chronic inhalant use damages the
liver, kidneys, and optic nerves, and leads to coma and death by respiratory
depression.41,

43, 52-54

Inhalant use by pregnant mothers can also cause complications

during pregnancy and child birth.55
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1.3.2 Behavioral and pharmacological effects of toluene
Toluene has similar neurobehavioral effects as other CNS depressants including
alcohol.37, 56 For example, toluene has reinforcing/rewarding effects. This consequence
is evident in existing work that showed that mice will self-administer toluene
intravenously.57 In earlier work that was done by Weiss et al., it was also demonstrated
that monkeys would work to gain brief access to toluene vapor just as they would for
amphetamine or opiates.58 Furthermore, condition placed preference model has shown
that rats and mice will spend more time in a chamber where they were previously paired
with toluene than in one without toluene.59-61 In addition to having reinforcing properties,
tolerance to toluene inhalation has also been identified in animal models.62-65 In early
work reported by Himnan, toluene induced tolerance developed to locomotor behavior
including ataxia and inhibition of rearing to repeated toluene exposure as measured in
an open field.64 In another study, monkeys, whose cognition functions were examined
using delayed matching-to-sample behavior following repeated exposure to toluene,
were noted to have developed tolerance to their response times for sample selection.65
Other toluene induced neurobehavioral effects that have been reported include
spontaneous

motor

activation,

behavior

sensitization,

toluene

dependence,

discriminative stimulus effects, disruption in operant behavior, anticonvulsant effects,
and synergistic effects with other drugs of abuse.37,

56, 66-76

These data together with

many more provide useful evidence that toluene abuse produces behavioral effects that
are similar to many other drugs of abuse.37, 56

13

1.3.3 Neurochemical evidence of toluene’s neural action
Though the exact mechanism underlining toluene’s neural action is not well
understood, existing reports have implicated a number of neurotransmitters in toluene’s
action. These neurotransmitters include GABA, glutamate, serotonin, glycine, and DA.36,
37, 62, 77

For example, high-resolution magnetic resonance spectroscopy data showed

that acute binge inhalation of 8000 or 12,000 ppm toluene reduced levels of GABA
(12%) and glutamate (8%) in the hippocampus, as well as the index of glutamatergic
tone (22%) in the dorsal anterior striatum of rat brains.78 Cruz and co-workers used
recombinant receptors expressed in Xenopus oocytes to examine the influence of
toluene on NMDA receptors and found that a toluene dose of up to ~ 9 nM inhibited
NMDA-mediated current in a rapid, reversible, and a dose dependent manner.79 In
addition, the extent of effect varied from one receptor sub-unit to another with the
highest in NR1/2B (IC50 = 0.17 mM) followed by NR1/2A (IC50 = 1.4 mM) and then
NR1/2C (IC50 = 2.1 mM).79 These results are consistent with the data obtained from a
more recent study where acute treatment of primary cultures of rat hippocampal
neurons with 0.1-10 nM toluene solutions inhibited NMDA-mediated currents (IC50 = 1.5
mM), while no effect on response induced by the non-NMDA-agonist kainic acid.80
Meanwhile, four day treatments of the neurons to 1 mM toluene increased the whole
cell response to exogenously applied NMDA, and reduced the GABA mediated
response, but did not alter responses generated by kainic acid.80 Chronic toluene
treatment was increased the amplitude of synaptic NMDA currents but decreased
GABA mediated current.80 Furthermore, toluene potentiates the function of α1 glycine
receptor subtypes in oocytes and mouse serotonin-3 receptor function, but inhibits
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nicotinic acetylcholine receptors (nAChRs) in rodents.77,

81, 82

There is also substantial

evidence about toluene’s influence on the DA system, particularly on the mesolimbic
dopaminergic pathway. Riegel and his team showed that perfusion of toluene directly
into the VTA of a rat’s brain increased DA concentrations in both the VTA and the
NAc.36 Gerasimov et al. also demonstrated that acute inhalation of 3000 ppm toluene
increased extracellular DA levels in the prefrontal cortex of freely moving rats.71
Furthermore, acute exposure of rats to 11,500 ppm toluene potentiated transient
neuronal firing in the VTA DA neurons while another study reporting that seven daily
intraperitoneal injections of 600 mg/kg toluene elevated DA levels in the CPu and
NAc.83, 84
Taken together, these data provide significant evidence that the abused solvent
toluene alters brain chemistry through multiple mediators that have also been implicated
in neuronal alterations induced by other drugs of abuse.85-89
1.4 Tools to evaluate neurochemical function
1.4.1 In vivo microdialysis
Microdialysis is an in vivo sampling technique that allows small molecules such
as neurotransmitters and neuropeptide to be sampled from freely moving animals and
analyzed using analytical tools. Microdialysis sampling is based on the principle of
diffusion and size exclusion where small molecules migrate along a concentration
gradient in to a probe and are collected and analyzed.90 The microdialysis probe plays a
central role in the sampling process. The probe consists of a semi-permeable
membrane with specific molecular weight cut-off allowing only molecules within certain
molecular weight range to be sampled (Figure 1.6). This feature of the probe provides a
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means of selectivity for the sampling process. There are different probe designs, each
of which is unique for sampling from a specific organ. For example, the concentric probe
is rigid and is suitable for use in brain sampling.91 Other types of microdialysis probes
are linear, shunt, and flexible probes.91
Microdialysis has been widely used in animal research (usually rodents) to probe
extracellular levels of neurotransmitters and their metabolites and how pharmacological
agents influence them. When sampling from the brain, the microdialysis probe is
inserted through a guide cannula, which is implanted in a brain region of interest during
stereotaxic surgery. Samples from the extracellular matrix are collected by slowly and
continuously perfusing artificial cerebrospinal fluid (aCSF) through the inlet of the probe.
Perfusion of the buffer, which is similar in composition to the brain fluid but typically
lacks the neurotransmitter(s) of interest, creates a concentration gradient that causes
molecules to diffuse through the semi-permeable membrane of the probe. The
neurotransmitters are collected from the outlet of the probe as dialysate samples
(Figure 1.6). The flow rate of the perfusing buffer depends on factors such as desired
sample volume, sample collection time, and the needed analytical sensitivity.90 The
semi-permeable membrane of the probe excludes large molecules like proteins from the
dialysate samples. The samples collected can be analyzed with a variety of analytical
techniques.
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Figure 1.6: Microdialysis sampling through a semi-permeable membrane.
Microdialysis probe consist of a semi-permeable membrane that allows selective
sampling of small molecules. Shown here is a schematic of a concentric probe
used for microdialysis sampling from the brain. It consists of inner and outer
tubing. During sampling, dialysate buffer (perfusate) is pumped through the inner
tubing to create concentration gradient between the brain tissue and the probe.
Molecules diffuse along their concentration gradient and only small ones pass
through the membrane into the outer tubing and are swept into a collection vial as
dialysate samples.
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1.4.1.1 Separation and detection of dialysate samples
Microdialysis samples are commonly analyzed using a separation technique with
a detection method. The separation techniques used in microdialysis measurements
include high performance liquid chromatography (HPLC) and capillary electrophoreses
(CE).92-95 Coupling microdialysis to these techniques allows the constituents of the
dialysate samples to be separated and subsequently detected with a vast array of
detection systems including mass spectrometers, fluorescence, and electrochemical
detectors.92, 94, 96 This combination allows microdialysis to be used to analyze multiple
analytes simultaneously. HPLC has been widely used as a separation tool in
microdialysis measurements because it is commercially available and does not involve
complex instrumentation, making it easy to use. Although CE has higher mass
sensitivity and better temporal resolution (in seconds) compared to HPLC (in minutes),
advances have been made in miniaturizing HPLC columns (4 – 5 mm internal diameter)
into microbore columns (0.3 – 1.0 mm internal diameter), which have led to
improvements in temporal resolution and mass sensitivity of HPLC measurements.92, 9698

HPLC with electrochemical detection has been widely used to analyze monoamine

neurotransmitters such serotonin and DA as well as their metabolites DOPAC, HVA, 3MT, and 5-hydroxyindoleacetic acid (5-HIAA). In electrochemical detection, the analyte
must be electroactive; therefore any other non-electroactive species are undetected.
Since, electroactive species are oxidized and reduced at unique potentials,
electrochemical detection provides high selectivity and is also known for its good
sensitivity.99 Examples of electrochemical detectors are amperometric detectors where
approximately 10% of the analyte are oxidized or reduced, and coulometric detectors,
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which have a flow through cell design making it possible for nearly a 100% of the
analyte to be oxidized.100 Since most amino acid neurotransmitters are not
electroactive, they require pre-column derivatization to make them electroactive.91,

99

Amino acid neurotransmitters have also been analyzed using HPLC with fluorescence
detection and mass spectrometry. Mass spectrometry provides high selectivity and
conclusive identification of analyte using their molecular masses.91 Also, mass
spectrometry allows analysis of small sample volumes containing low concentrations of
analyte.96 However, microdialysis samples are of high ionic strength that can cause
clogging of the ionization source of the mass spectrometer creating high background
noise and requires additional desalting procedures prior to analysis.91
Analysis of microdialysis samples can be done using an online or offline
arrangement of the separation and detection set-ups. In an online set-up, microdialysis
samples are directly transferred to a separation system that analyzes the samples as
they are collected. This arrangement eliminates the problem of sample degradation and
minimizes contamination due to sample handling.90,

96

In the offline arrangement,

samples are collected for later analysis. This procedure is susceptible to contamination
due to handling and sample degradation. However, the offline arrangement has been
used widely because most laboratories cannot afford the expensive instrumentation and
expertise that go with the online analysis.96
1.4.1.2 Advantages and disadvantages of in vivo microdialysis
One advantage of microdialysis is its ability to measure basal extracellular levels
of neurotransmitters and metabolites. In addition, the technique allows simultaneous
analyses of multiple analytes. The main drawback of microdialysis is low spatial
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resolution due to the relatively large size of the microdialysis probe (2 mm long, 240 µm
diameter) compared to distinct brain regions, which can be < 0.5 mm3.96 Compared to
the fast neuronal events (on a milliseconds time scale), microdialysis has poor temporal
resolution. Thus, microdialysis is a less suitable choice for measurements of
neurotransmitter release and uptake dynamics.
1.4.2 Fast scan cyclic voltammetry (FSCV)
FSCV belongs to a family of electroanalytical techniques that measures current
generated by electroactive species in response to an applied potential at the surface of
a working electrode. In FSCV, the applied potential is triangular in shape with
parameters sufficient for the test chemical to undergo a redox reaction. Typically, the
working electrode is held at a negative potential, ramped up to a positive potential, and
then brought back down to the starting negative potential. These potentials are scanned
with respect to a silver-silver chloride (Ag/AgCl) reference electrode (Figure 1.7). Unlike
classic cyclic voltammetry, the waveform in FSCV is scanned at a faster rate (> 100 V/s)
to improve sensitivity.101,

102

The waveform takes approximately 10 ms to complete a

cycle and is repeated several times (usually at 10 Hz) at 100 ms intervals. In the
forward scan of the applied potential, electrons are transferred from the analyte to the
electrode (oxidation) whereas the reverse scan causes electrons to move from the
electrode to the analyte (reduction, Figure 1.7). The flow of electrical charge is
measured as current, which is proportional to the concentration of the test chemical
according to Faraday’s law of electrolysis (Equation 1).
Q = nFN

(1)
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In this equation, Q is the total electric charge measured in Coulombs, n is the number of
moles of electrons per molecule lost or gained, F is Faraday’s constant, given as 9.649
x 104 Coulombs/mole, and N is the number of moles of analyte undergoing electrolysis.
Where current (I) is given as a change in charge (Q) with respect to time (Equation 2).
I = dQ / dt

(2)

In addition to the faradaic current, a large charging current is produced due to the fast
scan rate and therefore the small change in current caused by the electrolysis of the
analyte is obtained by background subtracting the charging current. This attribute
makes FSCV useful in measuring only changes in current and not the absolute
current.101,

103

Nonetheless, its temporal resolution in milliseconds has made it a

powerful tool to monitor the fast chemical events of several neurotransmitters in the
brain.
The working electrode used in FSCV serves as a key component in the
measurement. In brain measurements where FSCV is coupled to a microelectrode, high
spatial resolution is achieved because the microelectrode, which is typically 7 µm in
diameter and 50 – 200 µm in length allows measurements from discrete brain regions
with minimal tissue damage.104-106 The commonly used microelectrode consists of a
carbon fiber encased in a glass capillary. Carbon fiber microelectrodes offer several
advantages which include the fact that fabrication is easy and cheap, they are less
susceptible to fouling when implanted in brain tissue, and permit the use of large
potential windows.101
The data obtained from FSCV in brain measurements is in three different forms.
One form is a plot of the Faradaic current as a function of the applied potential referred
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to as cyclic voltammogram (Figure 1.8A). The cyclic voltammogram provides a unique
‘fingerprint’ of the analyte that is used for identification. Cyclic voltammograms are
unique for a given electroactive species in terms of shape and oxidation and reduction
potentials, providing selectivity for the FSCV technique. For molecules whose cyclic
voltammograms may look identical, their identities can be further confirmed using
pharmacological verification.107,

108

The FSCV data can also be visualized in a 3-

dimensional color plot of current (z-axis), time (x-axis) and applied potential (y-axis),
where the oxidation and reduction currents are color coded respectively (Figure 1.8B).
Finally, FSCV data can be represented as a current versus time trace, where the rising
phase of the plot primarily represents release and the decay phase is the uptake of the
neurotransmitter (Figure 1.8C).
With the above mentioned superiority over other available techniques, FSCV has
been used extensively both in vivo (in free moving or anesthetized animals) and in brain
slices to study the dynamics of many neurotransmitters including DA, serotonin,
norepinephrine, epinephrine, histamine, adenosine, tyramine, and octopamine.106, 109-114
1.4.2.1 Slice fast scan cyclic voltammetry
A complete description of slice FSCV with instructional video can be found in:
Maina, F. K,* Khalid, M.,*Apawu, A. K,* and Mathews, T. A. (2012) J. Vis. Exp, 59, pii:
3464. doi: 10.3791/3464.106 *Co-first-authors.
Slice FSCV is a useful tool to characterize the release and uptake profiles of
many neurotransmitters including DA dynamics in rodent models. In this method, the
test animal is euthanized and its brain is removed and sliced into coronal brain slices,
which are equilibrated in continuously oxygenated aCSF buffer. Voltammetric
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recordings are made from a coronal brain slice placed in a temperature controlled
chamber that is continuously perfused with oxygenated aCSF buffer. During
measurement, neurotransmitter release is evoked with a single (monophasic, 350 μA,
60 Hz, and 4 ms pulse width) or multiple electrical pulses delivered onto the brain slice
through a bipolar stimulating electrode and the neurotransmitter release is measured at
a working electrode, usually a carbon fiber microelectrode surface (Figure 1.7) as
described above and also in Maina et al.106
Slice FSCV has numerous advantages, which include the ability to make
measurements from different brain regions of the same coronal slice. Furthermore, in
this method, probe placement is easier since no stereotaxic coordinates are needed. A
working microelectrode and bipolar stimulating electrode are positioned on the brain
slice by viewing through a microscope. The brain region of interest is located with the
help of a rodent brain atlas and anatomical markings on the brain slice. With these aids,
measurements can be made from sub-anatomical brain regions that are very close to
each other. Slice FSCV allows test of pharmacological agents on neurotransmitter
dynamics like in vivo measurements. Since multiple coronal brain slices (typically 400
µm) can be obtained from the same brain region, it is possible to do multiple
pharmacological tests in a single animal using slice FSCV. Reproducibility of the
pharmacological tests is also high since it is done in a system that is controlled by the
experimenter. In addition, this method provides selectivity in probing autoreceptor
functionality since measurements can be made from the presynaptic terminals without
direct inputs from post-synaptic receptors.
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Figure 1.7: Slice fast scan cyclic voltammetric (FSCV) measurement of DA
dynamics. In slice FSCV of DA, coronal brain slice (top panel) is electrically
stimulated to evoke DA. The applied waveform at the microelectrode surface is
scanned from -0.4 V to +1.2 V and back to -0.4 V. DA oxidized to form dopamine-oquinone in the forward scan and in the reverse, dopamine-o-quinone is reduced
back to DA. The redox reaction generates current measured and converted to
concentration. The coronal brain slice was adapted from Mouse Brain Atlas with
permission from Elsevier 1.
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Figure 1.8: Representative FSCV data. Data obtained from FSCV experiments are
expressed in three different plots A) A cyclic voltammogram (CV) provides
information about the oxidation and reduction potentials of DA (~ 0.6 V and - 0.2 V
respectively). These characteristic potentials together with the shape of the
voltammogram can be used to identify DA. B) A 3-D color plot showing concentration
(z-axis) versus applied potentials (y-axis) versus time (x-axis), where green and blue
colors represent oxidation and reduction currents respectively. C) A plot of oxidation
current versus time gives a concentration-time trace where the red arrow shows the
point of electrical stimulation to evoke DA during measurement. The ascending
phase of the concentration-time trace primarily denotes DA release whereas the
descending phase shows DA uptake.
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1.4.2.2 Advances in fast scan cyclic voltammetry
Overwhelming progress has been made in the use of FSCV in brain
measurements. These advances span different aspects of FSCV including electrode
fabrication, waveform modification, miniaturization of instrumentation, and clinical use.
For example, the sensitivity of FSCV measurements has been improved significantly
through modification of the carbon fiber microelectrode surface.115, 116 Recent work by
Hashemi and colleagues showed that electrodeposition of a cation exchange polymer
called Nafion on a carbon fiber microelectrode surface increased the sensitivity of in
vivo FSCV detection of serotonin in rats, which was hampered by fouling of the
microelectrode surface by extracellular metabolites including 5-HIAA.115 In a related
study, coating the surface of a carbon microelectrode with a carbon nanotube (CNT)Nafion mixture also significantly enhanced the sensitivity (~ 4 fold increase) of FSCV
detection of adenosine in rat brain slices without altering temporal resolution.116 Other
electrode

modifications

include

microelectrode

arrays,

which

not

only

allow

simultaneous FSCV measurements from multiple electrodes but also measurement of
multiple molecules.117,

118

Another addition to the field was the development of

microelectrode that can be chronically implanted into the brain to make measurements
over a long period of time. 104 This chronically implanted microelectrode, which was first
reported by Clark et al., is useful in tracking neurotransmitter changes in behaving
animals over time and can help to study the progression of neurological disorders
including addiction.104 The chronically implanted electrode consists of a carbon fiber
encased in a fused silica with the fiber and silica interface insulated with two-component
epoxy and the protruding fiber (7 µm in diameter and 150 – 200 µm in length) treated
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with 2-propanol.104 This microelectrode is biocompatible and can be used to monitor
sub-second DA dynamics in rodents over 4 months with no significant tissue
damage.104, 119-121 In addition to microelectrode modifications, optimizing the wave form
of the applied potential and the scan rate have also improved sensitivity of FSCV
measurements.102 These modifications have contributed to the use of FSCV to
effectively measure a wide variety of electroactive species in the brain.5, 102, 108, 115
FSCV measurements have also been improved in the area of instrumentation.
Currently, a wireless instantaneous neurotransmitter concentration sensing system
(WINCS) has been developed that allows FSCV measurements to be made from
behaving animals in an environment without restrictions from cables while transmitting
neurochemical data remotely to an analysis system.122-124 This technology reduces
electrical noise interference and movement artifacts in the measurements.122 The
WINCS coupled to FSCV has been used to detect DA, histamine, adenosine, and
serotonin in animal models and is now being fine-tuned to be used in humans to monitor
neurochemicals in deep brain stimulation feedback.111, 122-125
1.4.3 Brain tissue content analysis of neurotransmitters
Brain tissue content analysis provides a means to assess intracellular levels of
neurotransmitters and their metabolites in animal brain tissues. The method has been
widely used to examine the intracellular levels and catabolism of most monoamines
including DA in rodent models.84,

94, 126, 127

It involves sacrificing animals (usually by

cervical dislocation followed by decapitation) and then their brains are removed and
dissected to obtain tissue from the region on interest. The use of cervical dislocation is
preferred to other methods of euthanasia such as anesthesia or carbon dioxide
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inhalation because it eliminates potential interference in the brain chemistry, since
stress as a result of injection of an anesthetic or suffocation may alter the levels of brain
chemicals.128, 129 Brain tissues are frozen immediately after they are removed to ensure
that the neurochemicals do not degrade. Prior to analysis, the tissues are homogenized
in a strong acid (perchloric acid is commonly used) to extract neurochemicals from the
tissue and then the samples are centrifuged. The supernatant is analyzed using a
separation techniques coupled to a detector. HPLC with electrochemical detection has
been widely used to analyze tissue samples.84,

94, 126, 127

First, standards of the

compound of interest are run individually to obtain their retention time to enable
identification of analyte peaks. The samples are then run at appropriate attenuation.
The analyte peaks obtained are integrated against calibration curves of their respective
standards to obtain their concentration in the tissue samples. Since tissue content
analysis uses free hand dissection, different sizes of tissues are taken from the regions
of interest, it is important to normalize the analyte concentrations to the tissue weight or
its protein content. Normalizing the analyte concentration to protein content of the tissue
is advantageous as it minimizes problems associated with weighing wet tissue samples
including loss of tissue and degrading neurochemicals if there is too much time delay.
Although tissue content analysis using HPLC does not have good temporal
resolution as compared to a technique like FSCV, it has been useful to understand how
intracellular neurotransmitter levels and metabolism are influenced by drugs of abuse,
neurological disorders, and gene modification.84,

94, 130, 131

Tissue content analysis has

also be used to investigate the biosynthesis of DA, in which case the activity of TH (the
rate limiting enzyme in biosynthesis of DA) is indirectly examined by inhibiting AADC
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(the enzyme that catalyzes the decarboxylation of L-DOPA) and then measuring the
accumulation of L-DOPA in tissue samples.94, 127
1.4.4 Behavioral testing in animal models
Behavioral assays used in animal models have provided useful clues to the
neural mechanism underlining the action of most drugs of abuse. They have also been
used to measure observable traits of genetically modified animals that are used as
models for most neurological disorders.132-135 The assays encompass simple locomotor
activity measurements to more sophisticated behavioral paradigms such as condition
placed preference and operant behavior.59, 61, 68, 104, 136, 137 Locomotor activity has been
widely used to characterize the neurobehavioral profile of most drugs of abuse. Such
characterization is based on existing data that have linked induced locomotion to
changes in the mesolimbic dopaminergic system. For example, direct injection of DA
into the NAc stimulates rat’s locomotor activity, while destroying DA neurons in the NAc
with 6-hydroxydopamine decreases drug induced stimulated locomotor activity.138-140
Thus, stimulation of locomotor activity is thought to correspond to increased
extracellular DA levels in the NAc.34, 141
Locomotor activity testing involves putting an animal in an activity chamber or
placing a whole cage of a singly housed animal into an activity set-up, depending on the
goal of the experiment. The activity chamber or set-up is equipped with three sets of
infrared (IR) emitter-detector arrays attached outside of the set-up, two of which are
positioned in the x- and y-axis to measure the position and horizontal movement of the
animal while the third pair is placed in the z-axis to measure the jumping and rearing
activities of the animal. During data collection, the position and locomotor activity of the
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animal is detected by interruption in the light beams emanating from the IR emitter to
the detector. This interruption in the IR beam generates an analog signal that is
recorded by automated activity software installed on a computer. The data obtained
from this type of measurement include total distance traveled during the experiment,
horizontal count, horizontal time, vertical count, vertical time, stereotypic count
(repetitive movements) and stereotypic time. In testing the effect of pharmacological
agent on locomotor behavior, the animals may be pre-treated or treated during
measurement depending on the mode of the drug administration. For volatile solvents
including toluene, a calculated amount of the solvent is introduced and volatilized in the
activity chamber, which is made airtight (static system) or the vapor is continuously
generated in a dynamic system. Locomotor activity is measured during the treatment.
1.5 Research objectives
Because dopaminergic innervations in the striatal region of the brain are involved
in several neuronal functions and have been implicated in many neuronal disorders
including drug addiction, understanding the DA dynamics in this terminal region is a
crucial component of the attempt to decipher the mechanism underlining neuronal
disorders.
The overarching objective of my research work is two-fold: 1) To understand how
the striatal DA system adapts to acute and chronic toluene inhalation, and 2) To
understand how a trophic factor, brain derived neurotrophic factor (BDNF) modulates
striatal DA release and uptake.
1.5.1 Research objective 1: To understand how the striatal DA system adapts to acute
and chronic toluene inhalation: This project is a collaborative work with Dr. Scott Bowen
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from the Department of Psychology, Wayne State University. Part of this work is in
revision for publication in Psychopharmacology.
Drug

addiction

involves

substances

such

as

amphetamine,

cocaine,

methamphetamine, and alcohol. However, one area that has received little attention is
inhalant abuse, which is defined as the deliberate inhalation of volatile organic solvents
in order to attain a euphoric feeling.45 One of the most widely abused inhalants among
the adolescent population is toluene.142 The abused inhalant toluene has potent
behavioral and neurochemical effects. Available evidence suggests that toluene
inhalation alters DA neurotransmission in the brain.36, 71 However, the exact mechanism
underling toluene’s effect on the DA system, particularly DA release and uptake
dynamics, has remained elusive. The present study seeks to elucidate toluene’s action
on the striatal DA system by using behavioral testing and neurochemical measurements
including techniques such as in vivo microdialysis, slice FSCV, and tissue content
analysis.
The overall hypothesis of this work was that both acute and repeated toluene
inhalation will alter DA release and uptake dynamics in the mesolimbic DA terminals.
This hypothesis is based on existing behavioral data that has shown that toluene
inhalation has a rewarding effect and can stimulate locomotor activity in rodent
models.58, 68, 74 Our hypothesis is also supported by neurochemical data that has shown
that acute toluene inhalation can potentiate extracellular DA levels in the pre-frontal
cortex and the NAc.36, 71, 143
1.5.2 Research objective 2: To understand how a trophic factor; brain derived
neurotrophic factor (BDNF), modulate striatal DA release and uptake. Portions of this
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work have been published in the manuscript by Aaron K. Apawu, Francis K. Maina,
James Taylor, and Tiffany A. Mathews in ACS Chem Neurosci., 2013, 4(5): 895 – 905.
Copyright © 2013, American Chemical Society.
BDNF regulates growth, differentiation, and survival of neurons through
activation of high affinity tyrosine kinase receptor, TrkB.144-147. There is also
considerable evidence that suggests that BDNF modulates striatal DA function.21, 148-150
From previous work in the Mathews laboratory, it was proposed that the reduction in
BDNF expression is directly responsible for decrease in evoked-DA release, while the
compensatory response to lifelong reductions in BDNF would lead to decreased DA
transporter function.94 Based on this work, we have hypothesized that BDNF modulates
presynaptic DA dynamics in the striatum through activation of the TrkB receptor.
Typically, molecular techniques have been used to probe the effect of TrkB receptor
activation and the potential pathways through which BDNF may influence DA
dynamics.148, 149 However, the exact mechanism by which BDNF regulates presynaptic
DA release and uptake processes remains elusive. The goal of the present work is to
examine the ability of FSCV to measure the action of tyrosine kinase receptors on
striatal DA dynamics and then characterize the involvement of presynaptic TrkB
receptors in regulating striatal DA release and uptake processes. FSCV provides the
unique ability to measure both DA release and uptake rate on a milliseconds time scale
consistent with release and uptake events. The use of a carbon fiber microelectrode of
~ 7 microns in diameter ensures high spatial resolution with negligible tissue damage.
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CHAPTER 2
Materials and Methods
The chapter expounds on the materials and methods used in all experiments
reported in this dissertation. The methods discussed here include behavioral assays
and neurochemical techniques used to understand brain function. Specific details of
each technique are discussed in subsequent chapters. All experimental protocols and
animal procedures used in this dissertation were approved by the Institutional Animal
Care and Use Committee (IACUC) of Wayne State University.
2.1 Chemicals
Toluene (purity > 99.5%) was purchased from Fisher Scientific Co. (Fairlawn,
NJ). Chemicals used to prepare artificial cerebrospinal fluid (aCSF) for voltammetry and
in vivo microdialysis, and mobile phase for HPLC analysis were purchased from Fisher
Scientific Co. (Fairlawn, NJ) and Sigma (St. Louis, MO). Pharmacological agents used
in this work were purchased from specific vendors as follows: BDNF from PeproTech
(Rocky Hill, NJ), 7,8-dihydroxyflavone, genistein, and tyrphostin 23 were from Tokyo
Chemical Industry Co. Ltd. (Portland, OR) or EMD Chemicals, Inc. (Gibbstown, NJ), and
K252a was from LC Laboratories (A Division of PKC Pharmaceuticals Inc., Woburn,
MA).
2.2 Animal subjects
Adolescent outbred male Swiss-Webster mice (~ 4 week old) were used in the
inhalant (toluene) abuse project. The choice of mouse strain was based on previous
work that has demonstrated that Swiss-Webster mice have higher toluene induced
locomotor activity than other mouse strains.74 Swiss-Webster mice were purchased
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from Harlan Breeding Laboratories (Haslett, MI) and housed in a vivarium at Wayne
State University, which is certified by the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC). Mice were kept in groups of 10 - 12 animals per
cage and had ad libitum access to Rodent Lab Diet 5001 (PMI, Nutrition International,
Inc., Brentwood, MO), and water. The environment of the vivarium was temperature
controlled (20 – 22 oC) with a 12-h light cycle (0600 – 1800 h).
The second project involved the use of genetically modified C57BL/6 mice,
where mice had no mutation (wildtype), or one copy of the mutated brain-derived
neurotrophic factor gene (heterozygote BDNF mice; BDNF+/-). BDNF+/- and their
wildtype littermates were purchased from Jackson Laboratories (Bar Harbor, ME) and
breeding pairs were established. All neurochemical experiments were performed on
offspring that were born and raised in-house. When mice were approximately 3 weeks
of age, they were separated from their parents, ear-punched (for identification
purposes), and less than 2 cm of their tail was taken to determine their genotype by
using polymerase chain reaction (PCR) analysis of tail DNA. (For detailed procedure,
see Bosse et al., 2012).94
2.3 Toluene exposure procedure
Toluene exposure was performed in static exposure chambers consisting of 26.5
liter cylindrical glass jars (diameter 28.5 cm; height 45 cm; total floor space = 638 cm 2)
housed within a fume hood (Figure 2.1). Each chamber was equipped with a vapor
diffuser with a fan attached to a PlexiglasTM lid. On the day of exposure, a mouse was
placed in the floor of a chamber approximately 50 cm from the vapor diffuser and
allowed a 5 minute acclimation period; after which, a known concentration of toluene
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(calculated using the ideal gas equation, simplified for room temperature151) was
injected through an injection port onto filter paper in the vapor diffuser. The fan was then
turned on to diffuse toluene within the chamber for a period of 30 minutes; after which
the fan was turned off and the chamber was opened to allow the mouse a 30 minute
period of no toluene vapor inhalation (recovery). For the air-control experiments, the
same procedure was followed, but no toluene was injected into the chamber. Routinely,
the concentration of toluene vapor in the chamber was confirmed and monitored using a
single wavelength-monitoring infrared spectrometer (Miran 1A, Foxboro Analytical) to
ensure that there were no leaks in the chamber. Mean concentrations of toluene were
within 2% of nominal, approximately 2.5 minutes after toluene was injected into the
exposure chamber it was within 2% of the desired concentrations throughout the 30minute exposure period followed by rapid clearance when chamber was opened (Figure
2.2).
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Figure 2.1: Schematic diagram of toluene exposure chamber.
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Figure 2.2: Representative infrared spectrograph of toluene vapor in toluene
exposure chamber. Data was obtained during routine check for leaks in the
chamber. Each block represents ~ 50 seconds. Following injection of a calculated
volume of liquid toluene, the vapor diffused quickly to reach 4000 ppm
concentration and remained within 2% of the desired concentrations throughout
the exposure period. When the lid of the chamber was removed, toluene cleared
quickly from the chamber. Infrared spectrograph was provided by Sean Callan
from the Bowen lab.
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2.4 Locomotor activity measurement
The toluene exposure set-up consisted of three pairs of 16-beam infrared (IR)
emitter-detector arrays (Med Associates, St. Albans, VT) located outside of the
chamber. Two of these (IR) emitter-detector arrays were positioned ~ 2.5 cm from the
floor of the chamber at a right angle to each other in the x- and y-axes allowing the
position and locomotion of the mouse to be detected and measured by the count of
interruptions in the IR beams in the horizontal and vertical planes. The third pair of IR
emitter-detector arrays were in the z-plane located ~ 7 cm from the floor of the chamber
recorded jumps and rearing activities of the mouse. The interruptions in the IR beams
generated analog signals recorded by automated activity software (Open Field Activity
Software [SOF-811], Med Associates, St. Albans, VT) as locomotor activity. In this work,
locomotor activity was defined as the sum of interruptions of the lower IR beams in the
x- and y-axes.
2.5 Slice fast scan cyclic voltammetry (FSCV)
Slice FSCV was used to measure electrically evoked DA release and uptake
dynamics in the striatum of mouse brain slices.
2.5.1 Brain slice preparation
Following asphyxiation, mice were decapitated and their brains were rapidly
removed and immediately placed into chilled pre-oxygenated (95% O2/5% CO2) sucrose
artificial cerebral spinal fluid (aCSF) for 10 minutes. The composition of the sucrose
aCSF was 180 mM sucrose, 30 mM NaCl, 4.5 mM KCl, 1 mM MgCl 2, 26 mM NaHCO3,
1.2 mM NaH2PO4, and 10 mM D-glucose, and pH = 7.4. The mouse brain was then
sectioned into 400 µm thick coronal brain slices using a vibratome (Vibratome, St.
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Louis, MO). Brain slices with the striatal complex consisting of the caudate putamen
(CPu) and the nucleus accumbens (NAc) were immediately transferred into
continuously oxygenated fresh aCSF (aCSF for voltammetric recordings consisting of
0.4 mM ascorbic acid, 126 mM NaCl, 2.5 mM KCl, 1.2 mM MgCl 2, 2.4 mM CaCl2, 25
mM NaHCO3, 1.2 mM NaH2PO4, 11 mM D-glucose, and pH = 7.4) and were allowed to
acclimate in the buffer for at least 1 hour before voltammetric recordings.
2.5.2 Electrode fabrication
Carbon fiber microelectrodes were made in-house by threading a single strand
carbon fiber (Goodfellow Oakdale, PA) of diameter 7 μm into a 10 cm long glass
capillary (dimensions o.d. 1.2 mm, i.d. 0.68 mm; A-M systems, Carlsborg, WA) using
vacuum suction. The glass capillary was then pulled into two equal halves using an
electrode puller (Model PE-21 with the following settings: main magnet = 90.7, submagnet = 23.2, and heater = 53.4; Narishige, Tokyo, Japan). There is a heating element
at the center of the electrode puller, which heats the center of the glass capillary,
stretching the glass capillary vertically until the magnetic force is the strongest, pulling
the capillary into two discrete electrodes. The pulled halves of the glass capillary had ~
4.4 mm glass taper which was tightly sealed around the glass-carbon fiber interface.
The carbon fiber protruded centimeters beyond the end of the taper was placed under a
microscope (Olympus, Tokyo, Japan) and trimmed using a scalpel to the length of 50 200 μm (Figure 2.2). The microelectrodes were stored at room temperature until they
were required for experimental use. When ready, they were backfilled with 0.15 M
potassium chloride and a lead wire (Squire Electronics Inc., Cornelius, OR) was
inserted to establish electrical contact. Silver/silver chloride reference electrodes
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(Ag/AgCl) were fabricated by coating a silver wire (250 µm in diameter; A-M Systems,
Carlsborg, WA) with silver chloride by anodizing (+1 V) the wire in 1 M hydrochloric acid
for 5 minutes.

Figure 2.3: Stepwise illustration of carbon fiber microelectrode fabrication.
Electrode fabrication was accomplished in three steps: aspiration of carbon fiber
into glass capillary, pulling of glass capillary and trimming carbon fiber extending
from glass capillary to a length of 50 – 200 µm.
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2.5.3 Microelectrode calibration
Following fabrication, the carbon fiber microelectrode was calibrated using flow
injection analysis to test for its viability and sensitivity. In this procedure, the
microelectrode was lowered vertically into one of the three ports of a flow T-cell. This
flow cell had the Ag/AgCl reference electrode sealed in it and one of the remaining two
ports of the cell was connected to a syringe pump which continuously pumped modified
aCSF (composition: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 2.4 mM CaCl2, 1.2
mM MgCl2, and 25 mM NaHCO3, and pH = 7.4) at a flow rate of 2 mL/min. The third
port was connected to a syringe that would be used to deliver a 3 µM dopamine (DA)
standard. During electrode calibration, 1 – 2 mL of the DA standard was manually
injected into the stream of modified aCSF. DA was detected at the microelectrode
surface when there was a rise in the current being measured. The calibration process
was repeated at least three times and the average of the maximum current obtained in
each injection was calculated by dividing the average current by the concentration of the
DA standard (3 µM). Besides calibrating the microelectrodes before use, a postcalibration of the microelectrode was performed after data collection from a mouse
brain. The post calibration factor obtained was used in determining the response factor
of the electrode for all data analysis.
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Figure 2.4: Flow injection analysis (FIA) set-up showing calibration of a
microelectrode. The microelectrode is calibrated using FIA. A) FIA set-up consists
of a flow T-cell connected to a Ag/AgCl reference electrode, a syringe pump
continuously supplying aCSF, and a another syringe containing 3 µM DA standard.
B) Background subtracted cyclic voltammogram of DA standard showing DA
oxidation and reduction peaks that identifies DA. C) Representative 3-dimensional
color plot of applied potential versus time versus current showing oxidation and
reduction current of DA in green and blue colors respectively. D) Current versus time
plot showing oxidation current (130 nA) generated from injection of 3 µM DA
standard. Injection of DA standard is repeated 3 times and the average of the
maximum current is divided by the concentration of the DA standard. The calibration
factor in the representative data is 130/3 = 43 nA/µM.
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2.5.4 FSCV data collection
Before voltammetric measurements were made, a recording chamber (Custom
Scientific, Denver, CO) was continuously perfused with oxygenated aCSF (aCSF for
voltammetric recordings) using a perfusion pump (Watson Marlow Limited, Falmouth,
England) set at a flow rate of 1 mL/min. The temperature of the chamber was adjusted
to 32 oC. The recording chamber where the slice would be placed had a submerged
Ag/AgCl reference electrode. A brain slice was placed into the slice holder where it was
submerged in aCSF. With the aid of a microscope, a bipolar tungsten stimulating
electrode (Plastics One, Roanoke, VA) and the carbon fiber microelectrode were then
lowered onto the brain surface in the striatum about 100 – 200 µm apart, while the
microelectrode was placed ~ 75 μm deep into the slice. All three electrodes were
connected to a head stage potentiostat (Dagan Corporation, Minneapolis, MN) and
were controlled by TH software (ESA Inc., Chelmsford, MA). To evoke DA release, a
single pulse electrical stimulation (monophasic, 350 μA, 60 Hz, and 4 ms pulse width)
generated by a Neurolog® stimulator (Digitmeter, Hertfordshire, England) was delivered
to the brain slice via the stimulating electrode. Evoked DA release was measured by
applying a potential to the microelectrode surface in the form of a triangular waveform (0.4 V versus a Ag/AgCl reference electrode, ramped to + 1.2 V and then back to - 0.4 V)
at a scan rate of 400 V/s. The DA response was measured by the electrode as current.
A single stimulation was applied to the brain slice every 5 minutes, and DA recordings
were measured for 15 seconds. When three successive DA release profiles were within
10% of each other with respect to current, then a stable baseline was considered and
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these pre-drug measurements were used to determine maximum stimulated DA release
and uptake.
2.5.5 FSCV data analysis
The DA release profiles were initially determined as current versus time, and by
using the post calibration factor (a conversion factor), the current was converted into
concentration. Once the results were in the form of concentration versus time, traces
were analyzed using LabVIEW™ National Instruments software (Austin, TX), where
each curve was fitted to a set of Michaelis-Menten based equations using nonlinear
regression.106,

110, 152-154

Stimulated DA release per electrical pulse ([DA]p) and DA

uptake kinetics expressed as maximum velocity of the DA transporter (Vmax) were
obtained by setting Km (which represents the affinity of DA to its transporter) to a fixed
value of a 160 nM, which allowed us to vary the [DA]p and Vmax. The goodness of fit was
determined by the coefficient of determination (R2) parameter generated by the software
(R2 values > 0.8 were used).
2.6 In vivo microdialysis
In vivo microdialysis was used to measure extracellular DA level during toluene
exposure. The microdialysis procedure involves stereotaxic surgery of a probe followed
by sample collection and analysis of dialysate samples.
2.6.1 Stereotaxic surgery
Prior to stereotaxic surgery, mice were transported to the laboratory and
weighed. Each mouse was placed into a chamber connected to isoflurane and oxygen
until the mouse was anesthetized. The mouse was removed from the chamber and
placed onto a heading pad (~ 37 °C) and covered with paper towels to maintain its body
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temperature. Isoflurane was delivered through a nosepiece. Then the pre-operative
preparation began. A small section of the animal’s fur covering the skull was shaved. To
protect the eyes from dehydration during the surgical procedure, sterile artificial tear
lubricant ophthalmic ointment was carefully applied to the eyes. The shaved area above
the skull was disinfected with betadine and 70% alcohol, and then a small incision was
made. The exposed skull was cleaned with 10% hydrogen peroxide to dissolve the thin
membrane covering the skull making Bregma visible. The mouse was placed into a
mouse stereotaxic frame (David Kopf Instruments, Tujunga, CA) where the anesthesia
plane was maintained by securing its nose to a tube connected to isoflurane and
oxygen, where their flow rates were adjusted as needed. The head of the mouse was
secured firmly on the frame using two non-puncture ear bars and a nose clamp so that
the top of the mouse’s skull was straight and stable. Bregma on the skull surface was
located, since coordinates for finding brain regions of interest are referenced using
Bregma. The coordinates used for the CPu were: anterior-posterior (AP) +0.80 mm,
lateral (L) -1.3 mm, and ventral (V) -2.5 mm; and NAc: anterior-posterior (AP), +1.2 mm;
lateral (L), -0.6 mm; ventral (V) -4.2 mm from Bregma, determined from a mouse brain
atlas and empirically refined.1 The coordinates for the CPu or the NAc were marked and
an approximately 1 mm diameter burr hole was drilled in the skull for guide cannula
placement. A second hole was drilled for a skull cap screw that does not require
coordinates. A CMA/7 guide cannula (CMA microdialysis, Chelmsford, MA) was
carefully lowered into the first hole. The guide cannula and the screw were firmly held in
place on the skull by dental cement, which was also used to cover any exposed area of
the skull. When the dental cement was dry, the mouse was taken from the stereotaxic
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frame and placed on a heating pad covered with a paper towel in a recovery chamber.
Following recovery from anesthesia (indicated by independent movement in the
recovery chamber), the mouse was transferred to a microdialysis bucket furnished with
bedding, food, and water.
2.6.2 Simultaneous collection of microdialysis samples and behavioral testing
during toluene treatment
Mice were allowed three days to fully recover from surgery before any behavioral
testing and dialysate samples were collected. Prior to sample collection, a dummy
probe in the guide cannula was removed and a microdialysis probe (CMA/7, 2 mm long
for CPu or 1 mm long for NAc, 240 µm diameter, 6 kDa molecular weight cut-off; CMA
Microdialysis, Chelmsford, MA) was inserted into the guide cannula. To measure
locomotor behavior and extracellular DA levels simultaneously, the mouse was placed
in an experimental chamber (glass tank of dimensions: 41 cm length x 20.3 cm width x
25.5 cm height) housed in a fume hood. The chamber was modified to allow
microdialysis sampling lines through a small hole in the lid. The chamber was equipped
with IR emitter-detector arrays (Med Associates, St. Albans, VT) located outside of the
chamber permitting locomotor activity of the mouse to be monitored during sample
collection. ACSF (composition in mM: 147 NaCl, 3.5 KCl, 2 Na2HPO4, 1.0 CaCl2, 1.2
MgCl2, and pH 7.4) was perfused through the probe overnight at a flow rate of 0.4
μL/min. The next day at approximately 0900 h, the flow rate of the perfusing aCSF was
increased to 1.1 μL/min (sampling from CPu) or 0.8 μL/min (sampling from NAc) for an
equilibration time of 1 hour prior to baseline sample collection. Dialysate samples were
collected in 15-minute fractions from the freely moving mouse before and during toluene
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exposure, during recovery from toluene exposure, and post recovery. During the post
recovery phase of dialysis collection, the regular aCSF was switched to a high K +
concentration aCSF buffer (composition in mM: 60 KCl, 89 NaCl, 2.0 Na 2HPO4, 1.0
CaCl2; 1.2 MgCl2; pH 7.4), and perfused through the microdialysis probe for 15 minutes,
after which it was switched back to regular aCSF. The infusion of high K + aCSF directly
into the striatum stimulates neurotransmitter release and enables evaluation of the
resulting changes in extracellular DA levels in toluene exposed and air-control mice.
Meanwhile, locomotor activity was simultaneously monitored by the count of
interruptions in the IR beams attached to the outside of the chamber generating analog
signal recorded by automated activity software (Open Field Activity Software). Toluene
exposure was accomplished using a dynamic exposure system equipped with Praxair
flow regulators, porter mass flow meters, and a Med PC interface that regulated the
amount of toluene vapor administered. During toluene exposure, toluene vapor was
generated by bubbling regulated amounts of air through toluene in a flask. The vapor
was channeled through tubing, where it was diluted with controlled amounts of air to
produce the desired concentration of toluene vapor (4000 ppm) that was perfused
through the experimental chamber for 30 minutes (Figure 2.1). The settings on the
dynamic system that produced the desired toluene concentration were obtained by
adjusting the regulators while monitoring and measuring toluene concentration in the
chamber prior to the experiment using a single wavelength-monitoring IR spectrometer.
During the recovery phase or air-control experiment, the toluene bubbler was turned off
to allow only air to perfuse through the chamber.
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Figure 2.5 Dynamic toluene exposure set-up for simultaneous monitoring of
locomotor activity and dialysate sample collection. By opening the first valve on
the air regulator, air was bubbled through toluene in the flask to generate toluene
vapor that was diluted with air in the tubing regulated by the second valve. The
amount of toluene perfused into the chamber was controlled by Praxair flow
regulators, porter mass flow meters, and a Med PC interface. Dialysate samples were
collected from free moving mouse in the experimental chamber through perfusion of
aCSF from the syringe through the microdialysis probe to sample small molecules
such as neurotransmitters from the brain region of interest. Simultaneously, locomotor
activity was monitored by the count of interruptions in the IR beams attached to the
chamber that generate analog signal recorded by automated activity software on the
computer.
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2.6.3 Sample analysis using high performance liquid chromatography (HPLC)
All collected dialysate samples were stored in a -80 oC freezer and analyzed
within two weeks of collection. HPLC with electrochemical detection was used to
separate and analyze samples by manually injecting 20 µL of dialysate samples (CPu
samples with 5 µL storage buffer consisting of 0.2 M perchloric acid, 0.2 µM ascorbic
acid, and 0.2 µM EDTA) or 10 µL (samples from the NAc) into a 20 or 10 µL injection
loop respectively. The mobile phase consisted of 75 mM NaH 2PO4, 3 mM 1octanesulfonic acid, 0.125 mM ethylenediaminetetraacetic acid (EDTA), 9% acetonitrile,
0.2 - 0.5% triethylamine, and pH = 3.0. The analytes were separated on a C 18 column
(Luna 100 x 3 mm, C18, 2.6 μm column; Phenomenex, Torrance, CA) using an isocratic
LC-20AD pump (Shimadzu, Columbia, MD) operated at a flow rate of 0.4 mL/min. DA
was electrochemically detected using an ESA 5014B microdialysis cell (E1 = -150 mV;
E2 = +220 mV; ESA Coulochem III) with an in-line ESA 5020 guard cell positioned
before injection loop. The voltage of the guard cell was set at +350 mV. Separation and
quantification of the analytes were controlled by LC Solutions Software (Shimadzu,
Columbia, MD). DA standards were run after the experiment and DA’s retention time
was between 7 – 8 minutes. Integration and quantification of the DA peak area were
performed against known concentrations of DA standards.
2.7 Histological verification of microdialysis probe placement
After microdialysis experiments, mice were sacrificed by CO2 narcosis,
decapitated, and their brains were removed. The brains were stored in 3.7%
formaldehyde solution until used for histological verification. Briefly, brains were
transferred into 2% dye and allowed to sit for about 18 hours. The brains were then
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removed from the dye and rinsed 3 times each with 95% ethanol and water and were
placed in 70% ethanol. Excess dye was washed off the brains by shaking in a 70%
ethanol solution for 3 - 4 hours by affixing vials on a plate shaker. The solution was
changed to a fresh 70% ethanol solution and allowed to shake overnight. The next day,
the brains were rinsed with 95% ethanol solution by sitting them in the solution for 30
minutes, followed by water wash where they were not shaken for 45 minutes. The
brains were wiped dry and fixed in 2% agarose solution (Agarose, type 1, Molecular
Biology Grade, 15 - 30 °C). After the agarose solidified with the imbedded brain, the
brains were sliced into 150 µm coronal slices with a vibratome until slices from the
striatal complex containing the CPu and NAc were obtained. The slices were viewed
under a microscope (Olympus SZX7) and photomicrographs of the track of the
microdialysis probe in the striatum were taken.
2.8 Brain tissue content analysis of dopamine and its metabolites following
toluene exposure
Following acute or repeated toluene inhalation, mice were sacrificed by cervical
dislocation after which their brains were rapidly removed and placed on a petri dish
covered with a paper towel soaked with ice cold aCSF (composition in mM: 147 NaCl,
3.5 KCl, 2 Na2HPO4, 1.0 CaCl2, 1.2 MgCl2, and pH 7.4). The mouse brains were
dissected and tissues were quickly taken from the brain regions of interest (the CPu and
NAc). The dissected regions of interest were placed in labeled tubes, which were
immediately frozen in liquid nitrogen and stored at -80 °C. On the day of analysis
samples were weighed and then prepared for homogenization by adding 200 µL (NAc
samples) or 250 μL (CPu samples) 0.1 M HClO4 to each sample. The samples were
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then homogenized using a Misonix MicrosonTM ultrasonic cell disruptor (continuous, 12 15 one second per pulse at 50% duty, 3 - 4 microtip setting; Misonix Incorporated,
Farmingdale, NY). The homogenates were centrifuge at 12,000 rpm for 10 minutes in a
refrigerated tabletop centrifuge (Eppendorf centrifuge 5424, Eppendorf AG, Hamburg,
Germany) and aliquots of the supernatant were analyzed for DA and its metabolites;
3,4-dihydroxyphenylacetic

acid

(DOPAC),

homovanillic

acid

(HVA),

and

3-

methoxytyramine (3-MT) using HPLC with an electrochemical detector. The HPLC and
electrochemical settings for tissue content were the same as was previously reported in
the microdialysis section (see Section 2.6.3). The results were analyzed by integration
of peak areas against calibration curves obtained from standards of DA and its
metabolites and expressed as nM concentration. The remaining supernatant of the
samples were used for protein analysis, which involves colorimetric detection and
quantification of total protein from the tissue sample. Bovine serum albumin (BSA)
standards (20 µL) or the tissue content samples were diluted with 30 µL distilled water
and then 1 mL bicinchoninic acid (BCA) working reagent (50:1, BCA Reagent A: BCA
Reagent B) was added to each sample. The content of each tube was mixed well and
incubated in a 37 °C for 30 minutes in an Isotemp 205 Water Bath (Fisher Scientific,
Pittsburgh, PA). After incubation, the tubes were cooled to room temperature and 200
µL of their contents were pipetted into 96-well microplate and analyzed on a VersaMax
ELISA Microplate Reader (Molecular Devices, Sunnyvale, CA) using SoftMax Pro
software to obtained µg of protein in tissue. Tissue content DA and its metabolites were
expressed as ng per mg protein.
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2.9 Statistical data analysis
All behavioral (locomotor) data were analyzed with SPSS statistical software
where data for acute toluene exposures was analyzed using a 3 x 10 repeated
measures analysis of variance (ANOVA) with toluene treatment (0, 2000, and 4000
ppm) as the between subjects factor, and the 3-minute time blocks as the withinsubjects factors. Locomotor data from the repeated toluene experiment were analyzed
using a 3 x 7 x 10 repeated measures ANOVA with toluene treatment (0, 2000, and
4000 ppm) as the between subjects factor with days and 3-minute time blocks as the
within-subjects factors. Significant main effects and interactions were determined using
Tukey’s post hoc contrasts and simple main effects analyses. Statistical analyses of all
data from neurochemical measurements (slice SFCV, in vivo microdialysis, and tissue
content analysis) were performed using GraphPad Prism Software (GraphPad Software
Inc., San Diego, CA) and statistical significance determine by Student’s t-test, one-way,
or two-way ANOVA followed by appropriate post-hoc tests. All data were expressed as
mean ± standard errors of the means (SEM) where differences were considered to be
statistically significant when P < 0.05.
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CHAPTER 3
Striatal Dopamine Dynamics in Mice Following Acute and
Repeated Toluene Exposure
Adapted from:
Apawu, A. K., Mathews, T. A., Bowen, S. E., “Striatal Dopamine Dynamics in Mice
Following Acute and Repeated Toluene Exposure”, in revision for Psychopharmacology.
3.1 Introduction
Toluene is inhaled by individuals to achieve intoxication.41,

43, 142

The repeated

deep inhalation of solvents like toluene can result in effects similar to alcohol
intoxication with diminished mental and physical capabilities.41 While research on
inhalants lags behind other drugs of abuse, the last decade has resulted in a significant
increase in knowledge about inhalants’ pharmacological properties and their effects.37,
41, 51, 142

Preclinical models of acute inhalant exposure have shown an extensive range

of neurobehavioral effects that are concentration-dependent, reversible, and occur at
concentration levels which are much lower than those necessary to produce explicit
toxicological signs.37, 43, 56 A growing number of preclinical studies demonstrate that
toluene influences a variety of neurotransmitter systems including, dopamine (DA),
gamma-aminobutyric acid (GABA), and glutamate (see review37). Toluene, like other
drugs of abuse, has been shown to elevate extracellular DA levels in the prefrontal
cortex
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and in the nucleus accumbens (NAc),36, 143 which is consistent with toluene’s

reported rewarding effects. However, the neurochemical adaptions within the striatum
following toluene exposure are not completely understood. Specifically, it is unclear
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whether increases in extracellular DA levels are due to alterations in DA release and/or
uptake mechanisms following toluene exposure.
The present experiments were designed to explore the neuro-adaptations of
striatal DA release and uptake mechanisms using slice fast scan cyclic voltammetry
(FSCV) following acute and repeated toluene inhalation. Toluene concentrations of
2000 and 4000 ppm were chosen because they are behaviorally stimulating.74, 155-157 A
major advantage of using FSCV to probe presynaptic DA dynamics is its high temporal
resolution, which is on the order of milliseconds, and it provides the ability to
differentiate DA release and uptake parameters.
3.2 Hypothesis
Based on acute toluene exposure as measured by microdialysis,36,

71, 143

we

hypothesized that, following acute toluene exposure, we would observe a dosedependent increase DA release, while decreasing DA uptake in the striatum. Although
there are no neurochemical measurements evaluating striatal DA after repeated toluene
exposure, we hypothesized that following repeated toluene exposure (i.e., withdrawal),
we would observe an opposite effect (as observed with other abused compounds 158, 159)
with a decrease in both DA release and uptake in the striatum.
3.3 Materials and Methods
The materials and methods used are as described in chapter 2, with, specific
details provided here. Toluene vapor exposure and locomotor activity measurements
were conducted using the procedure in sections 2.3 and 2.4, respectively. Briefly, after
being weighed, mice were placed into an exposure chamber, given 5 minutes to
acclimate, and then exposed to toluene or air vapors for 30 minutes during which time
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locomotor activity was recorded. Chambers were opened to diffuse toluene vapors and
locomotor activity was recorded for an additional 30 minutes recovery period. For each
concentration of toluene (0, 2000, or 4000 ppm), the amount of toluene injected was
calculated using the ideal gas equation, simplified for room temperature.151 Mice were
used in either an acute (single day) or repeated (7 days) toluene or air (control)
exposure. Prior to slice FSCV measurements, brain slices were obtained approximately
45 minutes after acute toluene or 24 hours after repeated toluene exposure. Electrically
stimulated DA release was evoked every 5 minutes using a single electrical pulse and
the response was measured with a carbon fiber microelectrode. After stable release
recordings (> 30 minutes), toluene was dissolved in increasing concentrations (0.01 –
10 mM) into oxygenated artificial cerebrospinal fluid (aCSF) and each concentration
was perfused over the slice for 30 minutes during which DA release and uptake were
measured. The peak oxidation current for DA was converted into concentration based
on a post-calibration factor calculated by calibrating the microelectrode with 3 µM DA.
3.3.1 Data Analysis
Locomotor activity was analyzed with SPSS software. Acute toluene data were
analyzed using a 3 x 10 repeated measures analysis of variance (ANOVA) with toluene
treatment (0, 2000, and 4000 ppm) as the between-subjects factor, and the 3-minute
time blocks as the within-subjects factors. Repeated toluene data were analyzed using
a 3 x 7 x 10 repeated measures ANOVA with toluene treatment (0, 2000, and 4000
ppm) as the between-subjects factor, with days and the 3-minute time blocks as the
within-subjects factors. An alpha level of P < 0.05 determined statistical significance.
Tukey’s post hoc contrasts and simple main effects analyses were used to determine
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the significant main effects and interactions. Statistical analysis of voltammetry data was
performed using GraphPad Prism Software. The criteria for statistical significance for
DA release and uptake parameters were set to P < 0.05. Statistical significance was
determined by one-way ANOVA with Dunnett's Multiple Comparison Test. All data are
reported as mean ± standard errors of the means (SEM).
3.4 Results
3.4.1 Distance traveled during and following acute toluene exposure
As seen in Figures 3.1A and B, a significant main effect was observed for acute
toluene exposure (F2,53 = 12.25, P < 0.001), time (F9,477 = 2.01, P < 0.05), as well as a
significant time x toluene interaction (F18,477 = 2.14, P < 0.01). Post hoc analysis
revealed that acute exposure to 2000 and 4000 ppm toluene significantly increased
locomotor activity of mice across the 30 min exposure period as compared to the aironly controls (P < 0.01) with no significant differences between the 2000 and 4000 ppm
concentrations.
Recovery from acute toluene exposure also resulted in concentration-dependent
effects in locomotor activity (Figures 3.1A and C). Significant main effects were
observed for toluene treatment (F2,53 = 17.95, P < 0.001), time (F9,477 = 53.76, P <
0.001), as well as a significant time x toluene interaction (F18,477 = 8.20, P < 0.01). Post
hoc analysis revealed that previous exposure to both concentrations of toluene
significantly increased locomotor activity of mice as compared to the air-only controls (P
< 0.01), with activity decreasing significantly over 30 min to levels comparable to aircontrols.
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Figure 3.1: Locomotor activity during and after acute toluene exposure. A) A
plot of distance traveled (cm ± SEM) versus time (3 minute bins) with three defined
partitions, from left to right: 5 minute acclimation, 30 minute toluene exposure, and
30 minutes recovery period. B) Effect of acute toluene exposure on total distance
traveled. C) Total distance traveled during recovery from acute toluene exposure.
Statistical significance was determined using one-way ANOVA with Dunnett's
Multiple Comparison Test. ***P < 0.001 (air-control, n = 15; 2000 ppm, n = 15; 4000
ppm, n = 15).
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3.4.2 Striatal dopamine release and uptake following acute toluene exposure
Striatal DA release and uptake (in caudate putamen (CPu), NAc core and shell)
were compared between air-controls (Figure 3.2) and mice receiving acute toluene
exposure (0, 2000, or 4000 ppm) followed by a 30-minute withdrawal period.
Voltammetry data from control (air) mice had the highest stimulated DA release and DA
uptake rates in the CPu, followed by the NAc core, then NAc shell, consistent with
previously reported regional differences in DA release/uptake dynamics in the
striatum160-164. One-way ANOVA with Dunnett's post test revealed that 45 minutes after
acute exposure to 4000 ppm toluene produced significant elevation in electrically
evoked DA release (Figure 3.2C) across the sub-anatomical brain regions in the
striatum (CPu: F2,134 = 3.80; P < 0.05, NAc core: F2,93 = 5.22; P < 0.01, and NAc shell
F2,60 = 5.37; P < 0.05) compared to control mice. Acute toluene (2000 and 4000 ppm)
exposure had no effect on DA uptake rates across the striatal regions (Figure 2D, CPu:
F2,134 = 2.51; P > 0.05; core: F2,93 = 1.36; P > 0.05, shell F2,60 = 2.06, P > 0.05).
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Figure 3.2: Acute toluene exposure increases electrically stimulated DA
release with no effect on DA uptake. A) Toluene exposure and neurochemical
protocol. Forty-five minutes after acute toluene exposure the brains were harvested
and DA release and uptake dynamics were assessed in the striatum. B)
Representative cyclic voltammograms (inset) and concentration versus time traces.
C) Stimulated DA release after a single 30-minute exposure to 0, 2000, or 4000 ppm
of toluene. D) DA uptake rates across sub-anatomical brain regions of the striatum.
Data are expressed as means ± SEMs (n = 6-12/brain region). Statistical
significance was determined by one-way ANOVA with Dunnett's Multiple
Comparison Test; where *P < 0.05, **P < 0.01.
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To determine if direct application of toluene on a brain slice influences DA
release and uptake dynamics, cumulative concentrations (0.01, 0.03, 0.1, 0.3, 10 mM)
of toluene were perfused over brain slices from either air-control or 4000 ppm toluene
exposed animals. Electrically evoked DA release was measured every 5 minutes for 30
minutes for each dose of toluene. Both control and 4000 ppm toluene mice showed a
decrease in electrically evoked DA when toluene was directly applied to the slice.
However, acute toluene exposure (4000 ppm) shifted the dose response curve to the
right compared to the control mice (Figure 3.3). The half maximal inhibitory
concentration (IC50) was significantly reduced (for toluene-exposed mice (IC50 not
reported because plot is not sigmoidal) compared to control mice (174 ± 2 μM;
Student’s t-test, P = 0.01, n = 4-5/ treatment group), suggesting toluene exposed mice
are less sensitive to the effects of toluene perfusion. Additionally, the decay side of the
concentration versus time curve was evaluated, which showed that DA uptake was
significantly reduced at concentrations equal to and greater than 0.03 and 0.10 mM in
air- and toluene-treated mice, respectfully (Figure 3.4).
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Figure 3.3: Right shift in toluene dose response curve after previous
exposure to toluene. Electrically evoked DA release was assessed during
perfusion of cumulative concentrations of toluene over the CPu. The shift in the
dose-response curve to the right suggests that toluene exposed mice are less
sensitive to direct application of toluene compared to air-controls. P = 0.01, n = 45/treatment group, Student’s t-test.
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Figure 3.4: DA uptake during perfusion of cumulative concentrations of toluene
over the CPu. A) Toluene exposure and neurochemical protocol. B) Effect of toluene
perfusion on DA uptake was measured from air-control mice and C) from mice
acutely exposed to 4000 ppm of toluene. Data are expressed as means ± SEMs (n =
4-5/treatment group). Statistical significance was determined by one-way ANOVA
with Dunnett's Multiple Comparison Test; where ***P < 0.001, **P < 0.01, *P < 0.05,
compared to air-control.
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3.4.3 Distance traveled during and following repeated toluene exposure
As seen in the exposure panels of Figure 3.5, repeated toluene treatment had a
significant main effect (F2,43 = 3.37, P < 0.05). There was also a main effect for Day
(F6,258 = 7.69, P < 0.001), and a significant Day x Toluene treatment interaction (F 12,258 =
3.72, P < 0.001). Significant main effects were also observed for Time block (F9,387 =
1.89, P = 0.05), and for the Time block x Toluene treatment interaction (F 18,387 = 1.61,
P = 0.05). As shown in Figure 3.5E and F, repeated toluene treatment produced
increases in locomotor activity across the exposure session and across days of
exposure with 4000 ppm of toluene producing the greatest increases in activity (P <
0.05).
As seen in the recovery panels of Figure 3.5, recovery from repeated toluene
treatment produced a concentration-dependent effect in locomotor activity with patterns
of locomotor activity changing when toluene was cleared from the chamber. There was
no main effect for Toluene treatment or for Day (P > 0.05). There was a significant Day
x Toluene treatment interaction (F12,258 = 2.82, P < 0.01). In general, activity decreased
across exposure days with locomotor activity after the 4000 ppm toluene exposure
producing the greatest decrease. A significant main effect was observed for Time block
(F9,387 = 45.27, P < 0.001) and for the Time block x Toluene treatment interaction (F 18,
378

= 5.28, P < 0.001). During the recovery period, locomotor distance traveled

decreased as the session progressed with toluene animals being more active initially
and less active finally than their air-controls.
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Figure 3.5: Locomotor activity during and after repeated toluene exposure.
The effects of 0 (air-control), 2000, or 4000 ppm inhaled toluene on mouse
locomotor activity. The left-most partition of each graph represents a 5 minute
acclimation period, the middle partition represents 30 minute toluene exposure,
with the right partition representing 30 minute post toluene exposure. The distance
traveled by mice was measured during and after toluene exposure and analyzed
using repeated measures ANOVA with toluene treatment (2000 or 4000 ppm) as
the between subjects factor, and the 3 minute time blocks as the within-subjects
factors. A) A plot of distance traveled (cm ± SEM) versus time (3 minute bin) for
air-control. B) A plot of distance traveled (cm ± SEM) versus days of toluene
exposure (days 1, 4, and 7 selected for simplicity). C) Distance traveled (cm ±
SEM) versus time (3 minute bin) for 2000 ppm toluene treatment with
corresponding D) distance versus day plot. E) A plot of distance traveled (cm ±
SEM) versus time (3 minute bin) and F) distance-day plot for repeated 4000 ppm
toluene treatment. Statistical significant main effects and interactions were
determined by Tukey’s post hoc contrasts and simple main effects analyses (aircontrol, n = 14; 2000 ppm, n = 16; 4000 ppm, n = 16).
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3.4.4 Striatal dopamine dynamics after repeated toluene exposure
Electrically evoked DA release was measured in the three discrete sub-regions of
the striatum 24 hours after 7 days of either 2000 or 4000 ppm of toluene exposure.
Repeated toluene exposure following withdrawal had no effect on stimulated DA release
(F2,85 = 0.388, P > 0.05; Figure 3.6C) or DA uptake in the CPu in either 2000 or 4000
ppm toluene exposure when compared to control mice (F2,85 = 0.265, P > 0.05; Figure
3.6D).
After repeated toluene exposure and a 24 hour withdrawal period, there was a
significant decrease in electrically evoked DA release in the NAc core (F2,67 = 15.4, P <
0.001, Figure 3.6C) and shell (F2,54 = 13.9, P < 0.001, Figure 3.6C) compared to their
air-controls. After seven days of repeated toluene exposure, electrically-stimulated DA
release from the NAc core had an approximately 25% reduction in DA release in 2000
and 4000 ppm toluene exposed mice, (2000 ppm: 0.6 ± 0.03 µM; n = 9, 4000 ppm: 0.6
± 0.04 µM; n = 6) compared to air-controls (0.8 ± 0.05 µM; n = 6, Figure 3.6C). In a
similar manner, repeatedly exposed toluene-treated mice had an approximately 25 and
50% decrease in evoked DA release in the NAc shell of 2000 and 4000 ppm toluene
exposed mice respectively (2000 ppm: 0.3 ± 0.02 µM; n = 7, 4000 ppm: 0.2 ± 0.03 µM;
n = 4) compared to air-controls (0.4 ± 0.02 µM; n = 8, Figure 3.6C). An inherent
advantage of using FSCV is its ability to resolve DA release and DA uptake. DA uptake
rates from the NAc core and shell were not different after repeated toluene exposure
following withdrawal compared to their air-controls (Core: F2,67 = 0.932, P > 0.05, Shell:
F2,54 = 0.182, P >0.05, Figure 3.6D).
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Figure 3.6: Repeated exposure to toluene attenuates electrically stimulated DA
release but not uptake in the nucleus accumbens (NAc). A) Toluene exposure
and neurochemical protocol. B) Representative cyclic voltammograms (inset) and
concentration versus time traces for the measurements in the NAc core. Below the
concentration versus time traces are corresponding color plots, where the x-axis
represents time in seconds, the y-axis is the applied potential of the triangular
waveform, and the current is shown in color. The triangle below the color plots
indicates the point of electrical stimulation. C) Maximum electrically-evoked DA
release from air-control, 2000, and 4000 ppm repeated toluene exposed mice across
sub-anatomical brain regions in the striatum. D) DA uptake rates after repeated
toluene treatment. Data are expressed as means ± SEMs (n = 4 -10/treatment
group). Statistical significance was determined by one-way ANOVA with Dunnett's
Multiple Comparison Test; where ***P < 0.001 compared to air-control.
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3.5 Discussion
The present study was undertaken to evaequate the components of the striatal
DA system following acute and repeated toluene exposure (2000 or 4000 ppm) by using
slice FSCV, a technique with millisecond temporal resolution allowing for differentiation
of DA release and uptake parameters. Previous studies have shown that acute and
repeated toluene administrations alter locomotor activity as well as striatal DA
dynamics.36, 56, 68, 143 However, the neurochemical reports to date have focused mainly
on how toluene influences striatal dopaminergic changes using microdialysis, which
does not provide the temporal resolution to tease apart contributions from release and
uptake. In the present study, slice voltammetry revealed that stimulated striatal DA
release was potentiated after an acute exposure to 4000 ppm of toluene with no effect
on striatal DA uptake. A single exposure to toluene resulted in a decreased sensitivity to
increasing concentrations of toluene perfusion compared to their air-control. To better
understand how the striatal complex adapts to the neurobiological changes of repeated
toluene exposure, a 7-day toluene protocol followed by a 24 hour withdrawal period was
evaluated. Unlike acute toluene exposure, repeated toluene exposure attenuated DA
release in the NAc at all doses with no difference in DA uptake rates, while there were
no differences in either DA release or uptake in the CPu. Together, these findings point
to the ability of toluene to differentially regulate pre-synaptic DA release depending on
the exposure and withdrawal length with no effect on DA uptake across the striatum.
Behaviorally, acute 30 min toluene exposure to either 2000 or 4000 ppm
increased locomotor behavior above what was observed for air-control animals and
these increases in activity were observed for approximately 30 min post exposure.

67

These results are similar to the increases in locomotor activity reported for acutely
inhaled toluene and extend earlier work demonstrating dose-dependent increases in
locomotor activity at concentrations between 500 to 5000 ppm with the largest
increases occurring in the range of 2000 to 5000 ppm.68, 156, 165, 166
Neurochemically, this FSCV study provides important insight on how toluene
influences DA release in acute and repeated toluene exposure models, while
demonstrating toluene inhalation following withdrawal does not alter DA uptake in the
striatum. After a single 4000 ppm toluene exposure there was significant potentiation in
electrically-stimulated DA release across the sub-regions of the striatal complex, while
there was no difference in DA uptake rates. Previous microdialysis studies suggested
that the rise in extracellular DA levels was a reduction of DA uptake attributed to
toluene.143 A limitation of using microdialysis to interpret release and uptake parameters
is that it does not have the temporal resolution to separate these components, but slice
voltammetry does. Although our coronal slices contain only the striatal terminals and
lacks input from the midbrain regions such as the ventral tegmental area and substantia
nigra, toluene exposure prior to FSCV demonstrated significant potentiation in DA
release even with a 30 min recovery period. Taken together, the FSCV results
demonstrate the sensitivity of slice FSCV to measure these subtle but persistent DA
changes after toluene inhalation followed by a 30 min recovery period. Finally, our slice
voltammetric data suggests that acute toluene inhalation has no direct effect on DA
uptake across the striatum.
Together, these results suggests that acute exposure to 4000 ppm toluene alters
the DA release mechanism in the CPu, which was further supported by results acquired
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after direct application of toluene over the slice. Unlike acute toluene exposed mice, airtreated mice had a significant decrease in electrically evoked DA when toluene was
directly applied indicating that toluene itself has the ability to influence DA release.
Despite these large concentrations (> 0.01 mM) of toluene, slice FSCV results suggest
that toluene is interacting directly at the DA terminal; however, its target is unknown.
The toluene dose-response curve is not like DA receptor agonist dose response
curves110,

167,

168

, as it does not asymptotically approach zero at the highest

concentrations of toluene perfusion. Instead the toluene dose response curves for both
air- and toluene-treated animals asymptotically approaches 70% and 90%, respectively
(an ~ 30% and ~ 10% reduction in stimulated DA release) suggesting that toluene may
be acting upon non-dopaminergic receptors such as N-methyl-D-aspartate (NMDA)
receptors, metabotropic glutamate receptor, or the nicotinic receptor, mediating this
response (for review see Bowen et al. 2006

37

). To determine which of these receptors

may be responsible for the decrease in DA release, future experiments should evaluate
antagonists of these receptors to determine if they can block the effects of direct
application of toluene. Interestingly, when acute concentrations of toluene were directly
applied to the slice, FSCV detected a decrease in DA uptake rates in air- and toluene
treated mice (Figure 3.4). The main objective when applying toluene directly to brain
slices was to evaluate DA release dynamics, even so we discovered that considerably
high toluene concentrations had to be used to induce subtle but significant changes in
the DA dose response curve. Thus, there appears to be a divergent effect on DA
transport kinetics depending on the route of administration of toluene. For example,
toluene inhalation followed by a 30 minute recovery phase does not influence DA
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uptake rates, while direct application of toluene causes a significant decrease in DA
uptake in both air- and toluene treated animals. Future studies, should further evaluate
these route difference in administering toluene; in particular, evaluation of DA uptake
immediately after toluene inhalation versus direct application. Overall, the acute toluene
FSCV results demonstrate that either pretreatment with toluene inhalation or direct
application of toluene leads to alterations in DA release, while only direct application of
millimolar concentrations of toluene decreases DA uptake in the CPu.
As compared to acute exposures, repeated administrations of toluene (4000
ppm) over 7 days resulted in increased locomotor activity across days of exposure with
marked decreases in electrically-stimulated DA release observed in the NAc core and
shell 24 hrs after the last toluene exposure. The increases in locomotor activity with
repeated exposure to 4000 ppm toluene in the present study are similar to previous
reports for inhaled toluene and other abused solvents 64,

74, 157, 169, 170

and can be

interpreted as sensitization to toluene. Previous studies have also reported
development

of

sensitization

after

toluene

was

repeatedly

administered

intraperitoneally38, 84, 171 or orally.72 Conversely, examination of the recovery data (see
Fig. 3.5E, right side) shows that animals returned to baseline levels more quickly as the
days of repeated exposure continued, suggesting the development of tolerance to
toluene’s stimulating behavioral effects. These observed effects of toluene are similar to
other investigations that have reported the emergence of tolerance after repeated
exposure to several abused inhalants.169, 172
Using slice FSCV to evaluate 7-day toluene exposure followed by 1-day of
withdrawal, our repeated toluene results showed no difference in DA uptake rates
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throughout the striatal complex as observed for the acute toluene inhalation. Therefore,
toluene’s mechanism of action after a withdrawal period does not appear to be like other
drugs of abuse (e.g., cocaine, methylphenidate, or amphetamines) that inhibit or
reverse the direction of the DA transporter to elevate extracellular DA levels in the
striatum. Instead, both the acute and repeated toluene inhalation following withdrawal
resulted in altering stimulated DA release dynamics in the striatal terminal most likely
through a heteroreceptor.
Repeated 2000 and 4000 ppm toluene exposure followed by 1-day of withdrawal
induced a significant reduction in evoked-DA release in both the NAc core and shell,
suggesting repeated exposure to toluene may be brain region specific since presynaptic
DA release in the CPu remained unchanged after 7 days of repeated toluene exposure.
This is the first FSCV study to evaluate DA dynamics after repeated toluene exposure
following 1-day of withdrawal. Slice FSCV results demonstrated that repeated toluene
exposure lead to specific dopaminergic changes in the NAc. The fact that this
attenuation in stimulated DA release was not observed immediately after acute toluene
exposure suggests that repeated exposure induces significant neurobiological changes
(i.e., sensitization) in the NAc.
There are numerous reports on the acute effects of toluene on striatal
dopaminergic dynamics, but relatively little neurochemical evidence of repeated
exposure after a sub-chronic or chronic toluene protocol and even fewer following a
withdrawal period. Few studies have evaluated the dopaminergic tone after repeated
toluene exposure, and those that have used various doses and exposures of toluene.
Long-term toluene (80 ppm and higher) exposure leads to an increase in DA D2 agonist
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affinity in the CPu, but DA D2 expression is not different.173 A tissue content study
demonstrated that DA catabolism was decreased in the putamen of rats after subchronic toluene (40 ppm) exposure, which was attributed to a decreased DA
degradation rate as the DA/DOPAC was elevated. Further, repeated toluene exposures
in rats potentiated the extracellular DA response in the NAc to cocaine.75 However,
baseline DA levels in the NAc were not different between the repeated saline and
toluene treated animals.75 Our slice FSCV results would suggest that a decrease in
stimulated DA release could possibly reflect lower amounts of DA in the terminal, which
could lead to decreased extracellular DA levels in the striatum. However, since DA
uptake is not altered it is possible that the change in DA release is not sufficient to
influence extracellular DA levels. Although extracellular DA levels were not different in
the microdialysis study by Beyer et al., this could be a result of the different
experimental procedures: 1) toluene levels of 8000 ppm versus 2000 or 4000 ppm, 2)
an intermittent repeated exposure (5 days with 2 days off followed by 5 days) versus 7
continuous days of repeated toluene exposure followed by 1 day of withdrawal, 3)
species differences (rats versus mice), and/or 4) quantitative microdialysis was not used
to evaluate basal DA levels. The attenuation in electrically-stimulated DA release in the
NAc after repeated toluene exposure could be a result of a compensatory down
regulation of the DA system; although further studies are required to verify this
hypothesis. In order to have a more comprehensive understanding of striatal and
accumbal effects of toluene, other neurotransmitter systems like GABA or glutamate
should also be evaluated. Taking the acute and repeated toluene exposure followed by
a withdrawal period together, our observations highlight the biphasic DA release
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response to toluene exposure depending on whether it was acutely or repeatedly
administered. These changes in striatal DA release are not a result of toluene
interacting with the DA transporter, since our FSCV results showed no difference in DA
uptake either after acute or repeated toluene exposure.
3.6 Conclusions
In summary, the present studies extend earlier work showing that acute and
repeated exposure to toluene potentiates locomotor activity. Acutely, toluene exposure
elevated stimulated DA release across the striatum, while repeated toluene inhalation
followed by 1 day of withdrawal attenuated DA release in the NAc regions only. Whether
toluene exposure is acute or repeated, DA uptake rates were not different across the
striatum, suggesting that toluene has no effect on DA transporter kinetics. Furthermore,
the toluene dose-response curve emphasizes that direct application of toluene to the
slice augments both terminal DA release and DA uptake, albeit through what receptor
sub-type toluene is influencing DA release is currently unknown.
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CHAPTER 4
An In-depth Examination of Acute Toluene Exposure on Striatal
Dopamine System
4.1 Introduction
The impact of toluene inhalation on the dopamine (DA) system has been of great
interest due to the central role DA plays in addiction and reward seeking behaviors.174177

Since increases in dopaminergic neurotransmission, particularly at the mesolimbic

terminal such as the nucleus accumbens (NAc) has been associated with the locomotor
stimulatory effect of drugs of abuse,141, 171 a number of studies have utilized behavioral
assays together with neurochemical and/or physiological techniques to understand
toluene’s action in the DA terminal regions.36, 71, 83, 171, 178 While the current behavioral
and neurochemical/physiological data available suggest that toluene can alter DA
neurotransmission, the neural mechanisms underlying toluene’s action on the DA
system are still not well understood.36, 38, 83, 143, 166, 179 In our initial characterization of the
behavior and neurochemical effect of toluene inhalation (Chapter 3), we showed that
acute exposure to 2000 and 4000 ppm toluene increased locomotor activity of mice
while, neurochemically, 4000 ppm toluene inhalation potentiated electrically stimulated
DA release across the caudate putamen (CPu) and the NAc (Figure 3.2). These
observations have led to numerous questions that need to be addressed in order to
better understand how toluene interacts with the DA system.
One such question is “How does acute toluene exposure exert immediate effect
on the DA dynamics, considering that neurochemical measurements were made after
30 minutes of withdrawal from the toluene treatment?” Because it was shown that the
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behavioral effect of toluene significantly dropped to levels comparable to that of their aircontrol counterparts by the end of the 30 minutes of withdrawal (Figure 3.1A), it is
possible that important details of toluene’s immediate action on DA dynamics could be
missed when fast scan cyclic voltammetry (FSCV) measurements were made
afterwards. Thus, in the present chapter, FSCV measurements of DA release and
uptake were taken following 30 minute of toluene treatment in order to examine the
immediate action of toluene on the DA system.
Furthermore, our previous data (Chapter 3) begs the question of whether the
alterations in DA release across the striatum were caused by inhibition of the
presynaptic DA autoreceptors. Presynaptic DA autoreceptors consist of D2 and D3
receptor subtypes which are differentially expressed across the brain with the islands of
Calleja having the highest density of the D3 receptors.180 Across the striatal region of
the brain, D3 receptors have higher density in the ventral striatum (NAc) than in the
dorsal striatum (CPu).181 Within the ventral striatum, D3 receptors are expressed more
in the NAc shell than the core.182-185 Meanwhile, the D2 receptors are expressed
homogenously across the striatum.184,

186

There are numerous reports in the literature

that have implicated D2/D3 autoreceptors in the action of addictive drugs. For example,
in both human and animal research, long term cocaine or nicotine use can increase D3
receptor density in the striatum and substantia nigra.184,

187-190

Moreover, DA D2

receptor-deficient mice have demonstrated enhanced sensitivity to the rewarding effects
of cocaine, while sub-chronic exposure to low (≥ 80 ppm) concentrations of toluene
increases the affinity of D2 receptor agonist and DA receptor density.191-193 Presynaptic
autoreceptors play an integral role in regulating extracellular DA levels through
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feedback inhibition, where activation of the receptors at the nerve terminal by locally
released DA leads to inhibition of DA synthesis and further DA release.182, 194-197 In the
initial characterization of toluene’s effect on DA dynamics, we observed impaired
stimulated DA release in the NAc core and shell following repeated toluene exposure
(Figure 3.6), which has led to the hypothesis that one potential target of abused toluene
could be the presynaptic DA autoreceptors. It is possible that the observed decrease in
DA release in the NAc core and shell could be a result of downward regulation of DA
release mediated by DA autoreceptors in response to repeated toluene exposure. Since
the attenuation in DA release was exclusive to the NAc, we expect that D3
autoreceptors, which are prominently expressed in the NAc, could be playing a major
role in toluene’s action. The implication of our hypothesis is that impairment of
presynaptic DA autoreceptors may potentiate DA neuron excitability and DA release,193
which could account for the increase in DA release across the striatum following acute
exposure to 4000 ppm toluene (Figure 3.2C).
In the present work, slice FSCV and pharmacological testing with a potent DA D3
autoreceptor

agonist,

(±)-7-hydroxy-2-dipropylaminotetralin

hydrobromide

(7-OH-

DPAT), was used to examine the functionality of presynaptic DA D3 autoreceptors in
toluene exposed and air-control mice. The functionality of presynaptic D3 autoreceptors
has been widely studied using 7-OH-DPAT.181, 198, 199 An important advantage of using
slice FSCV in this work is that it allowed us to selectively probe presynaptic
autoreceptors without any contributions from the postsynaptic terminal. 200
Another critical question this chapter seeks to address is, “Do the changes in DA
release induced by acute toluene exposure lead to alterations in extracellular DA

76

levels”? To answer this question, we built a toluene exposure chamber that allowed
dialysis samples and activity data to be collected simultaneously from a free-moving
mouse during exposure to either toluene or air. This set-up allowed for evaluation of DA
levels before toluene inhalation began, during and after exposure to see the direct effect
of toluene on extracellular DA levels in the mouse striatal brain region.
Lastly, because preliminary data showed changes in DA release, another
question that this chapter will address is whether these alterations are a result of
alterations in DA synthesis and catabolism, which can be measured by evaluating DA
tissue content. Herein, DA levels and its metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3-MT) were measured
using tissue content analysis, which exclusively examined intracellular concentrations of
neurotransmitters and their metabolites.
4.2 Materials and Methods
4.2.1 Toluene exposure and locomotor activity measurement
Acute toluene treatments before voltammetry and tissue content analysis used
the same set-up described in Section 2.3 but without a recovery phase. Mice were
exposed to 0 (air-control), 2000, or 4000 ppm of toluene vapor for 30 minutes, during
which their locomotor activities were measured using infrared (IR) emitter-detector
arrays attached to the chamber.
4.2.2 Slice fast scan cyclic voltammetry
Immediately after 30 minutes of toluene/air exposure, mice were sacrificed, and
their brains were removed (< 10 minutes) and prepared for slice FSCV measurements
using the procedure discussed in Section 2.5. To determine if the DA D3 autoreceptor
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was influenced by toluene, cumulative doses (0.001, 0.01, 0.03, 0.1, 0.3, 1, and 10 µM)
of DA D3 autoreceptor agonist, 7-OH-DPAT were perfused over brain slice following a
stable DA signal. The effect on DA release and uptake was measured every 5 minutes
for 30 minutes per dose of 7-OH-DPAT. DA was measured as current versus time
traces that were converted into concentration using a post-calibration factor of
microelectrode. The concentrations versus time plots were analyzed for DA kinetics (DA
release and uptake) using non-linear fits based on Michaelis-Menten sets of
equations.106, 110, 152-154
4.2.3 Brain tissue content analysis of dopamine and its metabolites
Following 30 minutes of toluene/air exposure, mice were sacrificed by cervical
dislocation and their brains were quickly removed, dissected into discrete regions of
interest, and prepared for tissue content using the same procedure outlined in section
2.8.
4.2.4 Simultaneous in vivo microdialysis and locomotor activity measurement
The procedure for simultaneous in vivo microdialysis and locomotor activity
measurement was first described in section 2.6. A graphical depiction of the time-line for
making the measurements in this acute toluene study is given in Figure 4.1.
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Figure 4.1: Graphical representation of the time-line for behavior and
microdialysis data collection. The experiment was partitioned into the following
sections: 2 hours of baseline, 30 minutes of toluene exposure, 1 hour recovery, 15
minutes of stimulated DA release with 60 mM high K+ artificial cerebrospinal fluid
(aCSF), and 1 hour post high K+ aCSF. High K+ concentration aCSF consist of
(mM): 60 KCl, 89 NaCl, 2.0 Na2HPO4, 1.0 CaCl2; 1.2 MgCl2; pH 7.4). Dialysate
samples were collected every 15 minutes throughout the experiment. Locomotor
activity was monitored the entire time.
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4.2.5 Data analysis
Statistical analyses of data from locomotor activity measurements and in vivo
microdialysis were performed with repeated measures analysis of variance (ANOVA)
using SPSS software and statistical significance was determined using Tukey’s post
hoc contrasts, simple main effects analyses, and Student t-test. Statistical analyses of
FSCV and tissue content data were performed with one-way ANOVA followed by
Dunnett’s Multiple Comparison Test, and Student t-test using GraphPad Prism
Software. Data were expressed as mean ± standard error of the mean (SEM) and
statistical significance determined as P < 0.05.
4.3 Results
4.3.1 Distance traveled during acute toluene exposure
Locomotor activity before and during toluene exposure was measured and
expressed as distance traveled in three minutes bins (Figure 4.2A), which is partitioned
into two main panels. The first panel represents the distance traveled by mice during 5
minutes of acclimation (baseline) and the second panel shows distance traveled during
30 minutes of toluene exposure. Statistical analysis of this data was done using 3 x 10
repeated ANOVA with toluene treatment (0, 2000, and 4000 ppm) as the between
subjects factor, and the 3-minute time blocks as the within-subjects factors. The result
obtained showed a significant main effect of Time (F5,140 = 5.82, P < 0.05, n = 5-8/group)
but not Time x Toluene interaction, even though the effect seems trending (F 10,140 =
1.75, P = 0.052, n = 5-8/group). This result suggests that the locomotor activity of mice
changes with time but is not dependent on toluene treatment. There was no effect of
toluene dose (F2,28= 0.76, P = 0.48 , n = 5-8/group). The locomotor activity was also
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condensed to the total distance traveled throughout the 30 minutes of toluene/air
exposure (Figure 4.2B). One-way ANOVA analysis of the toluene treatment groups
showed no effects of toluene treatment on locomotor activity (F 2,14 = 1.439, P = 0.26, n
= 5-8/group). This lack of effect of acute toluene exposure on locomotor activity is not
consistent with what we previously demonstrated in our initial behavior characterization
(Figure 3.1) but we believe the disparity may be due to low statistical power in the
present data.

Figure 4.2: Effect of acute toluene exposure on locomotor activity of mice. A)
Locomotor activity expressed as distance traveled versus time in 3 minutes bins.
Before the dashed line is the activity during 5 minutes of acclimation and after the
dashed line demonstrates activity during 30 minutes of toluene/air exposure. There
was a significant main effect of time (P < 0.05) but no effect of toluene dose (P > 0.05)
B) Total distance traveled versus toluene dose. Data as mean ± SEM, n = 5-8/group.
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4.3.2 Dopamine release and uptake following acute toluene exposure
Slice FSCV was used to characterize the effect of acute toluene exposure on
presynaptic DA dynamics in three sub-anatomical regions in the striatum of mouse the
brain: the CPu, NAc core and shell. Mice were exposed to 30 minutes of air, 2000 or
4000 ppm toluene vapor and immediately afterwards (in less than 10 minutes) were
sacrificed and their brains prepared for FSCV measurement. The measured electrically
evoked DA release was expressed as maximum stimulated DA release per a single
electrical pulse (µM) and DA uptake as maximum velocity of the DA transporter (V max in
µM/s). The DA measurements from the striatum of air-control mice showed the highest
DA release and uptake in the CPu, followed by the NAc core and then the NAc shell.
Statistical analysis of the data obtained using one way ANOVA showed a significant
main effect of toluene treatment on DA release in all three sub-anatomical brain regions
(CPu: F2,48 = 6.27; P = 0.004,; NAc core: F2,42 = 8.36, P < 0.001; NAc shell: F2,39 = 10.36,
P < 0.001; Figure 4.3). Dunnett’s Multiple Comparison Test between treatments
revealed that, following acute exposure to 2000 ppm of toluene, DA release in both the
CPu (1.70 ± 0.13 µM, n = 5) and the NAc core (0.66 ± 0.06 µM, n = 5) were not altered
compared to their air-controls (CPu: 1.77 ± 0.14 µM, n = 6; NAc core: 0.49 ± 0.06 µM, n
= 5, Figure 4.2). However, acute exposure to 2000 ppm toluene vapor did increase DA
release in the shell (2000 ppm toluene: 0.53 ± 0.05 µM, n = 5; air-control: 0.26 ± 0.04
µM, n = 4; P < 0.05). Consistent with earlier observations (Figure 3.2), acute exposure
to 4000 ppm toluene increased electrically evoked DA release in the three brain regions
(CPu: 2.23 ± 0.10 µM, n = 7; NAc core: 0.95 ± 0.04 µM, n = 5 and NAc shell: 0.63 ±
0.07 µM, n = 5) as shown by current-time traces and background subtracted cyclic
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voltammograms (Figure 4.3B). Similarly, DA uptake rates in the CPu and the core were
not altered following toluene treatment compared to their air-controls (CPu: F2,51 = 0.70,
P = 0.50; NAc core: F2,42 = 0.78, P = 0.46; one-way ANOVA, Figure 4.3E). Interestingly,
only 2000 ppm toluene exposure elevated DA uptake in the NAc shell (2000 ppm: 2.22
± 0.15 µM/s, n = 5; air-control: 1.31 ± 0.14 µM/s, n = 4; P < 0.001, Dunnett’s Multiple
Comparison Test).
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Figure 4.3: Effect of acute toluene exposure on DA release and uptake. A)
Acute toluene exposure and FSCV experimental timeline which includes 5 minutes
acclimation time, 30 minutes toluene exposure and ~ 8 minutes preparation before
FSCV measurements. B) Effect of acute toluene exposure on electrically evoked DA
release across the three striatal brain regions. C) DA uptake rates across the three
striatal sub-regions following toluene exposure. Data expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA with Dunnett’s Multiple
Comparison Test performed for each brain region (*P < 0.05, **P < 0.01, ***P <
0.001, n = 4 – 7/group).
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4.3.3 Effect of acute toluene exposure on presynaptic D3 autoreceptors
Dose response curves showing the effect of 7-OH-DPAT on DA release were
generated from mice exposed to 4000 ppm toluene and their air-control counterparts.
The toluene dose (4000 ppm) was chosen because of its profound effect on DA release
across all three sub-anatomical brain regions in the striatum (Figure 4.3). Dose
response curves obtained in the CPu with 7-OH-DPAT following stable DA signal did
not differ between air- and toluene-treated mice as shown by the overlap of the two
curves. The IC50 value is defined as the concentration at which the maximum DA
response was decreased by 50%. There was no difference between toluene treated
mice and their air-controls when comparing IC50 values (air: IC50 = 70 ± 1 nM, toluene
treated: IC50 = 32 ± 1 nM, P =1.00, n = 4-5/group, Student t-test, Figure 4.4A). The
effect of cumulative doses of the DA D3 agonist was also evaluated on DA uptake
kinetics between the two treatment groups. One-way ANOVA showed a significant
effect of 7-OH-DPAT on DA uptake in both groups of mice (air-control: F7,112 = 12.4, P <
0.0001, Figure 4.4B and toluene exposed: F7,112 = 12.4, P < 0.0001, Figure 4.4C).
Further statistical analysis of the DA uptake data with Dunnett’s Multiple Comparison
Tests revealed that perfusion of 0.1 µM 7-OH-DPAT attenuated DA uptake in only aircontrol mice.
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Figure 4.4: Effect of D3 agonist, 7-OH-DPAT on presynaptic DA release and
uptake in the CPu of toluene exposed and air-control mice. A) Dose
response curve showing the effect of cumulative doses (0.001 -10 µM) of 7-OH
DPAT on DA release in toluene treated mice (IC50 = 32 ± 1 nM) and their aircontrols (IC50 = 70 ± 1 nM). Statistical analysis was done with Student’s t-test. B)
The effect of 7-OH-DPAT on DA uptake in air-control mice, and C) in toluene
exposed mice expressed as Vmax (µM/s). Data was plotted as mean ± SEM.
Statistical analysis performed with one-way ANOVA with Dunnett’s Multiple
Comparison Test. *P > 0.05, ***P > 0.001, n = 4-5/group).
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4.3.4 Monitoring the effect of acute toluene exposure on locomotor behavior and
extracellular dopamine levels in the CPu
The main advantage of monitoring locomotor behavior simultaneously with
dialysate sample collection is that it will enable us to better understand how the
behavior effects of toluene relate to alterations in the extracellular DA levels. In this
experiment, the average distance traveled by mice during 5 main phases of
microdialysis experiments were examined. These phases were 2 hours of baseline, 30
minutes toluene/air exposure, 1 hour recovery, 15 minutes high K + aCSF infusion, and 1
hour post-high K+ aCSF infusion. To be able to compare the locomotor activities of each
phase to the other and also be consistent with dialysis collection time, the data obtained
have been expressed as average distance traveled per minute over the time course of
15 minutes. Statistical analysis of the results (Figure 4.5) using repeated measures
analysis showed significant within-subject effect of time (F3,25 = 6.96, P = 0.002) and a
significant Time x Toluene interaction (F3,25= 3.18, P = 0.04) from pre-toluene/air to
recovery. These observations demonstrate that the locomotor activity of the mice was
altered during the experiment and that the alteration was dependent on toluene
treatment. Further statistical analysis using Student t-test revealed a significant increase
in locomotor behavior during the second half (T2) of the exposure to 4000 ppm toluene
(11.4 ± 3.4 cm/min) relative to their air-controls (1.42 ± 1.42 cm/min, P < 0.05, n = 5).
Meanwhile, no significant differences in locomotor behavior were found between
toluene and air-control mice during recovery phase through to post-high K+ phase
(Figure 4.5).
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Figure 4.5: Effect of acute toluene exposure on locomotor behavior during
dialysate sample collection. Locomotor activity was expressed in 15 minutes
bins.T1-T2 represent the 30 minutes of toluene/air exposure; R1-R4 constitute the
1 hour recovery phase; K0 is 15 minutes of hight K + aCSF infusion; and K1-K4
denote post high K+ aCSF perfusion. Data compares locomotor activity of 4000
ppm toluene exposed mice to their air-controls. Statistical analysis was performed
with repeated measures ANOVA with toluene as the between subjects factor, and
15-minute time blocks as the within-subject factor. T1 and T2 in toluene and aircontrol mice were compared respectively using a Student t-test (*P < 0.05, n = 56).
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The microdialysis set-up allowed sampling and further detection of extracellular
DA levels using HPLC coupled to an electrochemical detector. Dialysis samples were
collected every 15 minutes across the five experimental phases to examine the
extracellular DA levels before, during, and after acute toluene exposure. The effect of
acute toluene exposure on chemically stimulated DA release was measured using high
K+ concentration aCSF infusion method. The presence of high K+ stimulates
neurotransmitter release leading to increased extracellular levels of neurotransmitters
like DA which can be measured by microdialysis. The extracellular DA levels collected
during the 5 phases of the experiment are expressed as percentage of the baseline DA
concentration in toluene exposed and air-control mice, respectively. These percentages
were plotted against time in 15 minute bins. There was no effect from 4000 ppm toluene
exposure on extracellular DA levels during or after toluene exposure. On the contrary,
statistical analysis using a Student t-test (two tailed) showed that infusion of high K+
aCSF caused a significant increase in extracellular DA level in mice that were exposed
to toluene compared to their air-control counterpart (t = 2.43, P < 0.05, df = 9, Figure
4.6). This alteration in chemically stimulated DA release is congruent with what was
observed using electrical stimulation in slice FSCV.
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Figure 4.6: Effect of acute toluene exposure on extracellular DA levels. Dialysis
sample collection was made every 15 minutes before (baseline), during (toluene/air),
and after toluene inhalation. There was no effect of toluene exposure on extracellular
DA levels in the CPu. However, prior toluene exposure to 4000 ppm alters high K +stimulated DA release (dashed red arrows). *P < 0.05, n = 5-6 (paired Student t-test).
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4.3.5 Effect of acute toluene exposure on extracellular DA and catabolism
To determine if intracellular DA and it catabolism are direct targets of toluene’s
neural action in the CPu and NAc, tissue content of DA and its metabolites (DOPAC,
HVA, and 3-MT) were measured in brain tissues obtained from mice acutely exposed to
4000 ppm toluene and their air-controls. Representative retention times for these
analytes were 6.5, 8.3, 15.0 and 18.0 minutes for DOPAC, DA, HVA, and 3-MT,
respectively (Figure 4.7). The tissue concentration of DA and its metabolites were
analyzed against their respective standards and expressed as ng per µg of brain tissue
protein. The DA tissue content and its metabolites measured from air-control mice were
compared to that of the toluene exposed mice (Figure 4.8B and C). In the CPu,
statistical comparison using a Student t-test showed no significant difference in DA
tissue levels between the two groups of mice (air-control: 877 ± 105 ng/mg protein;
toluene exposed mice: 1086 ± 72 ng/mg protein; t = 1.64, P > 0.05, df = 22). However,
in the CPu, there was a significant reduction of DOPAC in toluene exposed mice
compared to the air-control mice (air-control: 371 ± 44 ng/mg protein, toluene: 221 ± 17,
t = 3.20, P < 0.01, df = 22, two tailed Student t-test). Meanwhile, the metabolites HVA
and 3-MT levels in the CPu were not different between the air and toluene-exposed
mice (P > 0.05). Similarly, there was a significant reduction in only DOPAC, but not DA,
HVA or 3-MT, levels in the NAc following acute toluene exposure (DOPAC; air-control:
481 ± 76 ng/mg protein, toluene: 234 ± 30 ng/mg protein, t = 3.03, P < 0.05, df = 10, two
tailed Student t-test). The interaction between DA and DOPAC was evaluated. The ratio
of DA/DOPAC was significantly higher in the CPu of toluene exposed mice compared to
the air-control littermates (air-control: 2.3 ± 0.2, toluene exposed: 5.1 ± 0.4, t = 6.78, P <
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0.0001, df = 22, two tailed Student t-test) and in the NAc (air-control: 1.1 ± 0.03, toluene
exposed: 2.2 ± 0.2, t = 4.55, P < 0.01, n = 6, two tailed Student t-test). Collectively,
these observations suggest that acute toluene exposure influences DA catabolism,
particularly the conversion of DA to DOPAC in the CPu and the NAc.
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Figure 4.7: Representative chromatograms for neurotransmitters and
metabolites. A) Chromatogram of standard solution containing norepinephrine
(NE) , DOPAC, DA, 5-HIAA (5-hydroxyindoleacetic acid), HVA, and 3-MT run at
2 µA attenuation. B) Chromatogram of brain tissue sample run at 1 µA
attenuation showing DA and DOPAC peaks. C) Chromatogram of brain tissue
sample run at 20 nA attenuation showing peaks including 5-HIAA, HVA, 3-MT.
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Figure 4.8: Effect of acute toluene exposure on tissue content DA and its
metabolites. A-B) Average concentrations of DA, DOPAC, HVA, and 3-MT from
CPu and NAc of mice previously exposed to 4000 ppm toluene vapor compared to
their air-control littermates. C) Effect of acute toluene exposure on DA catabolism
expressed as DA/DOPAC ratio for CPu and NAc. Data shown as mean ± SEM.
Statistical significance determined using two tailed Student t-test (*P < 0.05, **P <
0.01, ***P < 0.001, n = 6).
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4.4 Discussion
Previously, we have shown that acute toluene inhalation influences striatal DA by
increasing DA release, but exerts no effect on DA uptake kinetics (Chapter 3). Our initial
study suggested potential neural targets for toluene’s action, which we decide to further
examine in the present chapter. In the previous study, mice were allowed a 30-minute
recovery period followed by another 15 minutes needed to obtain the brain slices; one
of the concerns with this approach was that the 30-minute withdrawal period could be
contributing to the changes observed in DA release. Therefore, the toluene treatment
was modified to exclude the recovery phase so that FSCV measurements were made
following toluene exposure (< 10 minutes). Consistent with previous findings (Chapter
3), the present data confirm that acute toluene inhalation potentiates DA release across
the striatum of mouse brain. Since similar observations were made after the recovery
phase of the toluene treatment in the earlier study (Chapter 3), collectively, our data
suggest that acute toluene inhalation elevates stimulated DA release for at least 30
minutes after toluene exposure. Evidence about the persistent nature of alterations in
the DA system induced by acute toluene exposure was demonstrated by Beckley et al.
in their recent work where retrograde labeling and slice electrophysiology were used to
examine the acute effect of toluene inhalation on the mesolimbic DA system.201 They
found that acute exposure of rats to 5700 ppm toluene increased excitatory synaptic
strength of DA projections in the NAc with elevations persisting for up to 3 and 21 days
in the NAc core and shell, respectively.201 Our previous acute FSCV data (Chapter 3)
compared with our present FSCV observation (Figure 4.3) further support the
hypothesis that toluene induces long lasting alterations in the DA system.84
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In the experiments presented in this chapter, mice exposed to 2000 ppm toluene
without a recovery period, showed increase in both DA release and uptake dynamics
only in the NAc shell. The sub-anatomical brain regions in the striatum differ in both
their anatomy182,

202-205

and function.206-208 Within the NAc, the core is implicated in

locomotor stimulatory effects of drugs, whereas the shell is noted for its involvement in
emotions and motivation.202,

203

From our FSCV data, inhalation of 2000 ppm toluene

vapor altered both DA release and uptake in only the NAc shell, while a higher
concentration (4000 ppm) potentiated DA release across all three sub-anatomical
regions of the striatum but had no effect on DA uptake. Taken together, these FSCV
data imply that toluene’s action across the striatum may be dose and region dependent.
A similar specificity was reported in the work done by Di Chiara and colleagues, where
they demonstrated that intravenous injection of 1 mg/kg of cocaine increased
extracellular DA levels in both the NAc core and shell, while a lower dose (0.5 mg/kg)
selectively increased extracellular DA levels in the shell.207 This kind of specificity is also
consistent with the action of amphetamine and morphine on the DA system in the
NAc.207 Thus, from our FSCV results, it is likely that toluene may share similar neural
sites(s) with other drugs of abuse.82
A common characteristic amongst drugs of abuse is that they elevate
extracellular DA levels,177 which is achieved by increasing DA neuronal firing (e.g.
nicotine and opiate), inducing DA release from the DA terminal (e.g. amphetamine) or
blocking DA uptake (e.g.cocaine).31, 193 Using slice FSCV, our results demonstrate that
acute inhalation of toluene increases striatal DA release; therefore, it is logical to expect
the increase in DA release to lead to an increase in extracellular DA levels across the
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CPu. However, our microdialysis results showed no difference in extracellular DA levels
in the CPu during toluene inhalation, although locomotor activity was elevated over the
same time period (Figure 4.5). These microdialysis results appear contrary to the work
reported by Stengard et al., where exposure to 1000 or 2000 ppm toluene vapor for two
hours increased motor activity and extracellular DA levels in the striatum by 47% in
rats.143 However, when toluene was administered (800 mg/kg) intraperitoneally, motor
activity was potentiated in rats, but extracellular levels of DA and its metabolites in the
striatum were not altered.209 These discrepancies in microdialysis results can be
attributed to differences in the animal model being used (rat versus mouse), dose (high
versus low), duration of treatment (brief versus extended), and the mode of toluene
administration (injection versus inhalation). The toluene exposure model used in the
present work was selected because it mimics brief and high doses of toluene that are
thought to be observed by those who ‘huff’ in real life. Since acute toluene inhalation
elicited similar effects across the CPu and the NAc, the CPu was chosen to examine the
effect of acute toluene exposure on extracellular DA levels because it is a DA rich
region in the striatum. By measuring locomotor activity and extracellular DA levels
simultaneously, it was hoped that a correlation or a direct relationship would be
observed between extracellular DA levels and locomotor behavior. Because there was
no correlation between toluene induced locomotor activity and extracellular DA levels in
the CPu, we believe that DA neurotransmission in the CPu may not be directly involved
in locomotor stimulatory effects induced by acute toluene inhalation. Another possibility
could be that toluene is directly influencing post-synaptic DA receptors or other
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receptors through a mechanism that does not increase extracellular DA levels in the
CPu as suggested by Kondo et al. 209
To better understand if DA release mechanisms were altered after toluene
inhalation, aCSF containing high K+ concentration (60 mM) was infused directly through
the microdialysis probe for 15 minutes. The presence of high K + causes depolarization
of neurons and exocytosis, such that neurotransmitters are released into the synapse
causing elevation in extracellular levels of neurotransmitters which can be measured by
microdialysis. This procedure has been widely used in microdialysis experiments to
probe the influence of drug treatment or gene alteration on DA release.94, 126, 210 From
our microdialysis data, the infusion of high K+ aCSF led to a greater DA response in
toluene exposed mice compared to their air-controls, confirming that acute toluene
exposure elevates presynaptic DA release in the CPu, just as we observed with FSCV.
Hypothesis that has been put forth by numerous groups is that toluene induces
DA release in the striatum could be mediated by presynaptic DA autoreceptors. In the
present work, we asserted that this release could be mediated by presynaptic DA
autoreceptors, possibly D3 mechanisms. To test this DA D3 autoreceptor hypothesis,
slice FSCV was used to evaluate the DA D3 receptor in the CPu. When a cumulative
dose response curve of DA D3 agonist, 7-OH-DPAT was obtained by perfusion of the
agonist over the CPu, there was no difference in the IC50 values between the control
and toluene-treated mice suggesting that there is no difference in the function or the
sensitivity of the DA D3 receptors in the striatum. Thus, although slice FSCV data
suggest that DA release is elevated in toluene treated mice, it does not appear to be
mediated via the DA D3 receptors. This FSCV data does not rule out the possible
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involvement of D2 autoreceptors in toluene’s action. However, considering that acute
toluene inhalation did not alter DA uptake or extracellular DA levels in the CPu, it is
possible that the toluene induced elevation may not be mediated by DA autoreceptors.
Since DA release was altered in both slice FSCV and microdialysis experiments,
it is possible that this alteration in DA release is due to the fact that there is more
intracellular DA available for release. Examining brain tissue content, we could evaluate
intracellular DA levels as well as its metabolites. Tissue content results from this study
highlight that acute toluene inhalation had no effect on intracellular levels of DA, HVA,
and 3-MT in both the CPu and the NAc. However, the intracellular concentration of
DOPAC was decreased in both the CPu and NAc. The DA/DOPAC ratio was increased
in the toluene exposed mice suggesting that the breakdown of DA into DOPAC is
decreased in toluene-treated mice.
Collectively, since our data demonstrate that acute toluene inhalation alters
presynaptic DA release but not DA uptake, D3 autoreceptors, extracellular DA levels,
and DA synthesis in the CPu, it is most likely that some other neurotransmitter system
such as glutamate or gamma-aminobutyric acid (GABA) that can influence presynaptic
DA release could be mediating acute toluene’s action on the DA system in the
striatum.37
4.5 Conclusions
In summary, the present data show that acute toluene exposure increases
stimulated DA release across the striatum. However, this increase in is not mediated by
presynaptic DA D3 autoreceptors. Although stimulated DA release is elevated after
acute toluene exposure, extracellular DA levels remain unchanged during toluene
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inhalation. Despite no changes in extracellular DA levels in the CPu during toluene
inhalation, locomotor activity was enhanced. Finally, intracellular DA levels were
unaltered suggesting that the increase in stimulated DA release is not a result of excess
DA accumulation in vesicles. The tissue content results do suggest that there are
alterations in DA catabolism in both the CPu and NAc. Taken together, the results here
suggest that acute toluene inhalation perturbs DA release in the CPu but most likely via
an indirect mechanism since intracellular DA and uptake were unaltered after toluene
inhalation.
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CHAPTER 5
An In-depth Examination of the Effect of Repeated Toluene Exposure
on Striatal Dopamine (DA) System
5.1 Introduction
Drug addiction is initiated by repeated drug administration, which leads to
neuroadaptations in the brain reward pathway including the mesolimbic dopaminergic
system.176, 177 This suggests that understanding how long term toluene exposure affects
the striatal DA system could provide clues to the underlining mechanisms of toluene
abuse. Few reports exist that have shown the effect of chronic toluene exposure on the
DA system.84, 191, 211 In our initial characterization of the effect of toluene exposure on
striatal DA dynamics, we showed that daily, intermittent toluene exposure for 7 days
significantly altered DA release in only the nucleus accumbens (NAc), a region
implicated in drug addiction2; but not the caudate putamen (CPu, Figure 3.6). One of the
caveats of our original study was that we waited 24 hrs after the 7 th toluene exposure to
make neurochemical measurements; this delay was because we were trying to
coordinate an appropriate time for FSCV measurements to be made. However, it was
noted that neurochemical examination should be made immediately after the final
exposure to better understand the effects of chronic toluene exposure. The present
chapter examines the alterations that repeated toluene exposure induces immediately
on the striatal DA system, particularly, the accumbal DA system, since our initial study
highlighted that this region had the greatest alterations in DA dynamics. Based on our
observations from Chapters 3 and 4, we hypothesized that, daily, intermittent toluene
exposure for 7 days would dose-dependently decrease DA release in the NAc as a
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result of compensatory response to chronic toluene inhalation. Furthermore, we expect
an increase in the extracellular DA level in the NAc and a decrease in DA tissue content
and it catabolism.
To determine if our hypothesis is valid, we will use slice fast scan cyclic
voltammetry (FSCV) to evaluate the possible role of DA autoreceptors in the proposed
compensatory response of the accumbal DA dynamics to chronic toluene exposure. We
will also evaluate baseline extracellular DA levels in the NAc after daily, intermittent
toluene exposure. To date there are no reports that have used this exact protocol to
measure extracellular DA levels. We believe that our model closely mimics the brief but
repeated toluene inhalation observed in toluene addiction. In vivo microdialysis will be
used to measure extracellular DA levels, with simultaneous measurement of locomotor
activity; this approach will allow us to understand how locomotor activity correlates with
extracellular DA levels in the NAc. Finally, brain tissues will be analyzed to determine
the effect of repeated toluene treatment on intracellular DA levels and its metabolites
(3,4-dihydroxyphenylacetic

acid,

DOPAC;

homovanillic

acid,

HVA;

and

3-

methoxytyramine, 3-MT). We expect tissue content analysis to shed light on toluene’s
influence on DA catabolism. Previous work by another group has shown that the region
of the putamen in rats has decreased DA catabolism after sub-chronic exposure to 40
ppm toluene, an effect the authors attributed to decreased DA degradation as the
DA/DOPAC ration was elevated.212 By examining DA dynamics using slice voltammetry,
in vivo microdialysis, and tissue content analysis, we anticipate developing a more
comprehensive understanding about the impact toluene inhalation has on the striatal
DA system.
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5.2 Materials and Methods
5.2.1 Toluene exposure and locomotor activity measurements
Repeated toluene exposures before voltammetry and tissue content analysis
were done using the same procedure described in section 2.3, where mice were
allowed 5 minutes of acclimation, followed by 30 minutes of exposure to 0 (air-control),
2000, or 4000 ppm and then 30 minutes recovery. This toluene exposure procedure
was performed each day for seven consecutive days. On day 7 the recovery phase was
excluded and mice were sacrificed immediately after the 30 minutes of air/toluene
exposure. Locomotor activity data were obtained during the acclimation, exposure and
recovery phases (except day 7) of the procedure.
5.2.2 Slice fast scan cyclic voltammetry following repeated toluene exposure
After the 7th toluene exposure, mice were immediately sacrificed (no recovery
phase) and their brains were prepared for slice FSCV measurements using the
procedure discussed in section 2.5. To determine if repeated toluene exposure can
influence presynaptic DA autoreceptors, DA dynamics in the NAc core were evaluated
using a cumulative dose response curve of 7-OH-DPAT (1, 10, 30, 100 nM). FSCV
measurements and analyses were performed using the procedure previously described
in section 4.2.2.
5.2.3 Brain tissue content analysis of DA and its metabolites
After the 7th exposure to toluene/air, mice were sacrifice by cervical dislocation
and their brains were rapidly removed, prepared, and analyzed for DA tissue content
and its metabolites using the same procedure discussed in section 2.8.
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5.2.4 In vivo microdialysis and locomotor activity measurement
Simultaneous in vivo microdialysis and locomotor activity measurements were
made as described in section 2.6. The timeline for the repeated toluene/air exposure
and microdialysis measurements is as shown in Figure 5.1.

Figure 5.1: Timeline for repeated toluene/air exposure and microdialysis
measurements.
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5.2.5 Data analysis
Statistical analyses of data from locomotor activity measurements were
performed with SPSS software using repeated measures analysis of variance (ANOVA)
where toluene treatment (0, 2000, and 4000 ppm) was represented as the between
subjects factor, with days and 3-minute time blocks as the within-subjects factors.
Statistical significance was determined using Tukey’s post hoc contrasts, simple main
effects analyses, Dunnett’s Multiple Comparison Test or Student t-test. Statistical
analyses of FSCV and tissue content data were performed with GraphPad Prism
Software using one-way ANOVA followed by Dunnett’s Multiple Comparison Test or
Student t-test. Data was expressed as mean ± standard error of the mean (SEM) and
statistical significance determined as P < 0.05.
5.3 Results
5.3.1 Distance traveled during and following repeated toluene exposure
The effect of repeated toluene exposure on locomotor behavior was monitored
within and across days of exposure. Statistical analyses of the results were performed
using 3 x 7 x 10 repeated measures ANOVA with toluene treatment (0, 2000, and 4000
ppm) as the between subjects factor with days and 3-minute time blocks as the withinsubjects factors revealed trends similar to those already established in Chapter 3
(Figure 3.5). However, some of these trends did not reach statistical significance
presumably due to low statistical power. The specific results from this chapter
demonstrate that the main effect of toluene treatment did not reach statistical
significance (F2,14 = 0.94, P = 0.42). There was also no effect of Day (F6,84 = 1.97 , P =
0.08) and Day x Toluene treatment interaction (F12,84 = 3.10, P = 0.70). However, there
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was a significant main effect of time (F9,126 = 0.75, P = 0.002) and a marginal Time x
Toluene treatment interaction (F18,126 = 1.67, P = 0.05). In all, the total distance traveled
during 4000 ppm toluene treatment increased across days of treatment (P < 0.05;
Dunnett’s Multiple Comparison Test) as seen in Figure 5.2F. Recovery from repeated
toluene treatment produced no main effect of Dose (F2,14 = 2.80, P = 0.10) or Day (F5,70
= 1.59, P = 0.18). However, there was a marginal effect of Day x Toluene treatment
interaction (F10,70 = 1.94, P = 0.05). Particularly for 4000 ppm toluene treatment,
locomotor activity during recovery decreased across days of treatment. Dunnett’s
Multiple Comparison Test of the total distance traveled during recovery revealed a
significant decrease in locomotor activity across days (P < 0.05, Figure 5.3F).
Furthermore, a significant main effect was observed for Time block (F9,126 = 20.6 , P <
0.001) and for the Time block x Toluene treatment interaction(F18, 126 = 5.52, P < 0.001)
suggesting that the progressive decrease in locomotor activity during the recovery
period was dependent on toluene treatment.
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Figure 5.2: Locomotor activity during and after repeated toluene (0, 2000 or 4000
ppm) exposure. The left graphs represent locomotory activity, with the first 5 min
acclimation, the middle section represents 30 minutes toluene exposure, and the right
section shows 30 min post toluene exposure. A) A plot of distance traveled (cm ± SEM)
versus time (3 minute bin) for air-control. B) A summation of distance traveled (cm ±
SEM) versus days of toluene exposure. C) Distance traveled (cm ± SEM) versus time
(3 minute bin) for 2000 ppm toluene treatment with corresponding D) A summation plot
of distance versus day. E) A plot of distance traveled (cm ± SEM) versus time (3 minute
bin) and F) A summation of distance versus day plot for repeated 4000 ppm toluene
treatment. For all graphs, days 1, 3, and 6 were selected for simplicity. Statistical
significant main effects and interactions were determined by Tukey’s post hoc contrasts
and simple main effects analyses. Significance between total distance traveled across
days was also examined using Dunnett’s Multiple comparison Test. *P < 0.05 (aircontrol, n = 10; 2000 ppm, n = 5; 4000 ppm, n = 6).
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5.3.2 DA release and uptake following repeated toluene exposure
Electrically stimulated DA release and uptake were measured across the CPu,
NAc core, and NAc shell following the 7th toluene/air exposure (no recovery). The
results obtained were expressed as maximum stimulated DA release in µM and DA
uptake as maximum velocity of the DA transporter (Vmax) in µM/s. Statistical analysis of
these data (Figure 5.3) using one way-ANOVA across each brain region showed no
significant main effect of repeated toluene exposure on DA release in the CPu (F 2,42 =
0.94, P = 0.40), which is consistent with previous observations (Figure 3.6C) where
FSCV measurements were made 24 hours after the last toluene exposure. In the NAc,
there was a significant main effect of repeated toluene exposure on DA release (F 2,72 =
10.64, P < 0.0001). Dunnett’s Multiple Comparison tests revealed that both repeated
exposures to 2000 and 4000 ppm toluene significantly decreased DA release in the NAc
core (air: 0.79 ± 0.08 µM; 2000 ppm: 0.47 ± 0.04 µM; 4000 ppm: 0.50 ± 0.03 µM; P <
0.001). However, there was no main effect of repeated toluene exposure on DA release
in the shell (air: 0.67 ± 0.04 µM; 2000 ppm: 0.53 ± 0.04 µM; 4000 ppm: 0.60 ± 0.08 µM;
F2,36 = 0.86, P = 0.43). These NAc core DA release results parallel the results obtained
after a 24 hour recovery period. Taken together these results highlight that toluene has
a significant impact on DA release in the core and that this alteration can still persist 24
hours after the toluene exposure.
With respect to DA uptake in the CPu, there was no difference between toluenetreated mice and their air-controls (air: 4.37 ± 0.11 µM/s; 2000 ppm: 4.67 ± 0.37 µM/s;
4000 ppm: 4.19 ± 0.11 µM/s; F2,42 = 0.86, P = 0.44). There was a significant main effect
of repeated toluene exposure on DA uptake in both the NAc core (F 2,72 = 8.37, P <
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0.001) and NAc shell (F2,36 = 6.43, P = 0.004). In the NAc core, only repeated exposures
to 2000 ppm toluene decreased DA uptake (air: 2.37 ± 0.13 µM/s; 2000 ppm: 1.50 ±
0.21 µM/s; 4000 ppm; 2.19 ± 0.12 µM/s; P < 0.001), while in the NAc shell only 4000
ppm toluene increased DA uptake (air: 1.63 ± 0.23 µM/s; 2000 ppm: 1.63 ± 0.20 µM/s;
4000 ppm; 2.57 ± 0.20 µM/s; P < 0.001). These uptake alterations in the NAc induced
by repeated exposure to 2000 and 4000 ppm are in contrast to our previous results
where a 24 hour wait period after the last toluene inhalation (2000 and 4000 ppm) had
no effect on DA uptake across all the striatal brain regions (Figure 3.6D). Collectively,
the present FSCV data show that the DA dynamics in the NAc is prone to the neural
action of repeated toluene exposure, which could be dose and region dependent.
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Figure 5.3: Effect of repeated toluene exposure on DA release and uptake.
A) Repeated toluene exposure and FSCV experimental timeline which includes
5 minutes acclimation, 30 minutes toluene exposure, and 30 minutes of
recovery performed every day for 6 consecutive days. The 7th day procedure
excluded the recovery phase and involved ~ 8 minutes preparation before
FSCV measurements. B) Effect of repeated toluene exposure on electrically
evoked DA release across 3 sub-anatomical brain regions of the striatum (CPu,
NAc core and shell) with their accompanying cyclic voltammogram indicating
the detection of DA. C) DA release in the CPu, NAc core, and shell. D) DA
uptake in the CPu, NAc core, and shell. Data expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA with Dunnett’s
Multiple Comparison Test performed for each brain region (**P < 0.01, ***P <
0.001, n = 4 – 10/group).
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5.3.3 Effect of repeated toluene exposure on presynaptic DA autoreceptors
There is considerable evidence that toluene may regulate DA release through DA
autoreceptors. The objective of this experiment was to determine if the DA D3 agonist
7-OH-DPAT would have a shift in its dose response curve; either to the left or to the
right after toluene inhalation. The agonist 7-OH-DPAT is a potent agonist of DA D3
receptors but has also been reported to activate D2 receptors in native tissue where
sodium and magnesium ions are present (Ki values are D3: ~ 1 nM, and D2: 10 nM;
from Tocris on-line catalog).181,

198, 199, 213, 214

The NAc core was chosen as the target

brain region because the DA release and uptake parameters in this region were
significantly altered during repeated toluene exposure (Figure 5.3). However, the 7-OHDPAT dose response curves did not significantly differ between toluene exposed
animals and their air-controls. The IC50 values which describe the concentration at
which the agonist exerts its half maximum effect, were also not significantly different
between the toluene exposed mice and their air controls (air: IC50 = 18 ± 1 nM, toluene
treated: IC50 = 20 ± 1 nM, P =1.00, n = 4 – 5/group, two tailed Student t-test, Figure
5.4A). However, increasing concentrations of 7-OH-DPAT (≥ 30 nM) decreased DA
uptake in only the air-control mice (F4,70 = 12.00, P < 0.0001) and not their toluene
exposed littermates (F = 1.06, P = 0.386).
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Figure 5.4: Effect of 7-OH-DPAT on presynaptic DA release and uptake in the
NAc core of toluene exposed and air-control mice. A) Dose response curve
showing the effect of cumulative doses (1-100 nM) of 7-OH DPAT on DA release in
toluene treated mice (IC50 = 20 ± 1 nM) and their air-control (IC50 = 18 ± 1 nM).
Statistical analysis was done with two tailed Student t-test (P > 0.05). B) The effect
of 7-OH-DPAT on DA uptake in air-control mice, and C) The effect of 7-OH-DPAT on
DA uptake in mice repeatedly exposed to 4000 ppm toluene vapor. Data were
plotted as mean ± SEM. Statistical analysis performed with one-way ANOVA with
Dunnett’s Multiple Comparison Test. ***P > 0.001, n = 4-5/group).
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5.3.4 Simultaneous monitoring of the effect of repeated toluene exposure on
locomotor behavior and extracellular DA level
Following recovery from stereotaxic surgery, mice were exposed to behavior
activating dose of toluene (4000 ppm) for six consecutive days in a static exposure
chamber. On the 7th day, mice were exposed to the same dose of toluene vapor in a
dynamic chamber fitted with a microdialysis set-up and the effect of toluene inhalation
on locomotor activity and extracellular DA levels were monitored simultaneously.
The activity data for the six days toluene exposure procedure was analyzed
using 3 x 6 x 10 repeated measures ANOVA with toluene treatment (0 and 4000 ppm)
as the between subjects factor with days and 3-minute time blocks as the withinsubjects factors. The results obtained revealed there was no main effect of the toluene
treatment (F1.8 = 0.98, P = 0.352). However, there was a significant effect of Day (F5,40 =
2.99, P = 0.02), but not Day x Toluene treatment interaction (F5,40 = 0.98, P = 0.44) and
a significant effect of Time (F9,72 = 2.69, P = 0.009), but not Time x Toluene treatment
interaction (F9,72 = 0.64, P = 0.76). For the activity measurement during the recovery
phase, there was no main effect of toluene treatment (F1,7 = 0.16, P < 0.70), day (F2,14 =
0.64, P = 0.55) or Day x Toluene treatment interaction (F2,14 = 1.89, P < 0.19). However,
there was a significant main effect of Time (F3,22 = 20.0, P < 0.0001) and Time x
Toluene treatment interaction (F3,22 = 7.78, P = 0.001). In all, the trends that did not
reach statistical significance could be a result of low statistical power in the repeated
measures design. Meanwhile, statistical analysis of the total distance traveled during
toluene exposure across days (using two tailed Student’s t-test) showed a significant
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effect of the toluene treatment in day 1 (P < 0.05) and day 3 (P < 0.01), but not day 6 (P
> 0.05; Figure 5.5).
The locomotor activity data for day 7 was expressed as a percentage of aircontrol baseline and plotted against time in 15 minutes bins. The data were graphed as
a percentage of control so it would parallel the microdialysis data from baseline to post
high K+ concentration artificial cerebrospinal fluid (aCSF) infusion, which is also reported
as a percent control. Statistical analysis was performed using 2 x 11 repeated measures
ANOVA with toluene treatment (0 and 4000 ppm) designated as the between subjects
factor, and the 15-minute time blocks as the within-subjects factors. As shown in Figure
5.6, there was a significant main effect of Time (F2,13 = 4.54, P < 0.04) but not Time x
Toluene treatment interaction (F2,13 = 2.34, P < 0.14), or main effect of toluene
treatment (F1,8 = 3.17, P = 0.11). Further analysis of locomotor activity at the first
recovery point (R1) using two tailed Student t-test showed no difference between the
activity of toluene exposed and air-control mice during recovery (P > 0.05; Figure 5.6).
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Figure 5.5: Effect of repeated toluene exposure on locomotor activity of
mice. Locomotor activity expressed as distance traveled (cm ± SEM) versus days
of toluene exposure. The data for each day are separated into distance traveled
during air or toluene exposure and their recovery. Activity data were analyzed
using repeated measures ANOVA with toluene treatment (0 and 4000 ppm) as the
between subjects factor, and time and day as the within-subjects factors.
Significant effect was determined using two tailed Student t-test (*P < 0.05, **P <
0.01; n = 6 - 7).
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Figure 5.6: Effect of repeated toluene exposure on locomotor behavior
during dialysate sample collection. Locomotor activity was expressed in 15
minutes bins. T1-T2 represents two 15 minute bins, where mice were exposed to
toluene or air for 30 minutes, R1 - R4 is the 1 hour recovery phase, K0 is 15
minutes of high K+ aCSF brain infusion, and K1 - K4 represent post high K+ aCSF
infusion. Distance traveled is expressed as a percentage of that of the air-control
baseline. Statistical analysis was performed with repeated measures analysis with
toluene as the between subjects factor, and 15-minute time blocks as withinsubject factor. Statistical significance was determined using two tailed Student ttest (n = 5).
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Microdialysis measurements were made to examine how extracellular DA levels
in the NAc are altered following repeated exposure to toluene. The NAc was chosen as
the brain region of interest from our earlier and present slice FSCV results that showed
a decrease in DA release in the NAc following repeated toluene exposure (Figure 5.3).
Dialysis samples were collected in 15 minutes fractions from toluene exposed and aircontrol mice during 2 hours of baseline (BL), 30 minutes of toluene exposure (T), 1 hour
of toluene recovery (R), 15 minutes of high K+ (K0), and 1 hour of post high K+ (K). The
extracellular DA levels are expressed as percentage of air-control baseline plotted with
time in 15 minute bins. Statistical analysis using 2 x 11 repeated measures ANOVA with
toluene treatment (0 and 4000 ppm) designated as the between subjects factor, and the
15-minute time blocks as the within-subjects factors showed a borderline significant
effect of toluene treatment (F1,5 = 6.37, P = 0.05), a significant main effect of Time (F10,50
= 4.15, P < 0.0001), and a significant Time x Toluene treatment interaction (F10,50 =
2.25, P < 0.03). Moreover, Student’s t-test revealed a significant increase in
extracellular DA levels during the second half of the toluene exposure (T2; P = 0.02)
and during recovery (R2 and R4; P < 0.01). An approximate 200% increase in percent
baseline DA levels was seen in toluene treated mice versus the controls, that were at
baseline (100%). This percent increase in DA after 60 mM K+ aCSF infusion was
significant in toluene-exposed mice compared to their air-control (K1 and K2, P < 0.05;
K3, P < 0.01; Figure 5.7). Taken together, repeated toluene exposure altered the
extracellular DA levels in the NAc during and following repeated toluene exposure.
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Figure 5.7: Effect of repeated toluene exposure on extracellular DA levels.
Dialysis sample were collected from the NAc in 15 minute fractions throughout the
experiment. The experimental time included 2 hours of baseline (15 – 120 min),
30 minutes of toluene/air exposure (135 – 150 min), 1 hour recovery (165 – 210
min), 15 minutes of high K+ aCSF infusion (225 min), and 1 hour of post high K+
aCSF infusion (240 – 285). Dialysate DA was expressed as a percentage of aircontrol baseline versus time in 15 minute block and analyzed using repeated
measures ANOVA with toluene treatment (0 and 4000 ppm) as the between
subjects factor, and the 15 minute time blocks as the within-subjects factors.
Statistical significance was determined using a two tailed Student t-test. *P < 0.05,
**P < 0.01, n = 5 – 6.
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5.3.5 Effect of repeated toluene exposure on DA tissue content and its catabolism
The present experiment was performed to examine how repeated toluene
exposure influences intracellular DA levels and its catabolism. Following 7 days of
exposure to 4000 ppm toluene, brain tissues were taken from the CPu and the NAc and
analyzed for DA, DOPAC, HVA, and 3-MT. The results obtained were expressed in
terms of ng DA or metabolite per mg protein. Furthermore, the DA/DOPAC ratio was
evaluated to determine if DA catabolism is altered in these specific brain regions.
Statistical analysis using two tailed Student’s t-test showed no difference in intracellular
DA levels in the CPu (air: 839 ± 136 ng/mg protein; 4000 ppm: 984 ± 126 ng/mg protein;
t = 0.78, P = 0.44, df: 22) between the two treatment groups, suggesting that repeated
toluene exposure does not alter intracellular DA levels. There was no difference in the
intracellular levels of DA metabolites following repeated exposure to 4000 ppm toluene
(DOPAC: air; 202 ± 30, 4000 ppm; 168 ± 20, t = 0.97, P = 0.35, df = 22. HVA: air; 60 ±
8, 4000 ppm; 79 ± 9, t = 1.61, P = 0.12, df = 22. 3-MT: air; 33 ± 5, 4000 ppm; 44 ± 6, t =
1.45, P = 0.16, all means are expressed as ng/mg protein). Thus, the DA/DOPAC ratio
was not different between the two groups of mice (air: 4.2 ± 0.7, 4000 ppm: 5.8 ± 0.5, t
= 1.82, P = 0.08, df = 22, Figure 5.8C). Similar observations were made in the NAc
(Figure 5.8B and C), demonstrating that repeated toluene exposure did not alter
intracellular levels of DA or its metabolites in the NAc.
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Figure 5.8: No difference in intracellular DA levels and its metabolites after
repeated toluene exposure. A-B) Intracellular levels of DA, DOPAC, HVA, and 3MT from the CPu and NAc of mice repeatedly exposed to 4000 ppm toluene vapor
for 7 days and their air-control littermates. C) Repeated toluene exposure has no
effect on DA/DOPAC ratio in the CPu and the NAc. Data shown as mean ± SEM.
Statistical significance determined using two tailed Student t-test (n = 6).
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5.4 Discussion
Repeated toluene administration alters striatal DA neurotransmission leading to
neuroadaptations that may underlie its compulsive and repetitive use.34,
Nevertheless,

the

exact

neural

mechanisms

behind

these

toluene

84, 171, 215

induced

neuroadaptations are not well understood. The primary goal of the present study was to
examine how repeated toluene exposure immediately alters DA neurotransmission in
the NAc and the CPu. Evidence from our initial characterization of the effect of toluene
inhalation followed by a 24-hour recovery period (Chapter 3) suggested that 7 days of
repeated inhalation of 2000 or 4000 ppm of toluene impaired DA release in the NAc, but
not in the CPu. In the present work, neurochemical measurements were made
immediately after toluene exposure on the 7th day, without recovery period. In this case,
similar impairment in DA release was observed exclusively in the NAc. Taking our two
studies together, the results suggest that repeated exposure to toluene exerts a lasting
effect on DA neurons in the NA, thus implicating the NAc as an important neural site for
toluene abuse.36,

216

This observation was not surprising because DA in the NAc is

associated with the abuse liability for most drugs.34,

217, 218

Repeated administration of

drugs such as amphetamine, cocaine, nicotine, and morphine induced differential
changes in DA neurotransmission in the core and shell of the NAc.219-221 The present
work is consistent with these reports; where slice voltammetry displayed decreased DA
release in the core, but not the shell of the NAc after repeated exposure to 2000 or 4000
ppm toluene. Meanwhile, 2000 ppm of toluene decreased DA uptake exclusively in the
NAc core, while 4000 ppm toluene increased DA uptake in the NAc shell. This regional
specificity of was also identified in the acute toluene study (see Figure 4.3) where acute
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toluene inhalation potentiated DA uptake only in the NAc shell. Taken together, the
present observations suggest that repeated inhalation of toluene vapor preferentially
decreases DA release in the NAc core while increasing DA uptake in the shell.
Throughout our numerous studies, a common observation was that DA release
and uptake were decreased in the NAc core. Therefore, we hypothesized that repeated
toluene inhalation would increase extracellular DA levels. We believed that elevated
extracellular DA levels would lead to the compensatory down-regulation of DA release
and uptake observed with slice FSCV in the core. Using in vivo microdialysis, increases
in the extracellular DA levels were observed in the NAc during the 7 th toluene treatment,
although there was no difference in extracellular DA levels prior to toluene inhalation,
which suggests that baseline DA levels are approximately the same between the two
treatment groups. However, an increase in extracellular DA levels occurred during the
exposure period and persisted through the 30-min recovery phase. There was also a
potentiated response in toluene treated animals following high K + stimulation. With the
increases in extracellular DA levels as determined by in vivo microdialysis, we
anticipated that there would be a concomitant increase in locomotor activity since there
is a strong correlation between drug induced elevations in extracellular DA levels in the
NAc and heightened behavioral stimulating effects.34,

171,

217

Although increase

locomotor activity was not observed in the toluene-treated mice, the locomotor activity
results suggest a trend towards increased locomotor activity in the toluene treated mice.
However, the locomotor activity results did not reach statistical significance presumably
because of low statistical power. We also hypothesis that, because the locomotor
activity was measured in their microdialysis cage modified to record locomotor behavior,

122

this confound could have led to not observing the statistical significance in locomotor
behavior. Future studies are aimed to address this concern. Although no difference was
observed in locomotor behavior, our neurochemical measurements did highlight that
toluene exposure elevated extracellular DA levels during and after the exposure, as well
as after a high K+ stimulation.
The neurochemical results thus far suggest that daily intermittent toluene
exposure for 7 days increases extracellular DA levels in the NAc, with a concomitant
decrease in DA release and uptake in the NAc core. Therefore, there is the possibility
that toluene influences presynaptic DA autoreceptors, which are contributing to the
significant alterations observed in the dopaminergic system in the NAc. DA
autoreceptors play an integral role in regulating DA synthesis and release. To determine
if DA autoreceptors directly mediate the action of repeated toluene inhalation on DA
dynamics in the NAc; slice FSCV was used to determine the effect of the DA D3
autoreceptor agonist, 7-OH-DPAT on DA release and uptake. There was no difference
between the 7-OH-DPAT dose response curves of DA release generated from toluene
treated and air-control mice, suggesting no involvement of presynaptic DA D3
autoreceptors in the alterations induced by repeated toluene exposure on DA release in
the NAc. This observation appears contrary to our hypothesis, where we anticipated
that the reduction in stimulated DA release observed in the NAc was a compensatory
down regulation of the DA D3 receptors. However, only DA D3 autoreceptor subtype
was examined; future studies could evaluate the D2 autoreceptor also found in the NAc
or examine heteroreceptors such as a GABA or glutamate receptor that may be
influencing DA release in the NAc.191 Although there was no difference in the 7-OH-
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DPAT dose response curve, a significant decrease in DA uptake was seen between
toluene exposed mice and their air-controls. The decrease in DA uptake was only
observed at the highest dose of 7-OH-DPAT, which is consistent with what has been
shown in other studies suggesting that higher doses of the autoreceptor agonists are
non-specific and have the ability to either directly or indirectly interact with the DA
transporter.222
To round up the neurochemical investigations with the toluene treated mice, our
last investigation was to evaluate intracellular DA levels. Since our initial work in this
study showed an increase in extracellular DA levels and impairment in DA release and
uptake in the NAc core, a final goal was to determine if toluene has the ability to
influence intracellular DA levels or its metabolites. However, repeated toluene treatment
did not influence the intracellular levels of DA and its metabolites in the NAc.
Furthermore, the DA/DOPAC ratio was also unaffected suggesting there was no
difference in DA catabolism. It is interesting that daily, intermittent toluene exposure had
no effect on DA intracellular levels, since our acute studies showed a significant
increase in intracellular DA catabolism (see Figure 4.8). These current observations
from the 7 daily, intermittent toluene exposure suggests tolerance to toluene inhalation,
but only with a sustained amount of toluene exposure. Taken together, the
neurochemical measurements made with slice FSCV, in vivo microdialysis, and tissue
content underscore the complexity of toluene’s neural action, which may involve not
only the DA, but other neurotransmitters and neuromodulators.37, 79, 84, 223, 224
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5.5 Conclusions
In conclusion, the present work demonstrated that repeated exposure to
locomotor activating dose of toluene preferentially impairs DA release and uptake in the
NAc core in a dose dependent fashion. The alterations in DA release were not directly
mediated by DA D3 autoreceptors. Furthermore, repeated exposure to 4000 ppm
toluene potentiated extracellular DA levels in the NAc, but there was no effect on
intracellular levels of DA and its metabolites across the striatum. Taken together, we
have proposed that toluene is most likely influencing the accumbal DA
system through a heteroreceptor, possibly the GABA or glutamate receptor.
.
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CHAPTER 6
Probing the Ability of Presynaptic Tyrosine Kinase Receptors to
Regulate Striatal Dopamine (DA) Dynamics
Adapted and Updated with permission from:
Apawu, A. K., Maina, F. K., Mathews, T.A., “Probing the ability of presynaptic tyrosine
kinase receptors to regulate striatal dopamine dynamics” ACS Chem Neurosci., 2013,
4(5): 895 – 905
Copyright (c) 2013, American Chemical Society
6.1 Introduction
Brain derived neurotrophic factor (BDNF) belongs to a specialized class of
proteins called neurotrophins that play a vital role in neuronal growth, differentiation,
synaptic plasticity, and survival of neurons.145-147 Other members of the family include
nerve growth factor (NGF), neurotrophin-3, (NT-3), and neurotrophin – 4/5 (NT-4/5).2, 15
These neurotrophins execute their functions by binding to specific isoform of tyrosine
kinase receptors called tropomyosin-related kinase (Trk) receptors which are TrkA, TrkB
and TrkC.18,
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BDNF propagates its effect by specifically binding to TrkB receptors,

which causes dimerization of the receptors and phosphorylation of its tyrosine residue
and subsequent activation of kinases.16 These actions lead to activation of a number of
small signaling proteins such as GRB2, SHC, and SOS that mediate various signaling
cascades through phosphorylation to regulate neuronal events including cell survival,
synaptic plasticity, synaptic transmission, and neurotransmitter release.2, 16, 18, 19
The interaction between BDNF and the DA system is well known. For example,
the mesencephalic dopaminergic neurons have been shown to express TrkB
receptors.226 In addition, in vitro data has revealed that BDNF augments survival and
differentiation of cultured nigral DA neuron whereas chronic infusion of BDNF directly
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into rat’s brain has been shown to enhance DA release, DA turnover and metabolism,
DA neuronal activity, and survival.150, 226-228 Moreover, BDNF has been reported to upregulate DA transporter activity in striatal synaptosomes of rat brain.149 Existing data
also shows that BDNF heterozygous (BDNF+/-) mice (with 50% reduction in BDNF
protein levels) have higher intracellular DA concentrations in the striatum, while
exhibiting decrease DA release in the striatum.229,

230

BDNF+/- mice have reduced

expression and function of the DA D3 receptors in the caudate-putamen (CPu) and
nucleus accumbens (NAc) compared to their wildtype littermates.183, 231 Our laboratory
has shown that BDNF+/- mice have an ~ 2.5-fold increase in extracellular DA levels in
the CPu compared to wildtype mice as measured by zero net flux, with fast scan cyclic
voltammetry (FSCV) data showing a decrease in electrically evoked DA release and
uptake.232 Our initial neurochemical analysis on CPu DA dynamics suggests that
endogenous BDNF influences DA system homeostasis primarily by regulating release
leading to adaptions in the DA uptake function.232 All these data together with many
more provide overwhelming evidence of the ability of BDNF to modulate DA function
across different brain regions including the striatum. Nevertheless, the mechanism of
how BDNF influences the DA function is still not well understood.
To examine the mechanism underlining the influence of BDNF on presynaptic DA
release and uptake processes, the experiments herein explores FSCV’s utility to
characterize the functional effect of Trk receptors on the presynaptic DA release and
uptake dynamics in the striatum. The functional effect of Trk receptors has been
examined previously using classic radiochemical methods in synaptosomes and brain
slices.149,

233, 234

These existing radiochemical methods provide high selectivity to
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examine each of the DA parameters. For example the DA transporter function can be
studied devoid of contributions from the DA release and diffusion.235 However, the
strength that FSCV brings to the field would be its high temporal resolution (up to 100
ms) and ability to assess DA release and uptake rate simultaneously. By using FSCV
on striatal brain slices, it eliminates contributions from post-synaptic TrkB receptors
allowing us to better understand how presynaptic TrkB receptors contribute to
modulating DA dynamics. In the present work, DA release and uptake dynamics have
been evaluated in the striatum by using the endogenous ligand BDNF, commercially
available TrkB agonist 7,8-dihydroxyflavone (7,8-DHF), and

inhibitors such as

genistein, tyrphostin 23 (AG 18), and K252a. Herein, we demonstrate the ability of
FSCV to assess the effect of non-DA receptors like the TrkB on striatal DA dynamics,
and will be useful to provide a better understanding of how other systems contribute to
the strength of synaptic DA transmission.
6.2 Hypothesis
We hypothesize that life-long reduction in BDNF results in compensatory
alteration in DA release and uptake dynamics, which we believe are being modulated by
presynaptic TrkB receptor activation.
6.3 Materials and Methods
6.3.1 Animals
Wildtype and BDNF+/- mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and offspring were raised as a colony in-house in a certified vivarium
(Association for Assessment and Accreditation of Laboratory Animal Care; AAALAC) at
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Wayne State University. Genotype identification was performed using PCR analysis of
tail DNA as already described by Bosse et al.94
6.3.2 Chemicals
Chemicals used in the preparation of artificial cerebrospinal fluid (aCSF) for
voltammetric solutions were purchased either from Sigma-Aldrich (St. Louis, MO),
Fisher Scientific Co. (Fairlawn, NJ), or EMD Chemicals, Inc. (Gibbstown, NJ) unless
otherwise noted. The following compounds were purchased from specific vendors: 7,8DHF from Tokyo Chemical Industry Co. LTD. (Portland, OR), BDNF from PeproTech
(Rocky Hill, NJ), and K252a from LC Laboratories (A Division of PKC Pharmaceuticals
Inc., Woburn, MA). In all slice experiments, the pharmacological agents were dissolved
in ultrapure (18 MΩ cm) water or dimethyl sulfoxide (DMSO), unless otherwise stated
and then diluted in oxygenated aCSF (composition in mM: 0.4 ascorbic acid, 126 NaCl,
2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 25 NaHCO3, 1.2 NaH2PO4, 11 D-glucose, and pH 7.4). All
chemicals used in calibration experiments, including the verification of the redox
capability of the drugs, were dissolved in DMSO and then diluted in a modified
calibration aCSF buffer (composition in mM: 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 25
NaHCO3, 1.2 NaH2PO4, and pH 7.4).
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Figure 6.1: Chemical structures of TrkB receptor agonist and antagonists
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6.3.3 Slice FSCV
Mouse brain slices were obtained and voltammetric recordings were made as
described in Chapter 2.5. Briefly, 400 μm coronal brain slices obtained from BDNF +/and Wildtype mice were stimulated every 5 minutes using a one pulse electrical
stimulation (monophasic, 350 μA, 60 Hz, and 4 ms pulse width) to elicit DA which was
measured using a homemade carbon fiber microelectrode (with a length between 50 200 μm and a 7 µm diameter held at initial potential of -0.4 V, ramped up to +1.2 V and
back to -0.4 V at a scan rate of 400 V/s at 10 Hz). Current generated at the
microelectrode surface as a result of the redox reaction of DA was subtracted from the
background current to obtain peak oxidation current for DA. The peak oxidation current
for DA was converted into concentration based on a post-calibration using 3 µM DA.
Following three stable DA release profiles (within 10% of each other), the effect of
cumulative concentrations of pharmacological agents; exogenous BDNF, 7,8dihydroxyflavone (7,8-DHF), gensitein, tyrphostin 23 (AG18), K252a, or a single dose of
BDNF-K252a, or 7,8-DHF- K252a cocktail was evaluated. To verify the redox capability
of the pharmacological agents, flow injection analysis as described in Chapter 2.5.3 was
used to measure the response of these pharmacological agents at a carbon fiber
microelectrode surface. Three different concentrations (3, 10, and 20µM) of each
pharmacological agent were made by dissolving the respective stock solutions in 20 mL
of aCSF (calibration buffer) with physiological pH of 7.40. Each concentration was run in
triplicates during which the microelectrode was held at initial potential of -0.4 V, ramped
up to 1.2 V and back down to -0.4 V at a scan rate of 400 V/s.
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6.3.4 Data Analysis
All voltammetric data were analyzed using LabVIEW National Instruments
software (National Instruments, Austin, TX). Current versus time traces were fitted to a
non-linear regression.154,

163

A Michaelis-Menten based kinetic model was used to

evaluate stimulated presynaptic DA release ([DA]p) and DA uptake kinetics (maximum
velocity, Vmax) and affinity of DA to its transporter (apparent Km) by fitting DA current
versus time traces.94,

163

In all voltammetric analysis, Km values were set to 0.16 μM,

which permits a non-linear fit of DA release and uptake. Statistical analysis was
performed using GraphPad Prism (GraphPad Software, Inc., San Diego, CA) during
which statistical significance was determined by one-way ANOVA with Dunnett's
Multiple Comparison Test. The criterion for the statistical significance of DA analysis
was set to P < 0.05. All data are reported as mean ± standard errors of the means
(SEMs).
6.4 Results and Discussion
6.4.1 Characterization of the electrochemical properties of 7,8-dihydroxyflavone,
K252a gensitein, and tyrphostin 23
The main goal of the experiments described in this section was to examine if the
pharmacological agents used have electrochemical properties that could directly
interfere with DA signals instead of their cellular action on the DA system during the
brain slice drug perfusion experiments. This goal stems from the fact that the structures
of 7,8-DHF and tyrphostin 23 are similar to that of DA insofar as the molecules contain
the catechol moiety, Thus, we expected these two molecules to have similar redox
reaction as that of DA at the electrode surface. Furthermore, although K252a does not
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contain a catechol moiety, it does have a single hydroxyl group that could be easily
oxidized like tyramine and octopamine.236 while genistein on the other hand, is a
polyphenol with three hydroxyl groups (Figure 6.1) which can undergo electron transfer
oxidation reaction like quercetin.237 To delineate the electrochemical properties of these
molecules, we used a flow cell apparatus to evaluate their oxidation and reduction
potentials. The results obtained have been expressed in terms of background
subtracted cyclic voltammograms. As expected, 7,8-DHF showed a single oxidation and
reduction peak at ~ 0.4 V and at -0.2 V respectively (Figure 6.2C). The single oxidation
and reduction peak for 7,8-DHF suggests that it is a reversible electrochemical reaction.
It is our hypothesis that the hydroxyl groups on the catechol are oxidized in much the
same way as it is in DA (Figure 6.2A) and other catecholamine molecules. A notable
difference in 7,8-DHF and DA cyclic voltammograms is that 7,8-DHF oxidizes at ~ +0.2
V less than DA. We believe this difference is due to the second ring structure attached
to the catechol moiety providing additional stability/resonance to the molecule. Similarly,
the background subtracted voltammograms of tyrphostin 23 showed oxidation and
reduction peaks at ~ 0.6 and ~ 0.02 V respectively (Figure 6.3C). Interestingly, these
oxidation-reduction peaks of tyrphostin 23 were suppressed in presence of DA (Figure
6.3D). K252a gave a very distinct cyclic voltammogram with oxidation peaks at ~ +0.4
and +1.1 V, and a reduction peak at ~ +0.9 V (Figure 6.2E). When DA and K252a were
combined, there appeared to be no overlap with oxidation peaks of the two components
(Figure. 6.2F). Genistein showed three oxidation peaks at 0.2, 0.8 and 1.0 V
respectively (Figure 6.3A; a-c) which appeared to be irreversible at physiological pH.
The genistein voltammogram could suggest oxidation of the para-substituted phenol
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and the resorcinol moiety.238 The DA-genistein mixture showed peaks characteristic of
the two constituents with DA masking the first peak of gensitein. Taken together, the
present background subtracted voltammograms demonstrated that each of the drugs
examined is electrochemically active at pH of 7.40 with most of them exhibiting
reversible oxidation reactions. However, the DA signals (current) and oxidation potential
are no different in the presence of these compounds which strongly support the notion
that background subtraction eliminates any possible electrochemical confounds
associated with the perfusion of the drugs. This assertion is further supported by the
voltammograms for the slice FSCV data as no interfering peaks were observed during
drug perfusion experiments (Figures 6.4-6.5).
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Figure 6.2: Background subtracted cyclic voltammograms and redox reactions
showing electrochemical properties of DA, 7,8-dihydroxyflavone and K252a.
Data was obtained using flow injection analysis of varying concentrations of each
molecule. A) Oxidation-reduction reactions of DA and 7,8-DHF respectively. Both
molecules oxidize in a similar electron transfer reaction to form ortho-quinones
during the forward scan of the applied voltage. In the reverse scan, the quinones are
reduced back to DA and 7,8-DHF respectively. B) Cyclic voltammogram shows
oxidation peak of DA at ~ 0.6 V and reduction peak at ~ -0.2 V. C) Cyclic
voltammogram of 7,8-DHF. Oxidation peak of 7,8-DHF occurs at ~ 0.4 V whereas
the reduction peak appears at ~ -0.2 V. D) A solution of both DA and 7,8-DHF
demonstrates the characteristic oxidation peaks of the two compounds only at higher
concentrations as depicted by their voltammograms. E) Cyclic voltammogram
showing oxidation and reduction peaks of K252a. F) Cyclic voltammograms showing
oxidation and reduction of DA-K252a solution.

135

Figure 6.3: Background subtracted cyclic voltammograms showing
electrochemical properties of genistein and tyrphostin 23. A) Cyclic
voltammograms of gensitein showed non-reversible three oxidation peaks of the
compound occurring at 0.2, 0.8 and 1.0 V respectively. B) In dopamine-genistein
mixture, cyclic voltammograms showed both oxidation-reduction profile of DA
and two non-reversible oxidation peaks of gensitein. C) tyrphostin 23 oxidizes at
~ 0.6 and reduces at ~ 0.02 V. D) The voltammogram showed the presence of
DA suppressed the oxidation property of tyrphostin 23.
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6.4.2 Effect of exogenous BDNF on electrically evoked DA release in BDNF+/- mice
Numerous reports suggest that exogenously applied BDNF enhances both DA
release and uptake.21,

149, 150, 239

To date, no one method has been used to

simultaneously analyze both release and uptake parameters. To evaluate the functional
effects of how exogenous BDNF influences presynaptic DA dynamics directly in the
CPu, electrically evoked DA release (Figure 6.4), and uptake rates (Table 1) were
monitored every 5 minutes in BDNF+/- mice. Direct application of cumulative
concentrations of exogenous BDNF (50, 100, and 200 ng/mL) was applied to brain
slices for 30 minutes. BDNF+/- mice were only evaluated with BDNF perfusion because
we have previously shown that DA release and uptake rates are not different in wildtype
mice.94 BDNF+/- mice showed a concentration-dependent increase in electrically
stimulated DA release after BDNF was applied to striatal brain slices compared to their
pre-drug controls (50 ng/mL BDNF: ~ 12%, 100 ng/mL BDNF: ~ 17%, and 200 ng/mL
BDNF: ~ 18%, Figure 6.4A). However, no difference in Vmax was observed after BDNF
perfusion (Table 1). We have extended and confirmed our previous findings,94 that
exogenous application of BDNF from 50 to 200 ng/mL elevates evoked-DA release with
no effect on DA uptake rates in BDNF+/- mice.
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Figure 6.4: Infusion of BDNF dose dependently increases electrically
stimulated DA release in the caudate-putamen of BDNF+/- mice. A) Current
versus time trace of baseline DA signal with corresponding cyclic voltammogram
(inset) compared to current versus time trace of electrically evoked DA release after
a 30 minute perfusion of 200 ng/mL BDNF (red line) with corresponding cyclic
voltammogram (red line, inset). B) Effect of varying concentrations of exogenous
BDNF on DA release expressed as a percentage of pre-drug DA concentration.
Data are means ± SEMs (n = 5 mice). One-way ANOVA (F3,36 = 9.42; P < 0.0001, n
= 5) followed by Dunnett’s post-test revealed that each concentration of BDNF
increased DA release significantly. **P < 0.01, ***P < 0.0001.
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6.4.3 Effect of genistein and tyrphostin 23 (AG 18) on presynaptic DA dynamics
To examine the mechanism underlining the influence of BDNF on presynaptic DA
dynamics, the experiments herein explores FSCV’s utility to characterize the functional
effect of Trk receptors by measuring the effect of Trk receptor antagonist; genistein and
tyrphostin 23 on electrically stimulated DA release and uptake in the CPu. Genistein
and tyrphostin 23 have been extensively studied as potent Trk receptor inhibitors.149, 240242

For example, using these two Trk receptor inhibitors, Hoover et al. successfully

demonstrated that tyrosine kinases modulate the DA transporter function in rat brain
preparations.149 In the present work, we first obtained stable electrically evoked DA
signal before perfusion of genistein or tyrphostin 23. The results obtained showed that,
BDNF+/- mice have significantly lower pre-drug electrically evoked DA release compared
to their wildtype counterpart (Figure 6.5A versus B, Figure 6.6A versus B, open bars, #P
< 0.05, Student t-test). Furthermore, the DA uptake in the BDNF+/- mice was lower
compared to their wildtype littermates (Figure 6.5C versus D, Figure 6.6C versus D,
open bars,

###

P < 0.001, Student t-test). This low stimulated pre-drug DA release and

uptake is in agreement with earlier work that has suggested that endogenous BDNF
affects the homeostasis of the DA system by regulating the release and uptake
processes.94 Following stable DA signal (successive peaks with peak height within 10%
of each other), cumulative concentrations of genistein (10, 50, and 100 µM) or
tyrphostin 23 (10, 20, and 50 µM) were perfused on brain slice during which
measurements were made every 5 minutes and the effect of each dose was monitored
for 30 minutes. These concentrations of the drugs have been chosen based on
preliminary experiments. When genistein was applied to the striatal brain slice, no
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significant alteration in electrically stimulated DA release was observed in wildtype mice
(P = 0.094, one-way ANOVA; Figure 6.5A) and BDNF+/- mice (P = 0.602; one-way
ANOVA; Figure 6.5B) compared to their respective pre-drug controls. However,
perfusing high concentrations of the inhibitor (≥ 50 µM in wildtype mice and 100 µM in
BDNF+/- mice) decreased DA uptake rate in the two groups of mice. This observation
suggests that tyrosine kinase receptors are involved in regulating the DA transporter
function at the presynaptic level. While inhibition of Trk receptors with genistein did not
seem to alter presynaptic DA release, we suspect that the drug could also be involved
in other non-tyrosine kinase effects.149,

241, 243-246

To verify that inhibition of Trk

receptors could alter both presynaptic DA release and uptake dynamics, stimulated DA
release and uptake in presence of tryphostin 23, a more selective Trk receptor inhibitor
149

was measured in both wildtype and BDNF+/- mice. The data obtained showed that

when tyrphostin 23 was applied to the striatal slice, there was a significant decrease in
electrically stimulated DA release in both genotypes. The uptake rate in the two
genotypes (Figure 6.6C and D) was also decreased with increasing concentration of
tyrphostin 23. Altogether, the decrease in stimulated DA release and uptake rate
observed in the two groups of mice is consistent with our expectation of Trk receptor
inhibitor and also with earlier report that that has shown that pre-incubation of rat dorsal
striatal synaptosomes with tyrphostin 23 reduces specific uptake of radiolabeled DA
into the synaptosomes in a concentration dependent fashion.149 The present results
thus, suggest that FSCV is an important tool to tease apart the effect of Trk receptors
on presynaptic DA release and uptake dynamics.
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Figure 6.5: Effect of genistein on electrically evoked DA release and uptake in
the CPu of wildtype (WT) and BDNF+/- mice. Evoked DA release in presence of
perfused genistein was expressed as percentage of WT baseline for A) WT mice and
B) BDNF+/- mice. DA uptake rate (Vmax) was attenuated in presence of high
concentrations of genistein for C) WT mice and D) BDNF+/- mice. **P < 0.01 and ***P <
0.001 compare to respective pre-drug concentration (one way ANOVA with Dunnette
Multiple comparison test), ###P < 0.001 versus WT baseline (Student t-test), n = 57/group.
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Figure 6.6: Effect of tyrphostin 23 (AG 18) on evoked DA release and uptake
in the CPu of wildtype (WT) and BDNF+/- mice. High concentrations of
tyrphostin 23 decreased electrically evoked DA release (expressed as percentage
of WT baseline) in A) WT mice and B) their BDNF+/- littermates. DA uptake rate
(as Vmax) was decreased in the presence of high concentrations of the inhibitor in
C) WT mice D) the mutant mice. ***P < 0.001 compare to respective pre-drug
concentration (one way ANOVA with Dunnette Multiple comparison test), #P <
0.05 and ###P < 0.001 versus WT baseline (Student -test), n = 4-5/group.
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6.4.4 Effect of K252a on presynaptic DA dynamics in wildtype mice
BDNF signaling is mediated by the TrkB receptor.2,

247

However, it is unclear

whether the TrkB receptor activation affects DA release and uptake. To find the answer,
we used potent Trk receptor inhibitor, K252a.248,

249

K252a was perfused over a brain

slice for 30 minutes per dose, and its effects were monitored every 5 minutes (Figure
6.7A). Dunnett’s post-test revealed a significant (P < 0.05) reduction in stimulated DA
release only at the highest K252a concentration (3 µM). Increasing the concentration of
K252a from 0.01 to 3 µM reduced Vmax in a concentration-dependent manner (Figure
6.7B and D).
Our results from the CPu of wildtype mouse brain slices show that concentrations
less than 3 µM of K252a alone has no effect on electrically stimulated DA release.
These results agree with previous studies showing that concentrations of K252a less
than 1 µM have no effect on stimulated DA release.250,

251

Only the highest

concentration of K252a applied to brain slices reduced electrically stimulated DA
release. We cannot rule out the possibility that K252a reduced the amount of stimulated
DA release by acting at other Trk receptors. Although K252a is used to selectively block
BDNF-TrkB signaling, it is also a non-specific inhibitor of tyrosine kinase protein activity
including the TrkA and TrkC receptor sub-types.252 Such actions could contribute to the
decrease in electrically evoked DA when K252a is applied at the highest concentration.
This is the first report demonstrating the rapid reduction in DA transporter kinetics
in the CPu of wildtype mice when K252a concentrations are greater than 0.1 µM and is
in agreement with the previous work by Hoover et al., where inhibition of tyrosine
kinases by genistein (a non-specific Trk inhibitor) or tyrphostin 23 (a selective Trk
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inhibitor) resulted in rapid (5 – 15 minute), dose-dependent decreases in [3H]DA uptake
rates in a dorsal striatal synaptosomal preparation.149 It may appear inconsistent that
activation of TrkB with BDNF increases stimulated DA release, while inhibition of this
receptor reduces DA uptake, but Trk receptors activate multiple signaling pathways.
Considerable evidence in the literature suggests a divergent role for TrkB where BDNF
activation increases neurotransmission,94,

233, 239, 251

while Trk inhibitors reduce DA

uptake.149 The exact mechanism causing this divergent response is unknown, but it is
hypothesized that inhibition of the Trk receptor blocks autophosphorylation, which
reduces activity in numerous signaling cascades such as phosphatidylinositol-3 kinase
(PI3K), mitogen-activated protein kinase (MAPK), and extracellular signal-regulated
kinase (ERK1/2) reaction pathways, all of which have been linked to decreases in DA
transporter activity by decreasing Vmax.149,

253-257

The results of this study suggest that

inhibition of the TrkB receptor reduces the DA transporter function, but more studies are
required to determine the specific Trk-signaling pathways that may be involved in
regulating DA transporter kinetics.
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Figure 6.7: Effect of TrkB inhibitor, K252a on stimulated DA release and
uptake in the CPu of WT mice. A) Representative DA release and uptake after
a 30 minutes perfusion of 0.03 µM K252a compared to pre-drug DA signal
shown by their representative current versus times traces with corresponding
cyclic voltammograms (inset). B) Effect of 3 µM K252a on DA release and
uptake represented in terms of concentration versus time trace and cyclic
voltammogram (inset). C) K252a produced a significant effect on stimulated DA
release as determined by a one-way ANOVA (F5,61 = 3.05; P < 0.05, n = 4-7). A
Dunnett’s post-hoc test confirmed that only 3 µM K252a perfusion attenuated
stimulated DA release. D) One-way ANOVA (F4,25 = 14.93; P < 0.0001, n = 4 - 7)
followed by Dunnett’s post-test revealed that K252a concentrations greater than
0.01 µM K252a significantly decreased Vmax. Data are means ± SEMs (n = 4 - 7
mice). *P < 0.05, **P < 0.01, ***P < 0.001.
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6.4.5 K252a inhibits BDNF’s ability to acutely modulate striatal DA release in
BDNF+/- mice
To demonstrate that exogenously applied BDNF modulates presynaptic DA
dynamics via the TrkB receptor electrically evoked DA release, and uptake rates were
monitored every 5 minutes following direct application of BDNF (100 ng/mL) only,
K252a (1 μM) only, or pre-treatment with K252a prior to BDNF administration to a slice
for 30 minutes. In the absence of exogenous applications of BDNF or K252a, electrically
evoked DA from the CPu of BDNF+/- mice (referred to as ‘baseline’ in Figure 6.8) was
reduced by ~ 40% compared to their wildtype littermates, which is delineated as the
dashed line at 100% (Figure 6.8). Exogenous application of BDNF significantly
potentiated stimulated DA release by ~ 16% in BDNF+/- mice (P < 0.001), while there
was no difference in that of the wildtype mice. Pretreatment of the striatal BDNF +/- slice
with K252a abolished this modulatory effect of BDNF, suggesting that the increased DA
release may be mediated by presynaptic TrkB receptors. There was no difference in
electrically evoked DA release in wildtype mice in the presence of BDNF, K252a or the
combination of the two.
The ability of K252a to block the BDNF-induced increase in DA release in the
CPu of BDNF+/- mice suggests that the TrkB receptor can mediate DA release. Our
findings are in agreement with previous results that have shown BDNF-induced
stimulated DA release is blocked in the presence of K252a.230,

239

An issue with

examining monoamine output after BDNF infusion is identifying the specific signal
transduction cascade(s) involved. For example, the acute BDNF-potentiation of DA
release is suggested to be dependent on PI3 kinase and Ras-MEK activation only.239
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However, the exact mechanism of how BDNF mediates DA release has remained
elusive.
6.4.6 Exogenous BDNF application has no effect on DA dynamics in wildtype
mice
Neurotrophic factors, like BDNF are typicallythought of as promoting long-term
effects on neurons such as synaptic plasticity, neuronal survival, and differentiation. Our
results demonstrate that the acute effects of TrkB activation via BDNF leads to a rapid
increase in DA release in the CPu of BDNF+/- mice, while there is no difference in
stimulated DA release with BDNF perfusion in our wildtype mice (Figure 6.8C). Previous
reports using wildtype mice/rats established that acutely, exogenously applied BDNF
enhances synaptic events such as DA release both in vivo and in vitro.21,

150, 233

We

hypothesize that this difference in BDNF-induced DA release between our wildtype mice
and those from previous studies is a result of methodological differences between slices
and synpatosomes. For example, all synaptosomal preparations required the coincubation of BDNF and high K+ artificial cerebral spinal fluid (aCSF) over a time course
of minutes to observe BDNF-potentiated DA release.21,

150, 233, 239

Furthermore, DA

release was measured as an accumulation of exogenously applied 3[H]-DA, while our
wildtype slices received a one-millisecond electrical stimulation that recruited
endogenous DA. Taken together, an acute perfusion of BDNF can rapidly potentiate DA
release in a system with low endogenous BDNF levels, but in a normal system, like that
of wildtype mice, stronger stimulation parameters may be required.
6.4.7 K252a does not modulate striatal DA transporter kinetics in BDNF+/- mice
Studies have also suggested a role for Trk receptors in modulation of DA uptake
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evidenced by the use of Trk inhibitors, which have been shown to alter DA transporter
function, expression and/or kinetics.149 An advantage of slice FSCV is that both
presynaptic DA release and uptake are simultaneously evaluated. The objective was to
use FSCV to determine if an exogenous application of BDNF influences DA transporter
kinetics as it does with DA release. Exogenous BDNF applications only potentiate
evoked DA release with no difference in DA uptake rates in BDNF +/- mice (Figure 6.8D).
Therefore, we have hypothesized that the 50% reduction in DA transporter function is
the compensatory response to having a life-long reduction in BDNF levels since this
parameter was unaltered.94 There was no effect of K252a on DA Vmax in BDNF+/- mice.
With respect to DA transporter expression in BDNF+/- mice, when the mice are less than
6 months of age, there is no difference in DA transporter expression or activity.258,

259

But little research has focused on evaluating whether TrkB inhibition influences DA
transporter function or expression in BDNF+/- mice. There is no difference in striatal
TrkB and phosphorylated TrkB (pTrkB) levels between the genotypes.108 However,
BDNF+/- mice show an increase in the ratio of striatal pTrkB/TrkB with a concomitant
potentiation in striatal pERK/tERK2 levels.108 In order to better understand if and how
tyrosine kinase receptors modulate DA transporter expression or activity, future studies
should evaluate specific intracellular cascades that may mediate the interactions
between TrkB and the DA transporter.
6.4.8 K252a modulates striatal DA transporter kinetics in the presence or absence
of exogenous BDNF in wildtype mice
Interestingly, perfusion of K252a in the presence or absence of BDNF
significantly attenuated DA uptake rates in wildtype mice (analyzed by Dunnett’s post-
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test P < 0.05). These results show that Trk inhibition in wildtype slices has the ability to
modify/regulate DA transporter kinetics given the reduction seen upon application of
K252a alone. Although K252a has been shown to have no effect on DA V max when
applied to rat dorsal striatal synpatosomes, the same cannot be said about nonselective tyrosine kinase inhibitors.149 When the non-selective tyrosine kinase inhibitors
genistein and tyrphostin-23 were acutely applied, a significant decrease of striatal DA
transporter surface expression and Vmax were observed, but Km was not different.149
Western blotting suggested that this mechanism of decreasing DA transporter V max and
surface expression was mediated via MAPK p42 and p44 isoforms as these
phosphorylated levels were decreased after inhibition.149 The difference between the
present results and those obtained by Hoover et al. with respect to K252a, could be due
to the 10-fold less concentration of K252a (10 vs. 1000 nM, respectively) than what we
used. In the present study, the high concentration of K252a could be non-selectively
binding to other tyrosine kinase receptors such as the TrkA and TrkC sub-types, which,
in turn, could be inducing a reduction of striatal DA uptake rates. Furthermore, there are
numerous methodological differences between our FSCV results and the results
obtained via the synpatosome preparations that Hoover et al. used. First, there is the
species difference, rat versus mouse. Second, different methods were used to analyze
uptake rates and their respective temporal resolution. Slice FSCV measures millisecond
stimulated endogenous DA to evaluate DA release and uptake rates (V max), where Km is
fixed, while synpatosome preparations require minutes to collect enough DA to analyze
uptake parameters.
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Figure 6.8: Effect of exogenous application of BDNF (100 ng/mL) on DA
release and uptake rates in the CPu of WT and BDNF+/- mice. A)
Representative current versus times traces with corresponding cyclic
voltammograms (inset) from BDNF+/- mice before and after BDNF infusion. B)
K252a blocked the ability of BDNF to potentiate DA release in the CPu of BDNF +/mice as shown in representative current versus times traces with corresponding
cyclic voltammograms (inset). C) Normalized single pulse, electrically evoked DA
release represented as % of WT baseline, wildtype mice are represented by the
dashed line. Two-way ANOVA of electrically stimulated DA release in response to
drug application showed a main effect of treatment (F3,74 = 10.37, P < 0.001),
genotype (F1,74 = 216.9, P < 0.001), while there was no treatment X genotype
interaction (F3,74= 2.612, P = 0.056). D) DA uptake rates in WT and BDNF+/- mice
before and after 30 minute perfusion of either 100 ng/mL BDNF, 1 µM K252a, or
both in the caudate putamen. A two-way ANOVA evaluating DA uptake kinetics
indicated there was no difference in the main effect of treatment (F3,82 = 2.09, P =
0.11) and treatment X genotype interaction (F3,82 =1.45, P = 0.23). There was a
significant main effect for genotype (F1,82 = 7.38, P < 0.01), corroborating that the
kinetics of the DA transporter are reduced in BDNF+/- mice versus wildtype mice (P
< 0.01). Data are means ± SEMs (n = 4 – 5 mice per treatment group). ***P <
0.001 compared to untreated BDNF+/- mice (two-way ANOVA). *P < 0.05 as
compared to WT mice baseline (one-way ANOVA).
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6.4.9 TrkB agonist, 7,8-DHF potentiates electrically evoked DA release in the CPu
of only wildtype mice
The TrkB agonist, 7,8-DHF has been reported to be neuro-protective when
administered prior to a DA-neurotoxic treatment using 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP).260 To examine the ability of 7,8-DHF to modulate
presynaptic DA dynamics, a cumulative dose (0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10, and 30
µM) of 7,8-DHF was applied to striatal brain slices following a stable, electrically evoked
DA signal. The effect of 7,8-DHF on DA release and uptake processes was measured
every 5 minutes for 30 minutes per dose in both wildtype and BDNF +/- mice. A dose
response curve for the effect of cumulative dose of 7,8-DHF on electrically evoked DA
release in wildtype mice was normalized to percent of baseline stimulated DA. In the
wildtype mice 10 μM 7,8-DHF significantly increased stimulated DA release, where the
half maximal effect (EC50 value) of 7,8-DHF is at ~ 150 ± 12 nM (n = 8, Figure 6.9C).
With respect to BDNF+/- mice, there was no difference in DA release after perfusion of
7,8-DHF (F8,90 = 0.014, P = 0.89). Stimulated DA release data from BDNF+/- mice was
normalized with respect to wildtype mice since stimulated DA release levels are
different under basal conditions (Figure 6.9C). Concentrations of 7,8-DHF greater than
1 μM show an ~ 10% further reduction in stimulated DA release levels in BDNF +/- mice.
These results in the BDNF+/- mice are surprising since we initially predicted that BDNF+/mice would have a leftward shift in their dose response curve based on their results with
BDNF perfusion. However, future studies are required to better understand how 7,8DHF induces DA release.
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6.4.10 TrkB agonist, 7,8-DHF has no effect on DA transporter kinetics in the CPu
across the genotypes
There was no difference in DA transporter Vmax rates in wildtype mice (F8,207 =
0.32, P = 0.99, Table 1). While a one-way ANOVA revealed a significant main effect of
7,8-DHF on the DA uptake rate in BDNF+/- mice (F8,89 = 3.19; P < 0.01, Table 1). Only
concentrations 3.0 and 30 µM 7,8-DHF had a significantly decreased DA Vmax rates in
BDNF+/- mice as analyzed by a Dunnett's post-test analysis (P < 0.05).
Similar to BDNF, acutely applied 7,8-DHF does not affect striatal DA transporter kinetics
in the wildtype mice. However, it is unknown what higher BDNF concentrations (> 200
ng/mL) will do given its prohibitive cost. Thus, it is difficult to know if higher
concentrations of BDNF would have a similar effect on DA transporter kinetics as 7,8DHF. Although it is possible that these high concentrations of 7,8-DHF (> 3.0 µM) are
non-specific and activating other Trk receptor subtypes like TrkA and TrkC, we have not
evaluated these receptor subtypes nor their ability to regulate presynaptic DA dynamics,
and cannot rule out their contribution to presynaptic DA dynamics especially at these
higher doses. Overall, the primary acute effect of 7,8-DHF does not appear to regulate
striatal DA transporter kinetics in wildtype mice.
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Figure 6.9: Effect of cumulative dose of TrkB agonist, 7,8-DHF on electrically
evoked DA release in the CPu of WT and BDNF+/- mice. A) Current versus time
trace of pre-drug DA signal with corresponding false color plot and cyclic
voltammogram (inset). The false color plots present data in terms of time (x-axis)
versus voltage (y-axis) versus current (color), where the green and blue colors
denote oxidation and reduction current, respectively. The red triangle represents the
point of electrical stimulation. B) Current versus time trace of electrically evoked DA
release after a 30 minute perfusion of 10 µM 7,8-DHF with corresponding false color
plot and cyclic voltammogram (inset). C) Dose response curve of the effect of
cumulative dose of 7,8-DHF on electrically evoked DA release in WT and BDNF+/mice, which is normalized to percent of wildtype baseline stimulated DA. In the
wildtype mice, there was a significant main effect of 7,8-DHF on stimulated DA
release (F8,204 = 0.18, P < 0.05) as determined by one-way ANOVA. A Dunnett’s
post-test analysis indicated that 10 μM 7,8-DHF significantly increased stimulated
DA release (P < 0.05) in wildtype mice. The cumulative dose of 7,8-DHF did not alter
electrically evoked DA release in BDNF+/- mice (n = 3 - 4). Data are means ± SEMs.
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6.4.11 K252a blocks the ability of 7,8-DHF to increases DA release in wildtype
mice
To demonstrate that 7,8-DHF is mediating its effect through the TrkB receptor,
K252a (30 nM) was applied to the brain slice prior to agonist application. The objective
was to block the 7,8-DHF mediated increases in electrically evoked DA in wildtype mice.
A concentration of 10 μM 7,8-DHF was applied to the slices; this dose was chosen
because it potentiated stimulated DA release in wildtype mice with no effect on DA
transporter kinetics. A one-way ANOVA showed a main effect that wildtype mice
respond differently depending on TrkB treatment (F3,68 = 3.29; P < 0.05, Figure 6.10C).
Wildtype mice showed an approximate 20% increase in stimulated DA release after 7,8DHF (P < 0.05) only. While there was no difference in stimulated DA release after
K252a only. When wildtype striatal slices were pretreated with K252a followed by 7,8DHF applications, stimulated DA release was blocked. These results with K252a and
7,8-DHF demonstrate that the potentiated stimulated DA release in wildtype mice is
mediated via the TrkB receptor. Numerous reports have indicated that 7,8-DHF is an
agonist for the TrkB receptor

261-268

and our results further confirm these previous

findings. 7,8-DHF, like exogenous BDNF applications can quickly regulate trophic factor
pathways leading to activation, and/or recruitment of DA release mechanisms. These
results further highlight the hypothesis that enhancement of trophic factors or their
agonist not only regulate long-term synaptic events such as synaptic plasticity, neuronal
differentiation, or survival, but that there is an immediate response to trophic factors.
Although with FSCV we have only evaluated DA in the CPu after 7,8-DHF, others have
shown that this acute TrkB activation via BDNF is not exclusive to DA or monoamines
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like serotonin, but influences other systems like GABA and glutamate.233, 239, 251
6.4.12 K252a and 7,8-DHF have no effect on DA transporter kinetics in wildtype
mice
To confirm that 7,8-DHF applications is exclusive to DA release dynamics, DA
uptake rates were evaluated. A one-way ANOVA showed no effect of TrkB treatment on
Vmax (F3,80 = 1.18, P = 0.32, Fig. 6B) in wildtype mice. By decreasing the amount of
K252a that is bathed over the slice, we demonstrated that this lower dose could still
inhibit TrkB release without effecting DA transporter kinetics in wildtype mice. Together,
these results from wildtype mice confirm the hypothesis that 7,8-DHF is mediating DA
release via the TrkB receptor in wildtype mice with no effect on DA uptake kinetics.
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Figure 6.10: K252a blocks the effect of 7,8-DHF in the CPu of WT mice. A)
Representative current verse time traces with corresponding cyclic voltammograms
(inset) showing perfusion of 7,8-DHF potentiates DA release in the wildtype mice.
B) Blocking the TrkB receptor with K252a inhibits the 7,8-DHF mediated increase in
DA release shown by representative current versus time traces and cyclic
voltamograms (inset) C) Perfusion of 10 µM 7,8-DHF significantly increases
electrically stimulated DA release in the wildtype mice. Evoked DA release
mediated by the TrkB agonist 7,8-DHF is blocked in presence of 30 nM K252a. D)
Neither 30 nM K252a nor 10 µM 7,8-DHF altered DA uptake rate in wildtype mice.
Data are means ± SEMs (n = 4 - 8 mice). Statistical significance was determined by
one-way ANOVA with Dunnett's Multiple Comparison Test; *P < 0.05.
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Table 6.1. The effect of TrkB agonist on dopamine uptake rates
Agonist table
Genotype

Agonist
BDNF
(ng/mL)

BDNF+/-

7,8-DHF
(µM)
Wildtype

[Agonist]
Pre-drug
50
100
200
Pre-drug
0.010
1.00
30.0
Pre-drug
0.010
1.00
30.0

Significantly different from pre-drug control, **P < 0.01.

Vmax (µM/s)
(Mean ± SEM)
2.2 ± 0.2
2.2 ± 0.2
2.2± 0.2
2.3 ± 0.2
3.0 ± 0.03
3.0 ± 0.02
2.7 ± 0.1
2.4 ± 0.2**
4.0 ± 0.01
4.1 ± 0.12
4.0 ± 0.1
3.9 ± 0.2
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6.5 Conclusions
A long-term goal in neuropharmacology has been to find small molecules that
could mimic trophic factors and be easily administered where the small molecules could
pass through the blood-brain barrier. With the recent discovery that 7,8-DHF is an
agonist for TrkB receptors, numerous in vivo studies have shown that sub-acute
applications of 7,8-DHF lead to many of the same benefits as that of a direct application
of BDNF.260, 263, 265, 266 The results from this study highlight the utility of FSCV to probe
acute, striatal BDNF/TrkB receptor mediated DA release and uptake. An advantage of
using FSCV versus traditional synaptosomal models is that we can quickly measure
both DA release and uptake in a close to normal physiological state. FSCV has shown
that a more “physiological” stimulation (1 ms) potentiates stimulated DA release in the
presence of 7,8-DHF and BDNF in wildtype and BDNF+/- mice, respectively. This
divergent role between 7,8-DHF and BDNF activating DA release may be a result of
using a mouse model with a 50% reduction in BDNF protein levels, where there are not
only intrinsic alterations in the BDNF/TrkB system but other neuroadaptions throughout
the brain that are still unaccounted for. Our FSCV results are not limited to the
evaluation of a TrkB agonist, but we also examined tyrosine kinase inhibitors. K252a did
not have any effect on stimulated DA release except at the highest dose (3 μM), while
concentrations greater than 1 μM altered DA transporter kinetics. Since DA uptake V max
was altered in both genotypes at concentrations greater than 1 μM of K252a, this
suggests a promiscuous response. Although K252a is often described as a TrkB
inhibitor, it is a non-selective protein kinase inhibitor that inhibits PKC, Ca2+/calmodulinstimulated phosphodiesterases (IC50 = 1.3 - 2.9 μM from Tocris on-line catalog), MLCK
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(Ki = 20 nM from Tocris on-line catalog) and receptor tyrosine kinases, suggesting that
TrkB or some other signaling system that K252a inhibits is influencing DA transporter
uptake rates. Genistein did not have any effect of stimulated DA release but at high
concentrations, it did significantly attenuated DA uptake. Tryphostin 23, on the other
hand, decreased both DA release and uptake in both genotypes of mice examined. By
using FSCV, we were able to delineate a more comprehensive understanding of how
TrkB receptor activation can modulate presynaptic DA dynamics using BDNF, a TrkB
receptor agonist, or inhibitors.
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CHAPTER 7
Summary and Conclusions
The striatal dopamine (DA) system is a key player in learning, memory, motor
functions, and reward related behaviors, and has been implicated in neurological
disorders including addition.2,

3, 14

Thus, understanding the DA system is crucial to

provide the opportunity for new and improved therapeutic options for addiction as well
as other neurological disorders. The present study was undertaken to: 1) provide insight
into how toluene exposure modulates the striatal DA system, and 2) understand how
the protein; brain-derived neurotrophic factor (BDNF), modulates striatal DA dynamics.
The present chapter highlights the findings from these two main projects discussed in
this dissertation and suggests future studies that will provide further insight to the
present work.
7.1 Understanding how toluene modulates the DA system
Toluene inhalation has debilitating consequences on mental health.47,

49, 192

However, not much is known about toluene’s exact neural target. Although existing
evidence has shown that toluene abuse influences the DA system, the mechanism
underlying toluene’s effect on the DA system remains elusive.36, 38 In the present study,
behavioral assays and neurochemical techniques were employed to better understand
the effect of toluene inhalation on the DA system. Behavioral assays serve as a
complimentary tool to neurochemical assays, since changes in behavior predict
possible neurochemical effects of toluene.34, 138, 141 The behavioral assays also provide
the opportunity to identify possible similarities between abused toluene and other drugs
of abuse whose neurobehavioral profiles have been well characterized in animal
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models.56 Neurochemical technique such as slice fast scan cyclic voltammetry (FSCV)
provides the ability to monitor the fast DA dynamics such as release and uptake and to
assess toluene’s effect on the functionality of the DA autoreceptors. In vivo
microdialysis provides the ability to monitor extracellular DA levels, whereas tissue
content analysis enables evaluation of toluene’s effect on intracellular DA levels and its
catabolism. In all, two main exposure models were used: an acute toluene exposure
model, which allowed evaluation of how brief exposure to toluene modulates the striatal
DA system and a repeated toluene model which enabled the impact of chronic toluene
inhalation on the DA system to be examined.
Using behavioral testing, we characterized the effect of acute and repeated
toluene exposure on locomotor activity in mouse models. The results suggest a biphasic
response where acute toluene exposure increased locomotor activity, while repeated
toluene exposure caused sensitization to toluene induced locomotor activity. Our
working hypothesis was that these differences in locomotor activity were linked to
alterations in the striatal DA system. To test this hypothesis, the first objective was to
characterize the effect of toluene inhalation on DA dynamics using FSCV. For the acute
experiment, mice were exposed to 30 minutes of toluene inhalation followed by 30
minutes of recovery before FSCV measurements were made. In the repeated model,
mice were treated to the same routine for seven consecutive days and neurochemical
measurements were obtained on the eighth day to evaluate the long-term effect of
chronic toluene inhalation. FSCV data revealed that acute toluene exposure potentiates
electrically evoked DA release across the striatum (caudate putamen, CPu; nucleus
accumbens, NAc core and shell), while repeated toluene inhalation attenuates
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electrically evoked DA release in the NAc core and shell but not in the CPu. Acute or
repeated toluene exposure does not affect DA uptake rate in the striatum. Taken
together, these acute and repeated toluene measurements suggest that repeated
toluene exposure has the opposite effects on DA dynamics compared to acute
exposure. On the basis of these initial data, our hypothesis was that repeated toluene
exposure would lead to downward regulation of DA release in the NAc, which may be
mediated by DA autoreceptors. DA autoreceptors play an important role in regulating
extracellular DA levels by modulating DA release and synthesis.182,

194-197

Across the

striatum, DA D3 autoreceptors are predominantly expressed in the NAc than in CPu
while DA D2 autoreceptors are homogenously expressed across the striatum.182-186
Since the attenuation in DA release caused by repeated toluene exposure was
exclusive to the NAc, we suspected that DA D3 autoreceptors would be involved in
toluene’s mechanism of action.
Building on our initial neurochemical characterization, the acute toluene exposure
model was modified by excluding the recovery phase from the regimen whereas in the
repeated model, neurochemical measurements were made on the seventh day
immediately after the seventh toluene exposure. The changes made to these exposure
protocols were to gain a better understanding of the immediate effects of toluene
treatment on the DA system. Using FSCV, we confirmed that acute toluene inhalation
potentiates DA release across the striatum, while repeated toluene exposure decreases
DA release in the NAc core. Overall, acute toluene exposure had no effect on DA
uptake in the striatum, but the only exception was the NAc shell, which showed an
elevation in DA uptake only at a low toluene dose. For repeated toluene exposure, there
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was no difference in DA uptake rates in the CPu, but DA uptake appeared altered in the
NAc. Furthermore, the follow up experiments extended the preliminary work by showing
that these toluene-induced alterations in the striatum are not mediated by DA D3
autoreceptors as previously proposed. To examine the influence of toluene exposure on
extracellular DA levels, a toluene exposure set-up that allowed toluene exposure and in
vivo microdialysis measurements to be made simultaneously was constructed. This setup also allowed monitoring of locomotor behavior of the mice during microdialysis
measurement. Microdialysis data showed that the potentiation in DA release induced by
acute toluene exposure (as measured by FSCV) does not lead to increased
extracellular DA level in the CPu, even though the behavior data taken simultaneously
showed increased locomotor activity. Thus, it appears that the increase in locomotor
activity was not mediated by extracellular DA levels in the CPu. Furthermore, acute
toluene exposure did not alter intracellular DA levels as measured by tissue content
analysis, suggesting that the increase in stimulated DA release induced by acute
toluene exposure (as measured by FSCV) was not a result of elevated intracellular DA
levels or excess DA accumulation in vesicles. However, there were decreases in DA
catabolism in both the CPu and NAc as measured by tissue content (Figure 7.1).
Meanwhile, repeated toluene exposure elevated extracellular DA levels in the NAc,
which we believe may be the alteration underlying the sensitization effect on locomotor
activity observed previously in our behavior characterization. On the other hand,
repeated toluene exposure did not alter intracellular DA levels or DA catabolism across
the striatum as shown by the tissue content data (Figure 7.1).
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Overall, with no effect of acute toluene exposure on DA uptake, DA D3
autoreceptors, extracellular and intracellular DA levels, it is most likely that toluene’s
action on stimulated DA release is mediated through an indirect mechanism rather than
a direct action on DA autoreceptors or synthesis. However, exactly how toluene is
influencing DA release is not known. Significant evidence has shown that toluene
influences glutamate receptors and gamma-aminobutyric acid (GABA) receptor
GABAA,78-80 as well as toluene’s influence on voltage-gated calcium, potassium, and
sodium channels.37, 269-271 In addition, there are reports that have shown that both acute
and chronic toluene treatment can stimulate the generation of reactive oxygen (ROS)
and reactive nitrogen species (RNS) in the brain, which can interfere with the functions
of enzymes, receptors, and ion channels.272,

273

It is therefore possible that toluene

could be influencing the DA system through these non-DA receptors and ion channels
that have been implicated in toluene’s neural action. In the work done by Avshalumov
and colleagues, a mechanism underlining normal striatal DA release process was
presented.274 In their work, slice FSCV was used to demonstrate that striatal DA release
can be modulated by glutamate and GABA receptors through a ROS; hydrogen
peroxide (H2O2).274 Since there are no glutamate and GABA receptors on the DA
terminal, this modulatory effect has been described as an indirect mechanism, where
the H2O2 mediating the effect is produced in a non-DA cell.274-276 Interestingly, the
actions of glutamate and GABA in this mechanism are independent of their conventional
roles in excitatory and inhibitory circuitries, respectively.274 In this mechanism, activation
of glutamate receptor; alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
(AMPA) receptors, generates H2O2 that diffuses to the DA terminal where it opens
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potassium channels causing hyperpolarization of the DA neuron and in turn decreases
DA release.274 However, activation of GABAA receptors is proven to inhibit this H2O2
mediating effect causing an increase in DA release.274 Since the key mediators in this
proposed pathway have been implicated in toluene’s action, it is possible that their
perturbation by acute or repeated toluene inhalation could lead to these alterations in
DA release.274 However, future studies will be necessary to validate this assertion.
7.1.1 Overall conclusion and future direction
Taken together, the present work has utilized behavior and neurochemical
techniques as complementary tools to provide useful insight into how the abuse solvent
toluene modulates the striatal DA system. The findings from the present work have led
us to propose that toluene’s action on the striatal DA release process may be mediated
through an indirect mechanism that involves other neurotransmitters such as glutamate
or GABA as well as the neuromodulator H2O2. Future studies are recommended to
examine this hypothesis by examining how inhibition or activation of these non-DA
receptors and ROS would influence toluene-induced alterations in the DA system,
particularly DA release.
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Figure 7.1: Schematic diagram summarizing the effects of toluene exposure
on striatal DA system. Acute toluene treatment involved 30 minutes toluene
inhalation followed by neurochemical measurements. Repeated toluene exposure
involved 30 minutes toluene treatment for 7 consecutive days followed by
neurochemical measurements. Striatal regions examined were caudate putamen
(CPu), nucleus accumbens (NAc) core and shell. DA parameters examined include
release and uptake as well as autoreceptor functionality measured by slice fast
scan cyclic voltammetry (FSCV); extracellular DA levels measured by in vivo
microdialysis; intracellular DA and metabolites measured by tissue content analysis.
Definitions from the diagram: L-DOPA, L-3,4-dihydroxyphenylalanine; VMAT,
vesicular monoamine transporter; DAT, dopamine transporter; MAO, monoamine
oxidase, COMT, catechol-O-methyltransferase; HVA, homovanillic acid; Gi and Gs,
G-protein coupled receptors; AC, adenylyl cyclase; cAMP: cyclic adenosine
monophosphate.
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7.2 Probing the ability of presynaptic tyrosine kinase receptors to regulate striatal
DA dynamics
Overall, the second objective of the present work seeks to understand how
BDNF modulates striatal DA dynamics. Since BDNF executes its neurotrophic functions
via activation of TrkB receptors, the main goal was to examine how these TrkB
receptors mediate the effect of BDNF on striatal DA dynamics. To achieve this goal,
slice FSCV’s ability to monitor the action of tyrosine kinase (Trk) receptors on DA
release and uptake was first assessed in the CPu of BDNF-deficient mice and their
wildtype counterparts. Previously, it was shown that activation of TrkB receptors by
exogenous BDNF increased electrically stimulated DA release, so we expected that
application of a Trk antagonists would decrease electrically stimulated DA release.94
Herein, we demonstrated FSCV’s ability to measure Trk receptor mediated changes in
the DA dynamics by showing that the presence of Trk antagonist, genistein decreases
only DA uptake while a more potent antagonist; Tyrphostin 23, decreases DA release
and uptake in both groups of mice examined. In subsequent experiments, we
characterized the functional effect of TrkB receptors on DA release and uptake using
BDNF, 7,8-dihydroxyflavone (7,8-DHF) and K252a (Figure 7.2). 7,8-DHF is a recently
discovered TrkB agonist shown to have similar ability to influence presynaptic DA
dynamics like BDNF.260 The abilities of BDNF and 7,8-DHF to increase striatal DA
release were demonstrated. The ability of BDNF and 7,8-DHF to elevate stimulated DA
release were abolished by the TrkB receptor antagonist, K252a. Hence BDNF and 7,8DHF modulate striatal DA release through activation of TrkB receptors.
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7.2.1 Overall conclusion and future direction
Taken together, our findings demonstrated FSCV’s ability to measure Trk
mediated alterations in the presynaptic DA dynamics. The unique advantage that FSCV
brings to studying the protein BDNF is its high temporal resolution of up to 100 ms that
allows monitoring of BDNF’s influence on DA dynamics in real time. Additionally, FSCV
allows monitoring of DA release and uptake simultaneously.
Overall, the results from the present work support the assertion that BDNF
modulates striatal presynaptic DA release through activation of TrkB receptors.
However, the intracellular signaling cascades that mediate this action of TrkB receptors
on presynaptic DA release are not well understood. The intracellular signaling cascades
that are evoked upon Trk activation are categorized into three main pathways:
phospholipase Cγ (PLCγ), the Ras/mitogen activated protein kinase (MAPK), and
phosphatidylinositol-3-kinase (PI3K).2,

19, 29

These intracellular signaling cascades are

known to mediate several biological functions including neurotransmitter release (Figure
7.2).2, 19-21, 29, 277 Future studies should further the present work by using FSCV to probe
how TrkB receptors and their intracellular signaling components modulate presynaptic
DA release and uptake in the striatum.
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Figure 7.2: Schematic diagram showing a summary of the present work and
recommended studies to understand how TrkB modulates DA dynamics. The
functional effect of TrkB was examined using exogenous brain derived neurotrophic
factor (BDNF); TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), and TrkB antagonist
including tyrphostin 23 (AG18) and K252a. Present work demonstrated that BDNF
modulate striatal DA release through activation of TrkB. The suggested study
focuses on the mechanism underlining how TrkB activation influences the striatal
DA dynamics by probing intracellular signaling cascade: Ras/mitogen activated
protein kinase (MAPK) pathway, Phosphatidylinositol-3-kinase (PI3K) pathway and
phospholipase Cγ (PLCγ) pathway.
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Dopamine (DA) neurons in the striatum mediate several functions of the brain
and have been linked to a host of neurological disorders including Parkinson’s disease
and addiction, both of which occur as a result of dysfunction in the DA system. In the
present study, our first objective was to understand how the striatal DA system adapts
to acute and repeated administration of inhalant toluene. The use of toluene as inhalant,
like other drugs of abuse, is known to perturb DA neurotransmission in the brain reward
pathway. However, the exact mechanism underling toluene’s influence on striatal DA
neurotransmission is unknown. The current work utilized behavior assays and
neurochemical techniques such as slice fast scan cyclic voltammetry (FSCV), in vivo
microdialysis, and brain tissue content analysis to examine how toluene inhalation alters
the striatal DA system. Overall, both behavior and neurochemical data confirmed that
toluene inhalation alters stimulated DA release in striatum. Mechanistically, the
neurochemical data indicated that acute toluene inhalation potentiates striatal DA
release and catabolism but there is no difference on DA uptake or extracellular DA
levels in the caudate putamen (CPu). Furthermore, toluene induced potentiation in DA
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release is not mediated by DA D3 autoreceptors. Meanwhile, chronic toluene exposure
attenuated DA release only in the nucleus accumbens (NAc). Repeated toluene
exposure also increased extracellular DA levels in the NAc, which is typical of addictive
drugs. However, repeated toluene inhalation had no effect on DA D3 autorecepetors,
and DA catabolism. Taken together, the present data suggest that acute or repeated
toluene alters the striatal DA system through indirect neuronal action.
The second objective was to understand how brain derived neurotrophic factor
(BDNF) modulates striatal DA dynamics. Aside from its conventional role as a
neurotrophic factor, BDNF has also been implicated in synaptic transmission and
neurological disorders. Since BDNF mediates it neurotrophic functions through tyrosine
kinase receptor TrkB, the functional effects of tyrosine kinase receptor TrkB on the
striatal DA release and uptake rate were examined. This work utilized FSCV to evaluate
the effect of exogenous BDNF, TrkB agonist; 7,8-dihydroxyflavone (7,8-DHF), and TrkB
antagonists; genistein, tyrphostin 23, and K252a, on DA dynamics in the CPu of brain
slices obtain from BDNF deficient (BDNF+/-) mice and their wildtype littermates. Overall,
the results obtained highlighted the utility of FSCV to probe the functional effect of Trk
receptors on DA dynamics. The results also showed that activation of TrkB receptors
with exogenous BDNF and 7,8-DHF potentiated presynaptic DA release in BDNF+/- and
wildtype mice respectively, with no effect on DA uptake. However, concentrations
greater than 3 μM 7,8-DHF attenuated DA uptake rates in only BDNF+/− mice. In the
presence of K252a, the BDNF or 7,8-DHF induced potentiation of DA release was
abolished, suggesting that the effect of BDNF or 7,8-DHF on presynaptic DA release is
TrkB mediated.
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